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ABSTRACT 
 
In the central nervous system (CNS), oligodendroglial cells (OLs) form the myelin that 
ensheaths axons to ensure fast, efficient neurotransmission. Multiple sclerosis (MS) is a chronic 
demyelinating disease where myelin and myelinating OLs are damaged, making the axons more 
susceptible to degeneration. The cellular and molecular mechanisms that control the myelinating 
ability of OLs are largely unknown. The RNA binding protein quaking (QKI) regulates the 
expression of several myelin specific genes. Sirtuin 2 (SIRT2) is a NAD+ dependent deacetylase 
predominantly expressed in OLs. Both qkI and Sirt2 are upregulated during the period of intense 
CNS myelination in vivo; however, it is not known whether these two genes interact to regulate 
OL differentiation. In the first study, I tested the hypothesis that QKI interacts with Sirt2 mRNA 
to promote the expression of SIRT2 in OLs during development. I report for the first time that 
QKI directly interacts with Sirt2 mRNA at the 3' untranslated region, protects Sirt2 mRNA from 
degradation, and promotes SIRT2 expression in OL lineage cells. 
 Considering the importance of Sirt2 in OL differentiation in vitro, I hypothesized that 
loss of Sirt2 would result in hypomyelination and increase the disease severity in an 
experimental autoimmune encephalomyelitis (EAE) mouse model of MS. My findings 
demonstrate that the loss of Sirt2 results in reduced expression of key myelin genes and a 
significant reduction in the number of myelinated axons in the CNS in vivo. In addition, Sirt2-/- 
mice displayed defects in OL precursor cells (OPC) proliferation and OL differentiation. EAE 
induction demonstrated that absence of Sirt2 results in an increased severity of EAE in Sirt2-/- 
mice compared to wild-type mice. These results suggest that Sirt2 plays a crucial role in OL 
development and myelination and a protective role in the EAE mouse model of MS. Finally, I 
investigated the targets through which Sirt2 could possibly regulate myelination. Cholesterol is 
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crucial for myelin biogenesis. In neurons, SIRT2 has been implicated in cholesterol biosynthesis 
by promoting the nuclear translocation of SREBP-2. In this study, I hypothesized that SIRT2 
positively regulates the translocation of SREBP-2 into the nucleus in OLs to promote cholesterol 
biosynthesis. My findings reveal that SREBP-2 and the downstream sterol biosynthesis pathway 
is not regulated by SIRT2 in OLs during CNS myelination. 
 Collectively, these findings suggest that QKI regulates the expression of Sirt2, which 
plays a critical role in oligodendrogenesis and myelination of axons in the CNS through SREBP-
2/cholesterol-independent mechanism. In addition, Sirt2 plays a protective role in the EAE 
mouse model. I believe this research will advance our knowledge in identifying target molecules 
that regulate the myelinating ability of OLs, leading to the development of potential nutrient and 
pharmacological therapies for MS.  
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1. GENERAL INTRODUCTION 
Oligodendrocytes (OLs) are the myelin forming glial cells in the central nervous system 
(CNS) (Baumann and Pham-Dinh, 2001; Bradl and Lassmann, 2010). In the CNS, OL precursor 
cells (OPCs) originate from the ventricular/subventricular (VZ/SVZ) zones, and proliferate, 
migrate and eventually differentiate into mature OLs (Baumann and Pham-Dinh, 2001; Bergles 
and Richardson, 2015). The mature OLs extend their plasma membrane rich in lipids and 
proteins to ensheath axons with a compact, multilayered membranous myelin sheath (Baumann 
and Pham-Dinh, 2001; Pfeiffer et al., 1993; Simons and Nave, 2015). Myelination is essential for 
fast, efficient conduction of action potentials from neuronal cell bodies to synaptic terminals. 
During demyelination (myelin loss) or axonal injury OPCs are recruited and induced to 
differentiate to promote remyelination.  However, both myelination and remyelination are 
impaired in multiple sclerosis (MS). MS, a chronic demyelinating disease caused by an immune 
reaction against myelin and myelin forming OLs (Hanafy and Sloane, 2011; Miron et al., 2011; 
Kotter et al., 2011). MS results in non-traumatic neurological disability in adults between 20 to 
50 years old, with a prevalence high in North America and Europe (140 and 108 in 100,000 
population, respectively) and low in Sub-Saharan Africa and East Asia (2.1 and 2.2 in 100,000 
population, respectively) (Multiple Sclerosis International Federation, 2013). The cellular and 
molecular mechanisms regulating OL to myelinate axons is of critical importance in 
understanding effective repair in MS.  
The RNA binding protein quaking (QKI) plays an important role in myelination by post-
transcriptionally regulating several myelin specific genes (Li et al., 2000; Wu et al., 2002; Zhao 
et al., 2006a, b; Zhao et al., 2010). QKI regulates splicing, stabilization, subcellular localization 
and/or translation efficiency of the target mRNA. The quaking viable (qkv/qkv) mutant mouse, 
 2 
which harbors a one megabase deletion upstream of qkI locus, exhibits hypomyelination in the 
CNS mainly due to a defect in OL maturation (Chenard and Richard, 2008; Hardy, 1998a, b). 
QKI has been reported to interact with target mRNAs such as myelin basic protein (Mbp) 
(Larocque et al., 2002; Li et al., 2000; Ryder and Williamson, 2004), proteolipid protein (Plp1) 
(Wu et al., 2002), myelin associated glycoprotein (Mag) (Wu et al., 2002), cyclin dependent 
kinase inhibitor p27Kip1 (Larocque et al., 2005), actin interacting protein 1 (Aip-1)  (Doukhanine 
et al., 2010), microtubule associated protein 1B (Map1B) (Zhao et al., 2006a) and heterologous 
nuclear ribonucleoprotein A1 (hnRNPA1) (Zearfoss et al., 2011) in OLs.  
 Sirtuin 2 (SIRT2) is a class III NAD+-dependent deacetylase predominantly expressed in 
the cytoplasm of OLs (North et al., 2003). Interestingly, the expression of SIRT2 protein but not 
mRNA is impaired in the qkv/qkv mutant mice (Zhu et al., 2012). Furthermore, SIRT2 expression 
is reduced in the myelin sheath of Plp null mice, which lacks both PLP and DM20 (Werner et al., 
2007) and Plp-ISEdel (deletion of intronic splicing enhancer of Plp) mutant mice in which PLP 
is selectively reduced but not DM20 (Zhu et al., 2012). Moreover, no putative QKI binding sites 
have been previously identified in Sirt2 mRNA. Thus, it was postulated that QKI indirectly 
regulates SIRT2 through PLP (downstream target of QKI), which aids in the transport of SIRT2 
into the myelin sheath (Zhu et al., 2012). However, the molecular mechanism that governs the 
direct or indirect interaction between QKI and Sirt2 during OL development has not been 
elucidated (Objective 1). In this thesis, I have investigated the post-transcriptional regulation of 
Sirt2 by QKI in CG4-OL cells and primary OL cells by RNA co-immunoprecipitation.  Results 
reveal that QKI binds to all the three variants of Sirt2 mRNA at the 3' untranslated region (UTR) 
through a common quaking response element (QRE) at 1853bp. My findings indicate that QKI 
interacts directly with Sirt2 mRNA to regulate its expression during OL development.  
 3 
In addition to investigating the regulation of Sirt2 by QKI, I explored the role of Sirt2 
during OL development, myelination and in MS. Our group has previously demonstrated that 
Sirt2 is essential for the OL process formation and plays a role in the maturation of OLs in vitro 
(Ji et al., 2011). Moreover, SIRT2 is upregulated during the peak period of myelination in the 
CNS (Southwood et al., 2007) as well as in the peripheral nervous system (PNS) (Beirowski et 
al., 2011). In addition, studies on myelin proteome revealed that the isoform SIRT2.2 integrates 
into myelin in close proximity to PLP and the alternatively spliced isoform of PLP (DM20) and 
is localized in paranodal loops (Li et al., 2007a; Southwood et al., 2007; Werner et al., 2007). 
Interestingly, the expression profile of SIRT2 is similar to that of MBP and myelin protein zero 
(MPZ) in the CNS and PNS, respectively (Ji et al., 2011; Beirowski et al., 2011). However, the 
role of Sirt2 in CNS myelination and in the disease severity of experimental autoimmune 
encephalomyelitis (EAE), a mouse model of MS, has not been investigated (Objective 2). Here, I 
examined the impact of loss of Sirt2 in myelination and in the disease severity of EAE using 
Sirt2 knockout (Sirt2-/-) mice. Loss of Sirt2 was associated with reduced myelin gene expression, 
hypomyelination and an increased disease severity in the EAE mouse model. 
Cholesterol represents one of the major components of myelin and defects in cholesterol 
synthesis significantly impair myelination (Norton and Poduslo, 1973a; Saher et al., 2005; Saher 
and Simons, 2010; Mathews et al., 2014). Interestingly, Sirt2 plays a role in the sterol 
biosynthesis mediating the nuclear translocation of sterol regulatory element binding protein 
(SREBP)-2 (Luthi-Carter et al., 2010; Taylor et al., 2011). SREBP-2 is a key transcription factor 
that enters into the nucleus under low intracellular sterol levels and binds to sterol responsive 
element (SRE) inducing genes encoding enzymes involved in cholesterol biosynthesis 
(Amemiya-Kudo et al. 2002; Eberlé et al. 2004; Horton et al. 2002; Horton et al. 2003). 
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Inactivation of enzymes involved in cholesterol biosynthesis such as squalene synthase (SQS) 
and HMG-CoA synthase 1 (HMGCS1) results in reduced myelin gene expression (Mathews et 
al., 2014; Saher et al., 2005). Overexpression of Sirt2 increases MBP expression and facilitates 
arborization of OLs in vitro (Ji et al., 2011).  It is not known if these changes are due to increased 
translocation of SREBP-2 into the nucleus by SIRT2 (Objective 3). To address this, I utilized 
Sirt2-/- mutant mice to investigate the role of Sirt2 in regulating cholesterol biosynthesis in vivo 
and in vitro in the developing CNS white matter and primary OL cultures, respectively. In 
addition, I evaluated the impact of loss or gain of function of Sirt2 on the expression of 
cholesterol biosynthetic genes, cholesterol content and nuclear translocation of SREBP-2 using 
CG4-OLs. My findings suggest that Sirt2 is not involved in the regulation of SREBP-2 
dependent cholesterol biosynthesis in OLs during CNS myelination.  
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1.1 Hypotheses 
1. QKI binds, interacts, and stabilizes Sirt2 mRNA at the 3' UTR to induce expression of Sirt2.  
2. Sirt2 is a positive regulator of OL differentiation and myelination by facilitating the 
expression of myelin specific genes. Sirt2 plays a protective role in the EAE mouse model of 
MS by improving myelin repair. 
3. SIRT2 facilitates the translocation of SREBP-2 from cytoplasm into nucleus and promotes 
cholesterol biosynthesis.  
1.2 Objectives  
1. To elucidate the post-transcriptional regulation of Sirt2 transcripts by QKI during OL 
development in vitro. 
2. To determine the impact of loss of function of Sirt2 in CNS myelination, OL development, 
and on the disease severity of the EAE mouse model of MS.  
3. To investigate the impact of Sirt2 in cholesterol biosynthesis during OL differentiation in vivo 
and in vitro. 
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2. REVIEW OF LITERATURE 
Myelination is an essential biological process required for the proper development and 
functioning of the vertebrate nervous system (Nave and Werner, 2014). Myelin is a multilayered 
membranous sheath formed by glial cells such as oligodendrocytes (OLs) in the CNS and by 
Schwann cells (SC) in the PNS. OLs and SCs differ in their developmental origin and capability 
to myelinate axons. OLs arise from the subventricular zone and SCs arise from the neural crest 
(Jessen and Mirsky, 2005; Levison and Goldman, 1993; Luskin and McDermott, 1994; Ndubaku 
and de Bellard, 2008). One OL can myelinate up to 60 axons (1:60) (Remahl and Hildebrand, 
1990) whereas one SC can myelinate only one internode of one axon (1:1).  In addition, there are 
also differences in the composition of structural proteins constituting the myelin sheath in the 
CNS and the PNS (Nave and Werner, 2014).  In this literature review, I will mainly focus on the 
CNS myelination by OLs. 
2.1 Oligodendrocyte development and myelination  
In developing CNS, the OPCs develop from the neuroepithelial precursor cells or neural stem 
cells (NSC) that originate in dorsal and ventral regions of brain and spinal cord (Kessaris et al., 
2006; Vallstedt et al., 2005; Bergles and Richardson, 2015). The progression of OPCs to mature 
myelinating OL is a complex and dynamic process regulated by transcription factors, growth 
factors, epigenetic factors and extrinsic signals (Emery, 2010; Emery and Lu, 2015). In the 
mouse spinal cord, the first set of OPC arise from the ventral ventricular zone at embryonic stage 
(E) 12.5 and then after 2 days a second set of OPCs arise from the dorsal ventricular zone (Warf 
et al, 1991; Lu et al., 2002; Fogarty et al., 2005; Cai et al., 2005). In the brain, the first set of 
OPC is generated from the ventral forebrain in the medial ganglionic eminence and anterior 
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entopeduncular area around E12.5. These OPCs migrate and populate the cerebral cortex. The 
second set of OPC is derived from the lateral and caudal ganglionic eminences around E15.5. 
The third set of OPC is generated locally in the cortex around birth (Kessaris et al., 2006). 
During postnatal development, OPCs continue to develop from NSC that arise from the 
subventricular zones and populate cortex (Levison and Goldman, 1993; Luskin and McDermott, 
1994; Baumann and Pham-Dinh, 2001; Nicolay et al., 2007). Although the ventrally and dorsally 
derived OPCs display similar electrical properties, they had different migration, settling and 
differentiation patterns (Tripathi et al., 2011; Crawford et al., 2016). Oligodendrocyte lineage 
transcription factor 2 (Olig2) plays a critical role in the specification of NSCs to OPCs (Lu et al., 
2002; Ligon et al., 2006). Once specified OPCs with bipolar morphology proliferate and express 
progenitor cell markers such as the platelet-derived growth factor receptor alpha (PDGFRα) and 
neuron-glial antigen 2  (NG2) proteoglycan (Nishiyama et al., 1996; Levine et al., 2001; 
Marques et al., 2016). These proliferating OPCs migrate to the site of myelination through 
vasculature (Tsai et al., 2016) and transform into intermediate immature OLs displaying a 
multipolar morphology with oligodendrocyte cell surface antigen-4 (O4) expression. Finally, the 
immature OLs differentiate into myelinating OLs that express mature OL markers such as 
myelin basic protein (MBP), proteolipid protein (PLP) and other myelin structural proteins 
(Marques et al., 2016). The myelin structural protein expression in the differentiated OL is 
mediated by transcription factors such as Olig1 (Xin et al., 2005; Li et al., 2007b), Olig2 (Lu et 
al., 2002; Liu et al., 2007), Sox10 (Stolt et al., 2002; Liu et al., 2007; Li et al., 2007b) and myelin 
gene regulatory factor (Emery et al., 2009). Deletion of each individual transcription factor 
impaired myelin structural protein expression, indicating that all these transcription factors play a 
non-redundant role to promote OL differentiation and myelination (Emery and Lu, 2015). The 
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myelinating OLs extend their plasma membrane to encapsulate axons (Fig. 2.1) (Pfeiffer et al., 
1993; Simons and Nave 2015; Snaidero and Simons, 2017).  
After establishing contact with an appropriate axon, the glial membrane starts to wrap the 
axon, leaving an inner tongue of cytoplasm (plasmalemma) close to the axon surface, which 
forms the inner mesoaxon (periaxonal layer). This inner tongue continues to grow under the 
previously deposited membrane leading to the formation of a multilayered myelin sheath 
(Snaidero et al., 2014). The newly formed myelin membranes extend laterally, constituting the 
paranodal loops (Snaidero et al., 2014). The paranodal loops are attached to the axon by 
neurofascin155 (NF155), contactin and contactin associated protein (caspr) (Simons and 
Trajkovic, 2006; Pedraza et al., 2009). As it continues to wrap, the plasmalemma fuses to form a 
condensed cytoplasmic membrane structure, which appears dark under the electron microscope 
and is called the major dense line (MDL). The closely opposed outer surface of the glial 
membrane appears lighter and is called the intraperiod line (IPL). Towards the end of wrapping, 
the plasmalemma leaves a loop forming the outer mesoaxon (abaxonal layers) (Soldan and Pirko, 
2012; Simons and Nave, 2015; Snaidero and Simons, 2017). Thus, under the electron 
microscope, the myelin sheath is visualized as having a compact region (MDL and IPL) and a 
non-compact region (mesoaxon and paranodal loops) (Nave and Werner, 2014). The region of 
axon that is covered by myelin forms the internode (Fig. 2.2). The space between two internodes 
that is left uncovered by myelin constitutes the nodes of Ranvier enriched in voltage-gated 
sodium channels (NaV) (Quarles et al., 2006; Soldan and Pirko, 2012). The NaV channels, which 
are diffusely distributed, become clustered at the nodes of Ranvier by oligodendrocyte protein or 
oligodendroglial contact with the axon and aids in fast and efficient action potential propagation 
(Kaplan et al., 1997; Kaplan et al., 2001; Simons and Trajkovic, 2006; Freeman et a., 2016).  
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Figure 2.1: Schematic representation of developmental stages involved in OL development. 
OL development initiates with NSC and OPC, which undergo proliferation and express stage-
specific markers while progressing to the pre-oligodendrocyte stage. The pre-oligodendrocytes 
with bipolar morphology migrate and develop into immature OLs with a multipolar morphology. 
These immature OLs differentiate to extend multiple cellular processes to wrap nearby axons 
with myelin, during which they express myelin specific markers such as MBP, PLP and MAG. 
Stage-specific markers are indicated in boxes (adapted from Baumann and Pham-Dinh, 2001).  
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Figure 2.2: Myelin sheath in the CNS. Axons in the CNS are wrapped around by OLs. The part 
of the axon covered by myelin forms the internode, and the uncovered part of the axon forms the 
Node of Ranvier. The spiraling of the myelin sheath starts at the inner mesoaxon (periaxonal 
loop), which fuses and continues to wrap as compact myelin and ends with non-compact outer 
mesoaxon (abaxonal loop) (adapted from Soldan and Pirko, 2012). 
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2.2 Myelin proteins and their impact on myelin structure 
Myelin is composed of approximately 70% lipids and 30% proteins (Quarles et al., 2006). 
Myelin forms as protein–lipid–protein-lipid-protein structure (Morell and Quarles, 1999). MBP 
and PLP constitute the major myelin structural proteins (Table 2.1).  The role of myelin 
structural proteins in CNS myelination is complex and unique with each protein mutation 
displaying a difference in ultrastructural myelin changes, motor function and coordination. In 
addition, different types of mutations of the same gene (e.g. Plp) exhibit structural and functional 
differences. 
2.2.1 Myelin basic protein (MBP) 
MBP constitutes 8% of the total myelin proteome in the mouse CNS (Table 2.1) (Jahn et 
al., 2009). It is an intrinsic cytosolic protein expressed in the inner surface of the OL membrane 
forming the MDL (Readhead et al., 1990). MBP is encoded as a product of a large gene complex 
called Golli (Genes of Oligodendrocyte Lineage), which has 11 exons and 3 transcription start 
sites  (Campagnoni et al., 1993; Givogri et al., 2001). The region downstream of transcription 
start site 3 has seven exons (exon I to VII) and encodes classic MBP isoforms of molecular 
masses 21.5, 18.5, 17 and 14 kDa as a result of alternative splicing of the primary mRNA 
transcript (de Ferra et al., 1985; Takahashi et al., 1985; Givogri et al., 2001). Among the four 
isoforms, 14 kDa and 18.5 kDa MBP isoforms lacking exon II are the most abundant in CNS 
(Akiyama et al., 2002). The positively charged MBP associates with negatively charged 
oligodendroglial phospholipids and facilitates the compaction of myelin sheath (Hu et al., 2004; 
Boggs, 2006; Muller et al., 2013; Harauz and Boggs, 2013). The Mbp mRNA is transported 
through RNA transport granules from the site of synthesis to the myelin compartment where 
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localized translation occurs (Colman et al., 1982; Muller et al., 2013). The transport requires OL 
cytoskeleton, microtubules and kinesin motors. Disruption of microtubule dynamics or kinesin 
restricts translocation of Mbp mRNA and results in failure in myelin sheath compaction (Lyons 
et al., 2009). 
Several studies on naturally occurring Mbp mutants have rendered extensive knowledge 
on the role of Mbp in CNS myelination (Table 2.2 and 2.3). In general, all Mbp mutants exhibit 
hypomyelination, tremor and shortened life span (Chernoff, 1981; Matthieu et al., 1992), 
underlining the critical role played by this gene in the functioning of the vertebrate CNS. One of 
the well-known naturally occurring Mbp mutants is the shiverer mutant mouse, where exon two 
to seven is deleted (Roach et al., 1985) resulting in complete absence of MBP expression (Jacque 
et al., 1983). Hypomyelination is observed only in the CNS but not in PNS. Furthermore, the 
CNS myelin is not compact with complete absence of MDL (Readhead and Hood, 1990).  
Myelin deficient mouse (mld) is another Mbp mutant mouse where the Mbp locus has two 
tandem Mbp genes. In this mld Mbp locus, the upstream gene at the 3' end from exon three to 
seven is in reverse orientation (Popko et al., 1987). In mld mice, the Mbp transcripts are 
abnormally unstable leading to reduced levels of Mbp mRNA levels (Popko et al., 1987). 
Conversely, with increasing age the Mbp mRNA levels recover to some extent albeit lower than 
in the wild-type, resulting in compaction of myelin in some axons (Matthieu et al., 1980; 
Matthieu et al., 1984).  
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2.2.2 Proteolipid protein (PLP) 
The PLP is the most abundant protein in the CNS myelin. PLP constitutes 17% of the 
total myelin proteome (Table 2.1) (Jahn et al., 2009). Plp gene is present on the X-chromosome 
with seven exons, which gives rise to two proteins (PLP and DM20) due to the 5' splice site 
present in exon 3. PLP is a 30 kDa protein and its alternatively spliced isoform DM20 is a 26.5 
kDa protein, which differs from PLP by lacking 35 amino acids (aa) (Nave et al., 1987). PLP is 
present in the extracellular membrane of OL forming the IPL (Barkovich, 2000). In mouse, 
bovine and human CNS, DM20 protein is expressed prior to PLP protein during development 
(LeVine et al., 1990). However, with development, PLP becomes the predominant protein in the 
CNS (LeVine et al., 1990). All the Plp mutations are inherited in an X-linked manner (Willard & 
Riordan, 1985). In humans, mutation in Plp has been associated with X-linked dysmyelinating 
leukodystrophies, Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia type 2 (SPG2). 
Similar to Mbp, Plp has also been studied extensively with several naturally occurring and 
transgenic mutant lines (Table 2.2 and 2.3). These mutants provide models for PMD/SPG2 with 
varying clinical presentation. 
In jimpy (jp) mice, a naturally occurring point mutation within intron four of the Plp gene 
results in aberrant splicing of exon five, causing a frameshift in the translation that gives rise to a 
protein with a truncated C-terminus (Dautigny et al., 1986; Nave et al., 1987; Hudson et al., 
1987). This causes misfolding of PLP and DM20 and eventually gets degraded after synthesis 
(Roussel et al., 1987). In jp mice, less than 5% of the axons are myelinated, which are 
ultrastructurally abnormal (Duncan et al., 1989). In addition, there is an increase in the number 
of immature OLs and increased apoptosis of differentiated OLs (Knapp et al., 1986; Skoff, 
1995).  
 14 
The myelin-deficient (md) rat is another Plp mutant rodent that exhibits severe 
hypomyelination in the CNS similar to jp mice (Dentinger et al., 1982). These rats are 
characterized by a point mutation (A-C transversion) in exon three of the Plp gene, which causes 
a threonine to proline (T75P) substitution. This mutation induces a conformational change and 
disrupts the integration of PLP within the membrane (Boison and Stoffel, 1989). The offspring 
develop tremors, ataxia and seizures, and die after 24-28 days (Boison and Stoffel, 1989). 
Furthermore, at 17-20 days of age these rats display axonal swellings (Dentinger et al., 1982). 
Most of the axons are unmyelinated and only a few are myelinated with non-compact myelin like 
loops of membrane (Dentinger et al., 1982; Duncan et al., 1987).  
In addition to the jp mouse and the md rat, importance of the Plp gene was studied using 
Rumpshaker (rsh) mouse (Griffiths et al., 1990), Shaking pup (Nadon et al, 1990) and paralytic 
tremor (Pt) rabbit (Tosic et al., 1993), all of which have unique missense mutations of 
the Plp gene causing single amino acid substitutions. In all these mutants, distinction between 
IPL and MDL is lost with less compaction at the IPL. Interestingly, the CNS is severely affected 
with very little defects noted in the PNS in these Plp mutants, highlighting the predominant role 
of PLP in CNS.   
In addition to spontaneous mutants, the Plp gene was studied with two lines of mice with 
targeted mutations. In Plp deficient mice, the splice site at exon three is disrupted leading to 
aberrant splicing of the primary transcript. Small diameter axons were unmyelinated while the 
myelin in the myelinated axons was uncompacted with normal MDL and missing IPL (Boison 
and Stoffel, 1994). In Plp-/- mice, the translation start site was disrupted (Klugmann et al., 1997). 
In contrast to the naturally occurring rsh mutant that showed defects in motor performance as 
early as six months of age (Klugmann et al., 1997), Plp-/- mice displayed motor defect only after 
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16 months of age (Griffith et al., 1998). Myelin compaction was normal with condensed IPL 
resembling MDL in Plp-/- mice. However, axonal swellings and degeneration was observed more 
predominantly in small caliber axons in the Plp-/- mice (Griffith et al., 1998; Rosenbluth et al., 
2006).  
In addition, deletion of the intronic splicing enhancer (ISE) in Plp (Plp-ISEdel mutant 
mouse) reduced Plp /Dm20 mRNA and protein ratio (Wang et al., 2008). Furthermore, the 
myelin sheath of Plp-ISEdel mutant mice was ultrastructurally abnormal with rare axonal 
degeneration (Wang et al., 2008). In addition, axonal injury and gliosis were increased during 
two to four months of age in Plp-ISEdel mutant mice (Bachstetter et al., 2013). In humans, 
deletion of a 19 bp sequence within intron three of the Plp reduced the Plp/Dm20 mRNA ratio 
and was associated with myelin instability and axonal loss (Hobson et al., 2002).  
2.2.3 Myelin-associated glycoprotein (MAG) 
MAG is a 100 kDa glycoprotein that is enriched in the inner tongue (adaxonal) of the 
oligodendrocyte membrane (Quarles et al., 2006). MAG constitutes 1% of the myelin proteome 
(Table 2.1) (Jahn et al., 2009). Mag is located on chromosome 7 and has 13 exons (Barton et al., 
1987). Exon 12 harbors a stop codon and alternative splicing of exon 12 generates an isoform 
with longer C-terminus, L-MAG (lacks exon 12) and another isoform with truncated C-terminus, 
S-MAG (Lai et al., 1987). L-MAG predominates early in development during active myelination 
of the CNS whereas S-MAG increases during development and becomes predominant in adults 
(Lai et al., 1987). In the Mag-/-mice, myelination in the PNS is affected more severely compared 
to the CNS (Li et al., 1994). Subtle ultrastructural abnormalities such as shortened periaxonal 
collar and double myelin sheath are observed in the CNS, with an increase in severity with aging 
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(Uschkureit et al., 2000). Loss of Mag results in increased MBP expression only in the PNS but 
not in the CNS (Li et al., 1994; Uschkureit et al., 2000).  
A better understanding of the role of Mag in myelination was achieved by generating 
double and triple knockout with Plp and Mbp (Table 2.3) (Uschkureit et al., 2000). In Plp-/-Mag-/- 
double mutant mice, axon degeneration is observed with cognitive and motor defects.  In Plp-/-
Mbp-/-Mag-/- triple mutant mice, hypomyelination is observed with pseudomyelin. Both Plp-/-
mice and Mag-/-mice exhibit normal phenotypic, while Plp-/-Mag-/- double mutants exhibit tremor 
beginning at four weeks of age. However, single (Plp-/-mice and Mag-/-mice) and double mutants 
(Plp-/-Mag-/- mice) possess normal life span (Uschkureit et al., 2000). Conversely, Mbp-/- 
(shiverer) mutants die around 3 months of age, while Plp-/-Mbp-/-Mag-/- triple mutants have a life 
span of around 7-9 months (Uschkureit et al., 2000). Axonal degeneration occurred at later stage 
of life in Plp-/- mice (Griffiths et al., 1998) while in double mutants axonal degeneration occurs 
at postnatal day (P) 40 (Table 2.3). Furthermore, in Mbp-/- (shiverer) mutants, OLs were unable 
to wrap axons, whereas in Plp-/- Mag-/- double mutants and in Plp-/-Mbp-/- Mag-/- triple mutants, 
OLs wrap large axons with few lamellae (Uschkureit et al., 2000). To sum up, deletion of Mag in 
Plp-/- or Plp-/-Mbp-/- double mutants causes an early onset of axon degeneration and shortened 
lifespan (Table 2.3) (Uschkureit et al., 2000). 
2.2.4 Myelin oligodendrocyte glycoprotein (MOG) 
MOG is a 28 kDa glycoprotein present in the outer tongue (abaxonal) of the 
oligodendrocyte membrane (Brunner et al., 1989). Similar to MAG, MOG constitutes 1% of the 
total myelin proteome (Table 2.1) (Jahn et al., 2009). MOG protein belongs to the 
immunoglobulin superfamily and the Mog gene is located within the major histocompatibility 
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complex gene locus (Pham-Dinh et al., 1993). MOG protein expression initiates during the onset 
of myelination and hence is considered a marker of OL maturation (Scolding et al., 1989). 
However, Mog null mice did not show any physical, behavioral, myelin structural or axonal 
abnormalities (Delarasse et al., 2003).  
2.2.5 2', 3'-Cyclic nucleotide 3'-phosphodiesterase (CNP) 
CNP is another myelin protein, which constitutes about 4% of the total myelin proteome 
(Table 2.1) (Jahn et al., 2009). Cnp encodes two protein isoforms due to the presence of 
alternative translation start sites in exons one and two.  The protein isoforms appear as a doublet 
with a molecular mass of 46 kDa and 48 kDa (O’Neill et al., 1997). The enzymatically active 
CNP hydrolyzes 2', 3'-cAMP preferably, in addition to cGMP, cCMP and cUMP. CNP is 
predominantly present in the soma of OLs (Nishizawa et al., 1985) and hence, is associated with 
the non-compact regions such as the inner mesaxon and paranodal loops (Braun et al., 1988; 
Trapp et al., 1988). Disruption of Cnp in mice leads to axonal swelling and neurodegeneration 
with increased reactive gliosis (Lappe-Siefke et al., 2003). In addition, motor performance is 
reduced at six months of age and the mortality increased around 13 months of age (Table 2.3) 
(Lappe-Siefke et al., 2003). Recently, CNP was reported to associate with actin cytoskeleton to 
counteract membrane compaction by MBP, thereby maintaining the cytoplasmic channels within 
the myelin compartment (Snaidero et al., 2017). 
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Table 2.1: Relative abundance of myelin proteins in CNS determined by mass spectrometry 
 
 
 
 
Myelin protein  Percentage 
(%) in CNS 
myelin 
proteome  
Localization Function 
Proteolipid protein 
(PLP) 
17% Compact 
myelin 
• Extracellular 
membrane protein 
• Forms the intraperiod 
line 
• Compaction  
Myelin basic protein 
(MBP) 
8% Compact 
myelin 
• Intracellular 
membrane protein 
• Forms the major 
dense line 
• Adhesion and 
Compaction 
Cyclic nucleotide 
phosphodiesterase 
(CNP) 
4% Noncompact 
myelin 
• 2', 3'-cAMP        
metabolism 
• Counteract 
membrane 
compaction 
Myelin 
oligodendrocyte 
glycoprotein 
(MOG) 
1% Abaxonal 
layer 
• Maintenance of 
myelin integrity 
Myelin-associated 
glycoprotein 
(MAG) 
1% Noncompact 
myelin 
• Maintenance of 
myelin integrity 
 
Sirtuin 2 (SIRT2) 1% Noncompact 
myelin 
• Deacetylase 
• OL maturation  
 19 
Table 2.2: Spontaneous mutations of myelin specific genes and their impact on myelination 
 
Names of 
mutants 
Affected 
gene 
Inheritance Observed defects References	
Jimpy mouse (jp), 
rumpshaker 
mouse (rsh), 
myelin-deficient 
(md) rat, shaking 
pup, paralytic 
tremor (Pt) rabbit 
Proteolipid 
protein 
(Plp) 
X-linked • Hypomyelination in 
the CNS  
• Variable degrees of 
oligodendrocyte 
death  
• Decreased 
compaction at IPL  
Quarles et al., 
2006; 
Campagnoni 
and Skoff, 
2001; Dentinger 
et al., 1982; 
Duncan et al., 
1989	
Shiverer mouse, 
myelin deficient 
(mld) mouse 
Myelin 
basic 
protein 
(Mbp) 
Autosomal 
recessive 
• Severe CNS    
hypomyelination 
• Tremor 
• Shortened life span 
• Failure in the 
compaction of MDL 
Quarles et al., 
2006; 
Campagnoni 
and Skoff, 
2001; Chernoff, 
1981; Matthieu 
et al., 1992; 
Readhead and 
Hood, 1990	
quaking viable 
mouse (qkv/qkv) 
Quaking 
(qkI5, qkI6 
and qkI7) 
Autosomal 
recessive 
• Severe CNS 
hypomyelination 
• Lack of compaction 
and poorly developed 
nodes 
• Defect in 
oligodendrocyte 
development 
• Tremor at the caudal 
part of the trunk 
Sidman et al., 
1964; 
Wisniewski and 
Morell, 1971; 
Hardy, 1998a; 
Chenard and 
Richard, 2008).  	
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Table 2.3: Phenotype and morphology changes in the myelin of mutant mice 
 
Data published in a Uschkureit et al., 2000; bLappe-Siefke et al., 2003 
Transgenic 
lines 
Morphology of myelin Morphology of 
axons 
Phenotype Life 
span 
aMbp
-/-
 • Hypomyelination in 
CNS 
• Increase in the number 
of OLs 
• Not altered 
compared to wild-
type 
• Tremor 
• Lack of 
motor 
coordination 
3-4 
months 
aPlp
-/-
 • Dissociation of IPL 
• Decompact myelin 
membrane 
• Late onset of 
degeneration in 
CNS 
• Normal 
phenotype 
>24 
months 
aMag
-/-
  • Reduced cytoplasmic 
collar 
• Doubled myelin sheaths 
in CNS 
• Late onset of 
degeneration in 
CNS 
• Normal 
phenotype 
>24 
months 
aPlp
-/-
Mbp
-/-
  • Hypomyelination in 
CNS 
• Pseudomyelin in CNS 
• Increase in the number 
of OLs 
• Late onset of 
degeneration in 
CNS 
• Tremor 
• Lack of 
motor 
coordination 
>24 
months 
aPlp
-/-
Mag
-/-
  • Dissociation of IPL  
• Decompact myelin 
membrane 
 
• Early onset of 
degeneration in 
CNS 
• Tremor 
• Lack of 
motor 
coordination 
>24 
months 
aPlp
-/-
Mbp
-/-
Mag
-/-
  
• Hypomyelination in 
CNS 
• Pseudomyelin in CNS 
• Increase in the number 
of OLs 
• Early onset of 
degeneration in 
CNS 
• Tremor 
• Lack of 
motor 
coordination 
7-9 
months 
bCnp-/- • Disrupts non compact 
myelin regions 
(mesoaxon and 
paranodal loops) 
• Increased reactive 
gliosis 
• Axonal swelling 
and 
neurodegeneration 
• Normal 
phenotype 
13 
months 
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2.3 Demyelination  
Loss of myelin forming OLs or the myelin sheath results in demyelination (Love, 2006; 
Kotter et al., 2011; Miron et al., 2011). Demyelination slows down the action potential 
propagation along axons, which eventually leads to axonal degeneration. In the CNS, 
demyelination is caused by several factors such as inflammation, viral infections, metabolic 
problems, hypoxia and focal compression (Love, 2006). However, the inflammatory 
demyelinating disease, multiple sclerosis (MS), is the most prevalent in the CNS (Hanafy and 
Sloane, 2011; Kotter et al., 2011; Miron et al., 2011).  
2.3.1 Multiple sclerosis  
MS is the leading cause of neurological disability in adults between the age of 20-50 and 
appears to be three times more common in females (Milo and Miller, 2014). MS has an incidence 
rate of 140 and 108 in 100,000 in North America and Europe, respectively (Multiple Sclerosis 
International Federation, 2013). Canada has one of the highest incidences of MS in the world 
(World Health Organization, 2008). MS is a complex disease caused by genetic susceptibility, 
immune system’s attack and environment (Gross and Jager, 2011). However, the exact 
pathogenic mechanism underlying the cause of disease is not yet fully understood.  MS is 
characterized as a prototypic immune-mediated disorder of the CNS mediated by autoreactive T 
cells against myelin proteins (Hafler et al., 2005; Compston and Coles, 2008). Upon entry into 
the CNS, these myelin-reactive T cells cause multiple areas of inflammation, demyelination, glial 
scarring (sclerosis), perivascular leukocyte infiltration, axonal damage and neuronal loss leading 
to the formation of lesions in brain and spinal cord (Frohman et al., 2005; Peterson and Fujinami, 
2007; Milo and Miller, 2014). Demyelinating lesions display heterogeneity in the pathology and 
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are categorized into four distinct patterns (pattern I to IV). These include macrophage associated 
demyelination in pattern I, complement and antibody mediated demyelination in pattern II, 
lesions with oligodendrocyte apoptosis as pattern III and lesions with oligodendrocyte 
degeneration as pattern IV (Lucchinetti et al., 2000) 
2.3.2 Clinical subtypes of MS  
The clinical course of MS is classified into four different types based on the progression 
and recovery of the disease (Lublin and Reingold, 1996; Hurwitz, 2009) (Fig. 2.3): 
1. Relapsing-remitting MS (RRMS):  
Nearly 85% of MS patients develop this form of MS at early onset (Jacobs et al., 1999). These 
patients generally recover after the first few weeks of attack, but the recovery is generally 
incomplete. This type of MS is characterized by inflammation, demyelination, axonal transaction 
and remyelination (Lublin and Reingold, 1996). With prolonged disease, plaques are formed in 
the white matter of the brain (Thompson et al., 1990). 
2. Secondary-progressive MS (SPMS):  
RRMS after prolonged progression of the disease could be transformed into SPMS (Hurwitz, 
2009). Approximately 50% of RRMS cases transform to SPMS after 10 years (Milo and Miller, 
2014). Severity of the motor dysfunction increases with enlarged ventricles. Thinning of corpus 
callosum (CC) occurs with atrophy in the whole brain and spinal cord (Lublin and Reingold, 
1996).  
3. Primary-progressive MS (PPMS): 
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This type of MS is characterized by gradual progression of the symptoms without any sign of 
relapses interrupted with brief periods of remittance (Lublin and Reingold, 1996). These patients 
have difficulties in walking and other motor dysfunction. Lesions in the brain are small; 
however, spinal cord lesions are large and numerous (Lublin and Reingold, 1996). PPMS is most 
commonly seen in males and older patients (Hurwitz, 2009). 
4. Progressive-relapsing MS (PRMS):  
These patients experience a gradual worsening of the disease from onset accompanied by 
progressive relapses with or without remittance (Lublin and Reingold, 1996). This type of MS is 
rare and occurs in about 5% of the MS patients (Jacobs et al., 1999).  
Recently, additional subtypes such as clinically isolated syndrome (CIS) and 
radiologically isolated syndrome (RIS) were included in clinical MS subtypes (Milo and Miller, 
2014; Lublin et al., 2014). CIS refers to first clinical presentation of neurological disability or 
inflammatory demyelination that could potentially be MS. The RIS subtype is categorized based 
on findings with imaging which shows MS lesions without any clinical symptoms (Milo and 
Miller, 2014; Lublin et al., 2014).  
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Figure 2.3: Clinical subtypes of multiple sclerosis. MS is classified into four forms depending 
on the clinical characteristics. Relapsing-remitting MS (RRMS) develops during the initial stages 
of MS and is characterized by relapse with subsequent impairment in recovery.  Prolonged 
progression of RRMS results in Secondary-progressive MS (SPMS). Primary-progressive MS 
(PPMS) is characterized by gradual progression with or without infrequent relapses with short 
periods of remittance. Continued progression of the disease worsens the condition resulting in 
Progressive-relapsing MS (PRMS), which is accompanied by minor relapses (adapted from 
Lublin and Reingold, 1996). 
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2.3.3 Animal models of MS 
Three animal models are commonly used to study MS. These include: 1) experimental 
autoimmune encephalomyelitis (EAE), 2) Theiler’s murine encephalomyelitis virus (TMEV)-
induced demyelination, and 3) chemical-induced demyelination. EAE is the most widely used 
animal model as it reflects many clinical, immunological and pathological features of human MS 
(Gold et al., 2006; Simmons et al., 2013; Bittner et al., 2014). EAE is a T cell-mediated disease 
that targets the myelin sheath in the white matter (Goverman et al, 2005). EAE is induced by 
immunization with crude brain tissue or proteins and peptides (active induction) derived from 
components of the CNS such as MOG, PLP, or MBP (Fritz et al., 1983; Amor et al., 1993; Amor 
et al., 1994; Gold et al., 2006; Mix et al., 2010; Bittner et al., 2014; Procaccini et al., 2015). EAE 
is also induced via adoptive transfer of activated myelin-specific T cells isolated from 
immunized animals into naive recipients (Linington et al., 1993; Mannara et al., 2012). In order 
to increase susceptibility, Bordetella pertussis toxin is injected, which may induce hyperacute 
EAE (Kamradt et al., 1991). The exact mechanism by which pertussis toxin provokes EAE has 
not been fully elucidated but non-selective expansion of T cells and vascular changes in the CNS 
may occur, which in turn results in the breakdown of the blood-brain-barrier and increased 
interferon-γ production (Hofstetter et al., 2002).  
EAE can be provoked as an acute, chronic, or relapsing-remitting disease course that is 
dependent on the type of antigen, dosage of antigen, method of induction and type of animal 
used (Berard et al., 2010; Mix et al., 2010; Procaccini et al., 2015).  For example, immunization 
of SJL/J mice with PLP139-151 peptide induces a relapsing-remitting subtype (Tuohy et al., 1989); 
immunization of C57BL6/J mice with MOG35-55 peptide at higher dose induces chronic disease 
(Tompkins et al., 2002), while at a lower dose, a relapsing-remitting disease course is induced 
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(Berard et al., 2010). In addition to the classical myelin proteins and peptides, paranodal protein 
NF155 (Mathey et al., 2007) and non-myelin components such as neuronal membrane protein 
NF186 (Mathey et al., 2007), neuronal cytoskeletal protein neurofilament M (Krishnamoorthy et 
al., 2009) and astrocyte protein S100β (Kojima et al., 1997) are reported to promote the 
autoimmune pathogenesis of EAE.  
EAE induction results in extensive demyelination, axonal and neuronal loss, microglial 
activation and marked gliosis (Hampton et al., 2008; Berard et al., 2010; Mix et al., 2010). 
Hence, EAE models are widely used to investigate the pathological mechanisms responsible for 
disease progression, neurodegeneration and for the development of therapy for neuroprotection. 
EAE models have been criticized recently because of the failure in reproducing therapies in 
human MS (Longbrake and Racke, 2009; Baker and Amor, 2014; Procaccini et al., 2015). This 
could be attributed to genetic and environmental factors that contribute to the complexity of MS 
in humans. Remyelination does not occur properly in EAE models because of infiltrating 
macrophages and microglia in the lesions (Procaccini et al., 2015). In addition, EAE was 
reported to primarily affect spinal cord white matter rather than brain as seen in human MS. 
However, forebrain demyelination has been reported recently in MOG induced chronic EAE 
(Mangiardi et al., 2011; Girolamo et al., 2011).  
 Theiler’s murine encephalomyelitis virus is single stranded RNA picornavirus that can 
replicate and persist within the CNS (Denic et al., 2011; Mecha et al., 2013). Although Epstein-
Barr virus infection has been linked to MS as an environmental risk factor (Ascherio et al., 2001; 
Ascherio and Munger, 2007), persistent viral infection of the CNS has not been reported in 
humans. TMEV induces early acute disease followed by chronic progressive demyelination in 
mice similar to MS pathology. However, TMEV induces demyelination only in mice and not in 
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other rodents or primates (Denic et al., 2011). In TMEV induced demyelination, axonal damage 
occurs first followed by inflammatory demyelination (Tsunoda et al., 2003; Tsunoda et al., 2007) 
whereas in MS demyelination precedes axonal damage.  
To study remyelination following demyelination, chemical induced demyelination using 
cuprizone and lysolecithin are used (Blakemore and Franklin, 2008). Cuprizone 
(biscyclohexanone-oxaldihydrazone) is a copper chelator, which is usually administered through 
the diet of mouse or rat. Cuprizone specifically targets mature OL by inhibiting copper-
dependent mitochondrial enzymes that disturb energy metabolism in OLs, resulting in OL cell 
death and demyelination followed by activation of astrocyte and microglia (Benardais et al., 
2013). Removal of cuprizone from the diet induces remyelination (Matsushima ad Morell, 2001). 
Lysolecithin is an activator of phospholipase A2, which is injected (mouse, rat and primate) to 
induce focal areas of demyelination (Blakemore and Franklin, 2008). However, the chemical 
induced demyelination does not reflect inflammatory demyelination in MS (Blakemore and 
Franklin, 2008). 
2.4 Quaking 
Given the role played by the myelin structural genes in compact myelin biogenesis and 
the importance of myelin and myelin forming OLs in MS, it is pertinent to understand the 
regulation of these myelin structural genes during OL development and myelination. The RNA 
binding protein, quaking (QKI), is known to control the expression of several myelin transcripts 
either directly or indirectly for proper OL development and myelination (Chen et al., 2007b; 
Larocque et al., 2005; Li et al., 2000; Wu et al., 2002; Zhao et al., 2006a; Zhao et al., 2010). 
Hence, QKI is considered to be a master regulator of myelin specific gene expression. 
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The quaking (qkI) gene contains nine exons (Kondo et al., 1999), which gives rise to 
three major isoforms due to alternative splicing such as QKI-5, QKI-6, and QKI-7 (Ebersole et 
al., 1996). All the three isoforms have the same conserved QUA1, KH (hnRNP K homology) and 
QUA2 domains in the N-terminus, which plays a role in RNA binding and dimerization 
(Ebersole et al., 1996; Kondo et al., 1999; Wu et al., 1999; Beuck et al., 2012). However, the 
three isoforms carry distinct C-terminus that determines their subcellular localization (Wu et al., 
1999). QKI-5 alone has the nuclear localization signal in the C-terminal (Wu et al., 1999) and is 
present in the nucleus while QKI-6 and QKI-7 are present in the cytoplasm. Since all the QKI 
isoforms have the same RNA binding domain, they may have similar selectivity and affinity 
towards their target transcripts (Galarneau and Richard, 2005). QKI selectively binds to the QKI 
Response Element (QRE) with the sequence ACUAAY or AUUAAY within the 3'UTR of its 
target mRNA (Ryder and Williamson, 2004; Galarneau and Richard, 2005; Hafner et al., 2010). 
QKI plays a role in pre-mRNA splicing, mRNA localization, transport, mRNA stability, and 
translation efficiency of the target transcripts (Galarneau and Richard, 2009).  
Quaking viable (qkv/qkv) mutant mice carries a deletion of ~1.1 Mbp region in 
chromosome 17 upstream of qkI gene which includes the promoter region of the qkI gene 
(Ebersole et al., 1996), part of the Parkin gene and the entire Parkin coregulated gene (Lockhart 
et al., 2004; Lorenzetti et al., 2004a; Lorenzetti et al., 2004b). These qkv/qkv mutant mice display 
a quaking phenotype with increased tremor at the caudal part of the trunk (Sidman et al., 1964). 
These mice are characterized by severe hypomyelination with thin myelin sheath, lack of 
compaction and poorly developed nodes (Wisniewski and Morell, 1971). In addition, there is 
reduction in the expression of myelin proteins and number of mature OLs in the CNS (Table 2.2) 
(Hardy, 1998a; Chenard and Richard, 2008). The dysmyelination and tremor phenotype observed 
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in qkv/qkv mutant mice is caused by deletion of the qkI locus, as Parkin null mice do not display 
these phenotypes (Itier et al., 2003). 
The qkI gene is located on chromosome 6q26 in humans, which lies within the region of 
6q25-6q27, a susceptibility locus associated with schizophrenia (SCZ) (Lindholm et al., 2001). 
In addition, a 0.5 Mb haplotype region which was found to be inherited among the SCZ patients 
lies within the qkI gene (Aberg et al., 2006a). Furthermore, the mRNA expression of qkI-7 was 
severely reduced in the SCZ brains (Aberg et al., 2006a), suggesting a post-transcriptional 
misregulation of qkI and its importance in the etiology of SCZ. Additionally, many of the defects 
observed in qkv/qkv mutant mice such as a lack of compaction of the myelin sheath and a 
reduction in the number of myelin lamellae have also been observed in patients with SCZ 
(Takahashi et al., 2011). Recently, the structural abnormalities in nodal, internodal and paranodal 
region with altered myelin thickness, uncompact myelin and abnormal distribution of ion 
channel complexes in the SCZ brains similar to that of qkv/qkv brains was proposed to be the 
reason for functional impairment in SCZ patients (Rosenbluth and Bobrowski-Khoury, 2013). 
Furthermore, several myelin-associated genes, which are downstream targets of QKI, were 
downregulated in the white matter of SCZ patients, including Mbp, Plp and Mag (Aberg et al., 
2006a; Aberg et al., 2006b).  
2.4.1 Expression pattern of QKI during OL development  
The expression of QKI is abundant in myelinating glial cells in CNS as well as in PNS 
(Hardy et al., 1996). Expression of qkI mRNA transcripts, qkI-5 and qkI-6 are detected early in 
embryonic development at E7.5 in neuroepithelium of head folds (Ebersole et al., 1996). The 
QKI-5 isoform is expressed earliest during embryonic and fetal development, with expression 
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decreasing during the peak of myelination (3-4 weeks in rodents and 2-3 years in humans) 
(Ebersole et al., 1996; Lauriat et al., 2008). In contrast, QKI-6 and QKI-7 are not expressed until 
closer to birth, with highest expression at the peak of myelination. The expression of QKI-6 and 
7 increases with increase in age both in mice and humans (Ebersole et al., 1996; Lauriat et al., 
2008). In addition, in vitro differentiation of primary OL cells showed increase in the expression 
of QKI-6 and QKI-7 as the OLs differentiate, whereas the expression of QKI-5 decreased during 
OL differentiation (Tyler et al., 2011). This is consistent with the findings that QKI-6 and QKI-7 
play a potential role in promoting the maturation of OLs and myelination (Chen et al., 2007b).  
Expression of QKI in the NSCs has been found to switch the NSC from neurogenesis to 
gliogenesis (Hardy, 1998b). During neuron-glia fate specification, a subpopulation of NSCs in 
the VZ expressing high levels of QKI-5 migrates away and enters the glial pathway expressing 
the markers of OL progenitor cells. In addition, the expression of qkI is silenced in the cells that 
are determined to become neurons (Hardy, 1998b). Furthermore, the cytoplasmic isoforms QKI-
6 and QKI-7 have also been demonstrated to promote glial cell fate specification from 
multipotent neural progenitors in vivo in mice (Larocque et al., 2005).  
2.4.2 Role of QKI in fine-tuning OL differentiation 
The importance of QKI in OL differentiation has been demonstrated using knockdown 
and overexpression studies both in vitro and in vivo (Larocque et al., 2005; Chen et al., 2007b). 
All three isoforms of QKI promote OL differentiation with varying efficiency (Chen et al., 
2007b). QKI plays a role in OL differentiation by regulating cell cycle and cytoskeletal 
organization.  
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2.4.2.1 QKI in cell cycle control  
OL differentiation is initiated soon after OLs exit cell cycle and cease to proliferate. 
Cyclin-dependent kinase (CDK) inhibitors turn off the cell cycle (Sherr and Roberts, 1999). 
CDK inhibitor p27Kip1 is involved in promoting cell cycle exit and differentiation in OLs 
(Casaccia-Bonnefil et al., 1997). The p27Kip1 mRNA harbors QRE that allows QKI to bind, 
stabilize and increase p27Kip1 protein expression (Larocque et al., 2005) (Fig. 2.4). Although 
p27Kip1 can effectively arrest cell cycle, ectopic expression of p27Kip1 alone is not sufficient to 
promote OL differentiation (Tang et al., 1999). In addition, loss of p27Kip1 increases the number 
of proliferating OLs and reduced the number of differentiating OLs but did not alter the initiation 
of OL differentiation (Casaccia-Bonnefil et al., 1997; Casaccia-Bonnefil et al., 1999). This 
indicates that qkI could regulate the expression of additional target mRNA that promotes cell 
cycle arrest and OL differentiation. 
2.4.2.2 QKI in reorganization of cytoskeleton and process outgrowth 
In addition to cell cycle arrest, OL differentiation involves process outgrowth, which is 
characterized by cytoskeletal rearrangements (Bauer et al., 2009; Michalski and Kothary, 2015). 
Cytoskeletal rearrangements involve continuous polymerization and depolymerization of the 
cytoskeletal proteins through addition or removal of monomer units (Fletcher and Mullins, 
2010). Process outgrowth in OL is regulated by increased levels of proteins involved in 
polymerization and decreased levels of proteins involved in depolymerization (Liu et al., 2003). 
Actin interacting protein 1 (AIP-1) plays a role in actin disassembly and inhibits OL 
differentiation (Doukhanine et al., 2010). Aip-1 mRNA contains QRE at the 3ʹ UTR that 
facilitates the binding of QKI (Doukhanine et al., 2010). Interestingly, qkv/qkv mutant mice had 
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increased levels of AIP-1 expression in OLs (Doukhanine et al., 2010). Overexpression of qkI 
destabilizes the Aip-1 mRNA and reduced the abundance of Aip-1 mRNA (Fig. 2.4).  
Another target of QKI that plays a role in cytoskeletal organization of OL is microtubule 
associated protein 1B (MAP1B). The 3ʹ UTR of Map1B comprises several QREs, which aid in 
interaction with QKI (Zhao et al., 2006a). Overexpression of qkI increases the expression of 
MAP1B, whereas knockdown of qkI reduces the expression of MAP1B in OLs (Fig. 2.4). This 
indicates that QKI interacts with Map1B during OL differentiation and increases its protein 
expression (Zhao et al., 2006a). Although MAP1B is expressed both in neurons and OLs, 
expression of QKI exclusively in OLs offers OL specific MAP1B regulation and not in neurons 
(Zhao et al., 2006a). It is plausible that QKI might interact with several other cytoskeletal 
proteins to regulate the morphological changes in OLs, but this remains to be explored. 
2.4.3 Role of QKI in myelination 
QKI has been proposed to control myelination by regulating stability, splicing and 
localization of target mRNAs (Fig. 2.4). 
2.4.3.1 mRNA stability 
In addition to the aforementioned mRNAs such as Map1B (Zhao et al., 2006a), Aip-1 
(Doukhanine et al., 2010) and p27Kip1 (Larocque et al., 2005), QKI is involved in the stabilization 
of myelin specific genes such as Mbp, Plp and Mag for proper myelinogenesis (Li et al., 2000; 
Roth et al., 1985; Sorg et al., 1986; Sorg et al., 1987; Wu et al., 2002; Zhao et al., 2010). The 
ratio of MBP isoform 14/21.5 (higher 14kDa MBP and lower 21 kDa MBP expression) is 
considered an index of myelin maturation, which increases during the peak of myelination 
(Campagnoni et al., 1978). In qkv/qkv mutant mice, the quantity of Mbp mRNA in the myelin is 
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reduced and there is isoform preferential destabilization of Mbp mRNA encoding 14 kDa protein 
(Li et al., 2000). The removal of 3ʹ UTR in the Mbp mRNA in vitro reduces its interaction with 
QKI, suggesting that 3ʹ UTR in the Mbp mRNA is stabilized by the QKI interaction (Li et al., 
2000). The expression of Plp mRNA is also reduced in qkv/qkv mutant mice, implicating the role 
of QKI in stabilizing Plp mRNA (Sorg et al., 1987). Interestingly, transgene overexpression of 
qkI-6 in qkv/qkv mutant mice was able to rescue the destabilization of Mbp and Plp mRNA with 
higher efficiency towards Mbp compared to Plp mRNA (Zhao et al., 2006b). 
Recently, QKI has been shown to bind to mRNAs of other RNA binding proteins such as 
heterologous nuclear ribonucleoprotein A1 (hnRNPA1) (Zearfoss et al., 2011). QKI binds to the 
QRE present in the 3ʹ UTR of hnRNPA1 mRNA, stabilizes the mRNA and inhibits its translation 
(Zearfoss et al., 2011). Stabilization mediated by QKI can either promote (p27Kip1) or inhibit 
(hnRNPA1) the downstream translation of target mRNA to protein (Larocque et al., 2005; 
Zearfoss et al., 2011). In addition, QKI-6 stabilizes and represses the expression of two canonical 
splicing factors, hnRNPF and hnRNPH (Mandler et al., 2014). Repression of hnRNPF and 
hnRNPH facilitates QKI-6 to regulate the alternative splicing of polyguanine containing 
transcripts and rescue aberrant splicing in qkv/qkv mutant (Mandler et al., 2014). 
2.4.3.2 Localization of myelin transcripts 
The transcription of Mbp increases during the active phase of myelination. The 
synthesized mRNA is transported along the OL processes into the myelin, where it is translated 
and incorporated into the myelin sheath (Ainger et al., 1993). It is pertinent to note that the OLs 
in the qkv/qkv mutants are defective in exporting Mbp mRNA from the nucleus (Barbarese, 
1991). All three QKI isoforms have been shown to directly bind to Mbp mRNA and control the 
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subcellular localization of Mbp transcripts (Larocque et al., 2002). Overexpression of QKI-5 in 
primary mouse OL cultures results in the retention of Mbp mRNA in the nucleus, which results 
in lower protein expression and reduced levels of mRNA transport to OL processes (Larocque et 
al., 2002). The presence of QKI-6 and QKI-7 releases the QKI-5 mediated nuclear retention of 
Mbp mRNA (Larocque et al., 2002).  
2.4.3.3 Regulation of alternative splicing 
QKI can regulate the splicing of Mbp, Plp and Mag mRNA (Wu et al., 2002; Zhao et al., 
2010). Homozygous qkv/qkv mutants display an imbalance in the ratio of alternative splice 
variants for Mbp, Plp, and Mag. In qkv/qkv mutant, dysregulated splicing results in reduction of 
the L-MAG (Fujita et al., 1988; Fujita et al., 1990; Wu et al., 2002; Zhao et al., 2010). The 
nuclear isoform QKI-5 binds to the 53 nucleotide QRE in the intronic region of Mag and 
represses the inclusion of exon 12 (Wu et al., 2002). Furthermore, cytoplasmic isoform QKI-6 
also can bind to and rescue the dysregulated MAG splicing (Zhao et al., 2010). Additionally, 
QKI is also found to modulate the splicing of Mag indirectly by regulating the expression of 
hnRNPA1, which is expressed highly in qkv/qkv mutant mice (Zhao et al., 2010; Zearfoss et al., 
2011). Microarray analysis revealed that a subset of QKI targets is co-regulated by hnRNPA1, 
suggesting that hnRNPA1 is an important target of QKI in regulating myelin specific gene 
expression (Zearfoss et al., 2011). 
Since the QKI isoforms vary only in their C-terminus, the distinctive functional 
differences between the three isoforms is largely attributed to the location of the target mRNA, 
combined with differences in spatial and temporal expression of the three isoforms (Larocque et 
al., 2002; Zhao et al., 2010). 
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Figure 2.4: Potential roles of quaking in oligodendrocyte differentiation and myelination. In 
OLs, QKI post-transcriptionally regulates the expression of several genes necessary for OL 
differentiation by four different mechanisms (indicated in black boxes), which include mRNA 
stabilization, splicing, sub-localization and export. Stabilization of mRNA by QKI results in 
either mRNA degradation or increased translation. The target mRNAs of QKI are indicated in 
the grey box beside each mechanism. 
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In addition to myelin structural proteins (MBP and PLP), sirtuin 2 (SIRT2) protein 
expression is also reduced in the myelin sheath of qkv/qkv mice throughout development and into 
adulthood (Zhu et al., 2012). QKI regulates the transport of SIRT2 to myelin through PLP (Zhu 
et al., 2012). Yet, the relationship between QKI and Sirt2 during OL differentiation is largely 
unknown. 
2.5 Sirtuin2 
Sirtuin2 (SIRT2) is predominantly expressed in the cytoplasm of OLs (North et al., 2003; 
Li et al., 2007a) and constitutes 1% of the myelin proteome (Jahn et al., 2009). 
2.5.1 Mammalian sirtuins 
Sirtuins (SIRTs) are class III protein deacetylase enzymes, which depend on the cofactor 
nicotinamide adenine dinucleotide (NAD+) for their enzymatic activity (Brachmann et al., 1995; 
Frye, 2000; Michan and Sinclair, 2007). SIRTs are evolutionarily conserved from bacteria to 
mammals (Brachmann et al., 1995; Frye, 2000; North et al., 2003). In mammals, seven SIRTs 
(SIRT1 to SIRT7) have been identified that are classified based on their homology to yeast Sir2 
(silent information regulator 2) protein (Blander and Guarente, 2004; Frye, 2000). All the SIRTs 
have a conserved NAD+-dependent catalytic core domain comprised of 275 aa, which display 
either NAD+-dependent deacetylase activity and/or mono-ADP-ribosyltransferase activity (Fig. 
2.5). The flanking N-terminal and C-terminal regions of SIRTs vary in length and amino acid 
sequence. The mammalian SIRTs are heterogeneously localized in sub-cellular compartments 
with differing deacetylase and/or ADP-ribosyltransferase activity (Fig. 2.6). SIRT1, SIRT6 and 
SIRT7 are mainly localized in the nucleus (Frye, 2000; Michishita et al., 2005), whereas SIRT2 
is localized in the cytoplasm (North et al., 2003; Michishita et al., 2005). SIRT3, SIRT4 and 
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SIRT5 are localized in mitochondria (Michishita et al., 2005). SIRT1 and SIRT2 are reported to 
shuttle between the nucleus and cytoplasm (Tanno et al., 2007; North and Verdin, 2007a). In 
addition to different sub-cellular localizations, the mammalian SIRTs are differentially expressed 
in various organs and tissues (Kelly, 2010). This suggests that SIRTs may have different target 
substrates and may affect a broad range of cellular functions (Haigis and Sinclair, 2010). 
Among all the SIRTs, Sirt2 is abundantly expressed in the CNS at mRNA and protein 
levels (Sidorova-Darmos et al., 2014), and it is the only SIRT protein that is present in the 
myelin sheath (Werner et al., 2007).  
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Figure 2.5: Sirtuin enzymatic activities. NAD+-dependent deacetylation and mono-ADP-
ribosyltransferase activity of sirtuins. Both deacetylation and ADP-ribosylation occur in the 
presence of NAD+. The acetylated lysine residue of the target protein serves as substrate for 
sirtuin deacetylation. NAD+ and acetylated protein are converted to free lysine side chain, 
nicotinamide (NAM) and 2’-O-acetyl-ADP-ribose (2’-OAADPr). (adapted from Michan and 
Sinclair, 2007) 
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Figure 2.6: Catalytic core domain and subcellular localization of mammalian SIRTs. 
Diagrammatic representation of the domains and localization of mammalian SIRTs (SIRT1 to 
SIRT7) within a cell. The conserved NAD+-dependent catalytic core domain performs either a 
deacetylase (DAC) and/or mono-ADP-ribosyltransferase (ART) activity depending on their sub-
cellular localization and biological function. SIRT1 and SIRT2 shuttle between nucleus and 
cytoplasm (indicated by arrow). SIRT3, SIRT4 and SIRT5 are localized in the mitochondria, 
while SIRT7 is localized in the nucleolus. 
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2.5.2 Organization of Sirt2 gene and its isoforms 
The Sirt2 gene is located on chromosome 19 in humans and on chromosome 7 in mice. 
The full length Sirt2 gene contains 16 exons in both human and mouse (Fig. 2.7) (Voelter-
Mahlknecht et al., 2005; Maxwell et al., 2011). The Sirt2 mRNA is alternatively spliced between 
exons two to four giving rise to three isoforms of SIRT2 protein with different amino termini 
(Maxwell et al., 2011). In mice, Sirt2 variant 1 (Sirt2.1) contains all 16 exons encoding SIRT2.1 
protein (389 aa) with a molecular weight of 43 kDa (Maxwell et al., 2011). The Sirt2 variant 2 
(Sirt2.2) is spliced at exon two and the resulting frameshift introduces a premature stop codon in 
exon three. Translation of Sirt2.2 variant initiates at a downstream start site present in exon four 
giving rise to SIRT2.2 protein (352 aa) with a molecular weight of 39.5 kDa. This SIRT2.2 is the 
most abundant isoform in the CNS white matter (Werner et al., 2007; Zhu et al., 2012) and the 
only isoform integrated into myelin sheath (Werner et al., 2007). Sirt2 variant 3 (Sirt2.3) has 13 
exons (lacking exon two, three and four) encoding SIRT2.3 protein (319 aa) with a molecular 
weight of 35.5 kDa. SIRT2.3 increases with age in brain and spinal cords (Maxwell et al., 2011). 
Crystal structure of the catalytic core of SIRT2 contains two domains, i) a large α/β Rossmann 
fold domain (six parallel beta strand linked to alpha helices on either sides) and ii) a small Zn2+ 
binding domain (most diverse region between sirtuins) (Finnin et al., 2001). These two domains 
are connected by four polypeptide chain loops, which form a gap where the acetylated substrates 
and the NAD bind (Finnin et al., 2001; Sanders et al., 2010). However, the sub-cellular 
localization, substrate specificity and the functional significance of SIRT2 isoforms are yet be 
characterized.  
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Figure 2.7: Structural organization of mammalian Sirt2 gene and its splice variants. The 
genomic organization of mammalian Sirt2 gene showing the relative position of exons, introns 
and translation start sites (ATG). The gene organization of Sirt2 splice variants are shown in the 
lower panel. The catalytic core domain of the SIRT2 protein is encoded by sequences from exon 
5 to exon 15.  The Zinc binding module (exon 9 and exon 10) and the substrate binding (exon 9 
to exon 12) region are present within the catalytic domain.  
 
 
 
 
	 		 	 	 	 	 	 	 	 	 		 	 		
ATG	 ATG	 TAA	
Substrate binding domain 
	 		 	 	 	 	 	 	 	 	 		 	 		
ATG	 ATG	 TAA	
Sirt	2.1	(43kDa)	
	 		 	 	 	 	 	 	 	 	 	 	
ATG	 TAA	
Sirt	2.3	
(35.5kDa)	
Substrate binding domain 
Substrate binding domain 
	 		 	 	 	 	 	 	 	 	 		 		
ATG	 ATG	 TAA	TGA	
Sirt	2.2	
(39.5kDa)	
 42 
2.5.3 Interacting partners, substrates, and downstream effectors of SIRT2 
In the CNS, SIRT2 is predominantly expressed by OLs in the cytoplasm where it 
deacetylates α-tubulin at lysine 40 (K40) (Li et al., 2007a). Given that reversible acetylation of 
tubulin modulates microtubule dynamics (Zilerman et al., 2009), SIRT2 could possibly play a 
role in cytoskeletal organization. SIRT2 was found to interact with histone deacetylase 6 
(HDAC6) in microtubules to deacetylate α-tubulin in HeLa cells and 293T cells (North et al., 
2003). However, HDAC6 is expressed only by neurons in the CNS (Southwood et a., 2007), 
indicating that this interaction does not occur in OLs. In our laboratory it was demonstrated that 
the homeodomain transcription factor NKX2.2 binds to the promoter region of Sirt2 in the 
presence of HDAC1 and represses SIRT2 expression in OPCs (Ji et al., 2011). 
SIRT2 is localized in the cytoplasm throughout the cell cycle and translocates into the 
nucleus during G2/M transition phase (Dryden et al., 2003; North and Verdin, 2007a; North and 
Verdin, 2007b), where it deacetylates histone H4 at lysine 16 (H4K16) at a global level. Knock 
down of Sirt2 increases acetylated H4K16, which promotes mitotic exit (Vaquero et al., 2006).  
In addition, SIRT2 deacetylates H3K56 (Das et al., 2009) and H3K9 (Vaquero et al., 2006) to 
promote chromatin condensation. However, the acetylation of histones H3 and H4 are not altered 
in OLs transfected with Sirt2 (Li et al., 2007a). 
Although α-tubulin is the only known substrate of SIRT2 in the CNS (Li et al., 2007a), 
other interacting partners and substrates of SIRT2 have been identified using cancer cell lines 
and mouse fibroblast cells (Jin et al., 2008; Bae et al., 2004; Jing et al., 2007; Wang et al., 2007; 
Wang and Tong, 2009; Rothgiesser et al., 2010; Wang et al., 2014;Xu et al., 2014). SIRT2 can 
interact with 14-3-3 β/γ in HEK293 cells, which allows SIRT2 to deacetylate and inhibit the 
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transcriptional activity of p53 (Jin et al., 2008). Interaction of SIRT2 with homeobox 
transcription factor A10 (HoxA10) suggests the role of SIRT2 in mammalian development (Bae 
et al., 2004). Furthermore, SIRT2 interacts with Forkhead box, class O1 transcription factor 
(FOXO1) in the nucleus to modulate adipocyte differentiation (Jing et al., 2007; Wang and Tong, 
2009). SIRT2 deacetylates FOXO1, which inhibits Akt/PKB mediated phosphorylation of 
FOXO1 at Ser253 and retains FOXO1 in the nucleus. Deacetylated FOXO1 binds to peroxisome 
proliferator-activated receptor γ (PPARγ) and transcription factor CCAAT enhancer binding 
protein α	 (C/EBPα), which in turn represses the expression of adipocyte differentiation markers 
and inhibits adipocyte differentiation (Jing et al., 2007; Wang and Tong, 2009). 
SIRT2 has been implicated in inflammation, oxidative stress response and metabolism 
(Rothgiesser et al., 2010; Wang et al., 2007; Wang et al., 2014; Xu et al., 2014). SIRT2 
deacetylates the p65 subunit of nuclear factor kappa B transcription factor (NF-κB), which 
down-regulates the expression of NF-κB dependent genes in mouse embryonic fibroblasts 
(Rothgiesser et al., 2010). During oxidative stress, SIRT2 deacetylates FOXO3a and promotes 
the expression of FOXO3a downstream targets such as p27kip1, MnSOD (manganese 
superoxide dismutase) and Bim to reduce cellular levels of reactive oxygen species in NIH 3T3 
cells (Wang et al., 2007).  SIRT2 has also been reported to interact with metabolic enzymes, 
glucose 6-phosphate dehydrogenase (Wang et al., 2014) and phosphoglycerate mutase (Xu et al., 
2014) to counteract oxidative damage. 
In addition, the activity of SIRT2 is modulated by post-translational modifications such 
as phosphorylation and acetylation. CDK such as cyclin B-CDK1, cyclin E-CDK2, cyclin A-
CDK2 and p35-CDK5 phosphorylate SIRT2 at a consensus sequence located in the C terminus, 
serine 368 in SIRT2.1 and at serine 331 in SIRT2.2. Phosphorylation by CDK inhibits the 
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catalytic activity of SIRT2 and interferes with its functions such as cell adhesion, cell migration, 
neurite outgrowth and growth cone motility (North and Verdin, 2007b; Pandithage et al., 2008). 
SIRT2 is predicted to have AKT phosphorylation sites (Jin et al., 2008). SIRT2 is 
dephosphorylated by the phosphatase CDC14B, which results in ubiquitination and 26S 
proteosome mediated degradation of SIRT2 leading to mitotic exit (North and Verdin, 2007b; 
Inoue et al., 2007). Furthermore, SIRT2 is acetylated by p300, which attenuates the deacetylation 
activity of SIRT2 (Han et al., 2008). 
2.5.4 SIRT2 in oligodendrogenesis 
SIRT2 deacetylates α-tubulin and modulates the cytoskeleton during oligodendrogenesis 
(Li et al., 2007a; Tang and Chua, 2008). There are controversies in the regulatory role of Sirt2 in 
OL differentiation. Initially, it was reported that Sirt2 prevents OL differentiation through tubulin 
deacetylation (Li et al., 2007a). These observations were made using gene overexpression and 
knockdown in vitro (Li et al., 2007a). However, OLs with endogenous higher expression of Sirt2 
displayed complex process outgrowth (Li et al., 2007a). In addition, SIRT2 was found to be 
colocalized with CNPase and identified as an early OL differentiation marker (Southwood et al., 
2007). In our laboratory, it was shown that Sirt2 promotes OL differentiation and enhances OL 
arborization with an increase in MBP expression in CG4-OL cells (Ji et al., 2011). These 
findings suggest that Sirt2 promotes OL differentiation. Moreover, SIRT2 deacetylates H3K56 
(Das et al., 2009), and a decrease in the levels of acetylated H3K56 has been reported to initiate 
differentiation (Xie et al., 2009). This correlates with our findings that the expression of SIRT2 
continues to increase as CG4-OLs differentiate and its expression remains prominent in adult 
CNS (Ji et al., 2011). 
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Disruption of microtubules using nocodazole or colchicine inhibits the transport of Mbp 
mRNA (Carson et al., 1997) and incorporation of PLP into myelin sheath (Bizzozero et al., 
1982). In addition, increased microtubule polymerization compromises OL process outgrowth 
(Song et al., 1999). Thus, normal microtubule structure is critical for the transport of myelin 
components and process extension in OLs (Song et al., 1999). During oligodendrogenesis, 
SIRT2 modulates the microtubule dynamics by deacetylating α-tubulin (Li et al., 2007a). Hence, 
SIRT2 may also function in modulating microtubule-based vesicular transport, which is critical 
during differentiation and myelin formation (Tang and Chua, 2008). SIRT2 may also regulate 
OL differentiation and myelin formation by modulating the acetylation status of other myelin 
proteins (Werner et al., 2007).  
Moreover, SIRT2 is upregulated during the peak period of myelination in the CNS 
(Southwood et al., 2007) as well as in the PNS (Beirowski et al., 2011). Interestingly, the 
expression profile of SIRT2 is similar to that of MBP and MPZ in CNS and PNS, respectively (Ji 
et al., 2011; Beirowski et al., 2011). In addition, studies on myelin proteome revealed that the 
isoform SIRT2.2 integrates into the myelin sheath (Werner et al., 2007) in close proximity to 
PLP and DM20 near paranodal loops (Li et al., 2007a; Southwood et al., 2007). The transport of 
SIRT2 into the myelin sheath is mediated by PLP (Werner et al., 2007; Zhu et al., 2012). The 
localization of SIRT2 in paranodal loops suggests that SIRT2 may be involved in axo-glial 
interaction and axonal integrity (Werner et al., 2007). In Schwann cells, knockout of Sirt2 delays 
myelin formation by regulating the activity of the polarity complex signaling component aPKC 
via deacetylation of Par-3 (Beirowski et al., 2011). In addition, loss of Sirt2 in PNS results in 
extensive outfoldings in compact myelin close to paranodes (Beirowski et al., 2011). 
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2.5.5 SIRT2 and signaling molecules in CNS myelination  
The serine/threonine kinase AKT is involved in regulating many vital cellular functions. 
In the transgenic mouse Plp-Akt-DD (phosphorylation of aspartic acid residues at Thr308 and 
Ser473), the constitutive activation of AKT1 throughout the OL lineage leads to enhanced 
myelination with increased thickness and increased expression of major myelin genes such as 
Plp, Mog and Mbp (Flores et al., 2008). Further, the activation of mammalian target of 
rapamycin (mTOR) and its downstream substrate p70 S6 Kinase and S6 ribosomal protein are 
increased in Plp-Akt-DD mice (Narayanan et al., 2009). In addition, when mTOR signaling is 
inhibited in vivo with chronic rapamycin treatment, the hypermyelination and the associated 
changes are all rescued (Narayanan et al., 2009). Conditional knockout of mTOR in the OLs 
using CNP-cre-mTORfl/fl mice exhibits hypomyelination in CNS (Wahl et al., 2014). This 
indicates that Akt-mTOR signaling plays a critical role in CNS myelination (Narayanan et al., 
2009). In addition to AKT-mTOR, ERK 1/2 is also involved in myelin compaction during the 
active stages of myelination in the spinal cord, with negligible roles in OPC proliferation and OL 
differentiation (Ishii et al., 2012).  
Although the role of SIRT2 in the signaling pathways that promote myelination has not 
been studied in OLs, a few studies in other cell types have demonstrated the interaction of SIRT2 
with these signaling molecules. In myeloid leukemia cells, it has been demonstrated that the 
deacetylase activity of SIRT2 activates protein kinase B/AKT (Dan et al., 2012). Moreover, 
when SIRT2 or its activator, nicotinamide phosphoribosyl transferase (NAMPT- key enzyme 
involved for the synthesis of NAD+) is inhibited, acetylation of protein kinase B/AKT increases, 
which in turn inhibits protein kinase B/AKT activity (Dan et al., 2012). Furthermore, SIRT2 is 
found to interact with AKT in an AMP-activated kinase dependent manner in vitro in fibroblast 
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and cancer cell lines (Ramakrishnan et al., 2014). AMP-activated kinase phosphorylates SIRT2 
at Thr101, which mediates the interaction of SIRT2 with AKT and this interaction enhances AKT 
activity (Ramakrishnan et al., 2014). In addition to AKT, SIRT2 interacts with ERK1/2 in human 
embryonic kidney cells (Choi et al., 2013). Interestingly, this interaction increases SIRT2 protein 
expression with high stability and increases deacetylase activity (Choi et al., 2013). SIRT2 also 
increases the phosphorylation and activation of ERK1/2, which enhances the expression of cell 
cycle regulatory proteins such as cyclinD1 and CDK2 to promote cell proliferation in myoblast 
cells (Wu et al., 2014).  
2.5.6 SIRT2 in neuroprotection 
In addition to OLs, SIRT2 is expressed in neurons in the CNS (Southwood et al., 2007; 
Suzuki and Koike, 2007; Pandithage et al., 2008; Maxwell et al., 2011). Pharmacological or 
genetic inhibition of SIRT2 has neuroprotective effects against neurodegenerative diseases such 
as Parkinson’s (PD) (Outeiro et al., 2007), Alzheimer’s (AD) (Silva et al., 2017) and 
Huntington’s (HD) (Luthi-Carter et al., 2010) disease. PD is characterized by loss of 
dopaminergic neurons and aggregation of α-synuclein to form Lewy bodies in the substantia 
nigra (Beitz, 2014). Pharmacological inhibition of SIRT2 in neuroglioma cells transfected with 
α-synuclein and in a Drosophila model of PD displays dose-dependent protective effects 
(Outeiro et al., 2007). Silencing Sirt2 in cellular models of PD rescued the α-synuclein mediated 
cell death, suggesting that SIRT2 inhibition could be a useful strategy in combating PD (Outeiro 
et al., 2007). The inhibition of Sirt2 might also increase the stabilization of α-tubulin (by 
increased tubulin acetylation), which could lead to stronger interactions with α-Syn through 
microtubules, stabilizing the formation of larger protein aggregates that are less toxic (Outeiro et 
al., 2007). In contrast, SIRT2 inhibition in oxidative stress induced α-synuclein aggregation 
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enhanced cell death, while overexpression of SIRT2 protected neural cells from α-synuclein 
mediated toxicity (Singh et al., 2017).  
In AD cells containing patient mitochondrial DNA and in AD brain, expression of SIRT2 
is high with an increase in tubulin deacetylation, which leads to amyloid-β accumulation (Silva 
et al., 2017). Loss of SIRT2 in AD cells recovers the microtubule assembly and cell survival by 
eliminating amyloid-β (Silva et al., 2017). In Huntington’s disease model, SIRT2 inhibition 
using pharmacological inhibitors AK-1 and AGK2 rescue neuronal death in a dose-dependent 
manner whereas overexpression of Sirt2 counteracts neuroprotection (Luthi-Carter et al., 2010). 
Molecular pathway analysis and gene ontology classification revealed that this neuroprotection is 
mediated by downregulation of genes involved in cholesterol biosynthesis (Luthi-Carter et al., 
2010). 
2.6 Cholesterol  
Cholesterol is the major lipid component of myelin, constituting around 25% of total 
myelin lipids (Norton and Poduslo, 1973a; Saher and Simons, 2010). Cholesterol is supplied to 
the cell by de novo synthesis or by uptake from circulation (Saher et al., 2011). However, in 
brain, cholesterol is mainly supplied by de novo synthesis (Jurevics and Morell, 1995; Jurevics et 
al., 1997) as the blood brain barrier prevents the uptake of cholesterol from circulation (Dietschy 
and Turley, 2004).  
2.6.1 Cholesterol biosynthesis in brain 
Myelin accounts for around 80% of brain cholesterol (Dietschy and Turley 2004; Muse et 
al. 2001). In the brain, cholesterol needed for myelin biogenesis is primarily produced by OLs 
(Jurevics and Morell, 1995; Jurevics et al., 1997) with little being imported from circulation 
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(Dietschy and Turley, 2004). In mice, the brain cholesterol concentration is about 3.5 mg/g at 
birth, which increases during the peak of myelination and is tripled (12 mg/g) three weeks after 
birth (Dietschy and Turley, 2004). Cholesterol synthesis occurs through the isoprenoid 
biosynthetic pathway, which starts with the conversion of acetyl-CoA to 3-hydroxy-3-
methylglutaryl-CoA (HMG-CoA). HMG-CoA is converted into mevalonate by HMG-CoA 
reductase, which is the rate-limiting step in cholesterol biosynthesis. Mevalonate is then 
converted into 3-isopentenyl pyrophosphate and farnesyl pyrophosphate. The conversion of 
farnesyl pyrophosphate into squalene by squalene synthase (SQS) is the first committed step in 
the isoprenoid biosynthetic pathway to form cholesterol. Squalene undergoes a series of 
enzymatic reaction to form cholesterol (Saher et al., 2011). 
2.6.2 Importance of cholesterol in myelination 
In mouse, conditional mutation of Sqs gene in OLs reduced myelin specific gene 
expression and severely delayed myelination (Saher et al., 2005). Similarly, mutation of Hmg-
CoA synthase 1 (Hmgcs1) in zebrafish impaired myelin specific gene expression and axon 
wrapping (Mathews et al., 2014; Mathews and Appel, 2016). In addition, usage of the cholesterol 
lowering drug, statin, which inhibits HMG-CoA reductase reduced myelin specific gene 
expression and process outgrowth in OLs (Miron et al., 2007; Smolders et al., 2010). Besides 
being an important component of the myelin membrane, cholesterol aids in the transport and 
sorting of PLP and DM20 to promote tight compaction and myelin assembly (Saher and Simons, 
2010; Saher et al., 2005; Saher et al., 2009; Simons et al., 2000; Werner et al., 2013). Hence, the 
availability of cholesterol is a rate-limiting factor for OL process outgrowth and myelination 
(Saher et al., 2005; Saher and Stumpf, 2015; Mathews et al., 2014; Mathews and Appel, 2016).  
 50 
2.6.3 Sterol regulatory element binding protein (SREBP)-2 
Cholesterol biosynthesis occurs under the control of a transcription factor, sterol 
regulatory element binding protein (SREBP)-2 (Brown and Goldstein, 1997; Amemiya-Kudo et 
al., 2002; Eberlé et al., 2004). SREBP-2 is produced as an inactive precursor containing three 
domains, 1) NH2-terminal domain harboring the basic helix-loop-helix-leucine zipper region, 2) 
hydrophobic transmembrane-spanning segment, and 3) a COOH- terminal domain (Horton et al., 
2002). The SREBP-2 precursor is bound to the endoplasmic reticulum (ER) along with SREBP 
cleavage activating protein (SCAP) (Yabe et al., 2002; Yang et al., 2002). When the cellular 
concentration of cholesterol is low, the SREBP-SCAP complex is released from the ER and 
enters the golgi apparatus (Yabe et al., 2002; Yang et al., 2002).  In the golgi apparatus, the 
precursor SREBP-2 is cleaved by two proteases, site-1 protease and site-2 protease (Sakai et al., 
1996; Wang et al., 1994). This releases the NH2-terminal domain of SREBP-2, which 
translocates to the nucleus (nSREBP-2) and binds to sterol responsive elements (SREs) in the 
target genes encoding cholesterogenic enzymes (Amemiya-Kudo et al., 2002; Eberlé et al., 2004; 
Horton et al., 2002). However, excess sterol negatively regulates cholesterol synthesis by 
retaining SREBP-SCAP complex in the ER and inhibiting SREBP processing (Wang et al., 
1994; Yang et al., 2002). 
2.6.4 Sirt2 in cholesterol biosynthesis 
Acetylation and deacetylation of lysine residues within the DNA binding domain of 
SREBPs can modulate SREBP activity and downstream target gene expression (Giandomenico 
et al., 2003; Ponugoti et al., 2010; Walker et al., 2010). In neuronal cells, overexpression of Sirt2 
promotes cholesterol biosynthesis by facilitating the nuclear translocation of SREBP-2 (Luthi-
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Carter et al., 2010; Taylor et al., 2011). In addition, pharmacological inhibition using SIRT2 
specific inhibitors, AGK2, AK-1 and AK-7, retained SREBP-2 in the cytoplasm, which reduced 
the expression of genes encoding enzymes involved in cholesterol biosynthesis and total 
cholesterol content (Luthi-Carter et al., 2010; Taylor et al., 2011). Similarly, overexpression of 
deacetylase-deficient Sirt2 mutant (Sirt2H150Y) impaired nuclear translocation of SREBP-2 and 
cholesterol biosynthesis (Luthi-Carter et al., 2010). This indicates that deacetylase activity is 
crucial for the nuclear translocation of SREBP-2. However, SREBP-2 translocation and 
cholesterol synthesis was not altered in the whole brain of Sirt2 knock-out mice (Bobrowska et 
al., 2012). This difference could be cell type specific. Therefore, it remains to be understood if 
SIRT2 regulates SREBP-2 in OLs during myelination.  
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Preamble to Chapter 3: QUAKING PROMOTES THE EXPRESSION OF SIRT2 
DURING OLIGODENDROGLIAL DIFFERENTIATION 
Rationale: SIRT2 is a NAD+ dependent deacetylase, predominantly expressed in OLs. Previous 
work from our group showed that Sirt2 is essential for OL differentiation in vitro using CG4-
OLs, although the mechanism involved in regulating the expression of SIRT2 during 
oligodendrogenesis is largely unknown. The RNA binding protein Quaking (QKI) regulates the 
expression of several myelin specific genes either directly or indirectly. Moreover, SIRT2 
protein is absent in qkv/qkv mutant mice. It is not clear whether QKI protein directly interacts 
with Sirt2 mRNA to modulate OL development. In this study, I investigated the molecular 
mechanism by which QKI regulates the expression of SIRT2 during OL development.  
Publication 
Merlin P. Thangaraj, Kendra L. Furber, Jotham K. Gan, Shaoping Ji, LaRhonda Sobchishin, J. 
Ronald Doucette and Adil J. Nazarali. (2017) “RNA-binding Protein Quaking Stabilizes Sirt2 
mRNA during Oligodendroglial Differentiation” The Journal of Biological Chemistry, 292; 
5166-5182. doi:10.1074/jbc.M117.775544. 
Contribution statement 
I designed and performed the experiments to investigate how QKI regulates SIRT2 expression in 
oligodendrocytes. The data generated are shown in figures 1-8 of the manuscript. Kendra L. 
Furber, Jotham K. Gan, Shaoping Ji and LaRhonda Sobchishin contributed to the data generated 
using QKI-5 isoform shown in figures 9 and 10 of the manuscript. Adil J. Nazarali and J. Ronald 
Doucette conceived and coordinated the study. In this chapter, I am presenting only the data I 
generated (Figure 3.1-3.12).  
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3. QUAKING PROMOTES THE EXPRESSION OF SIRT2 DURING 
OLIGODENDROGLIAL DIFFERENTIATION 
3.1 Summary  
Myelination is controlled by timely expression of genes involved in the differentiation of OPCs 
into myelinating OLs. SIRT2, a NAD+-dependent deacetylase, plays a critical role in OL 
differentiation by promoting both arborization and downstream expression of myelin specific 
genes in vitro. However, the mechanisms involved in regulating SIRT2 expression during OL 
development are largely unknown. The RNA binding protein Quaking (QKI) plays an important 
role in myelination by post-transcriptionally regulating the expression of several myelin specific 
genes. In qkv/qkv mutant mice, SIRT2 protein is severely reduced; hence, I hypothesized that QKI 
interacts with Sirt2 mRNA to regulate OL differentiation. Here, I report for the first time that 
QKI directly binds to Sirt2 mRNA via a common quaking binding site located in the 3' UTR to 
control SIRT2 expression in OL lineage cells. This interaction is associated with increased 
stability and longer half-lives of Sirt2.1 and Sirt2.2 transcripts leading to increased accumulation 
of Sirt2 transcripts. Consistent with this, overexpression of qkI promoted the expression of 
SIRT2 protein. Collectively, this study demonstrates that QKI directly plays a crucial role in the 
post-transcriptional regulation and expression of Sirt2 to facilitate OL differentiation. 
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3.2 Introduction 
OLs are the myelinating glial cells in the CNS. In the mammalian cortex, OPCs 
originating from the VZ/SVZ proliferate, migrate, and eventually differentiate into mature, 
myelinating OLs (Baumann and Pham-Dinh, 2001; Emery and Lu, 2015; Nicolay et al., 2007). 
The RNA-binding protein QKI is expressed by glial progenitors (Hardy, 1998a). QKI controls 
OL development and myelination by governing the post-transcriptional regulation of several 
myelin-specific transcripts (Chen et al., 2007b; Larocque et al., 2002; Wu et al., 2002; Li et al., 
2000; Zhao et al., 2006a; Zhao et al., 2010). The qkv/qkv mutant mouse (Sidman et al., 1964) 
carries a spontaneous one megabase pair deletion in the upstream of qkI locus covering a part of 
the Parkin gene, entire Parkin co-regulated gene and the promoter/enhancer region of the qkI 
gene (Ebersole et al., 1996; Lockhart et al., 2004; Lorenzetti et al., 2004a; Lorenzetti et al., 
2004b). In qkv/qkv mutant mouse there is OL specific decrease in the expression of QKI, which 
leads to severe hypomyelination in the CNS (Hardy et al., 1996; Lu et al., 2003). 
qkI encodes three alternatively spliced transcripts, qkI-5, qkI-6, and qkI-7. All three 
variants contain exons encoding common QUA1 – K homology (KH) – QUA2 domains in the 
N- terminal that confer RNA binding specificity and dimerization (Ebersole et al., 1996; Kondo 
et al., 1999; Chen and Richard, 1998). QKI interacts with target mRNAs that possess a specific 
quaking response element (QRE) ACUAAY[N1-20]UAAY (Galarneau and Richard, 2005) or its 
variant AUUAAY (Wu et al., 2002). In OLs, efficient binding of QKI to QREs has been reported 
for transcripts of Mbp (Larocque et al., 2002; Li et al., 2000; Galarneau and Richard, 2005; 
Ryder and Williamson, 2004), Mag (Wu et al., 2002), p27Kip1 (Larocque et al., 2005), Aip-1 
(Doukhanine et al., 2010), Map1B  (Zhao et al., 2006b) and hnRNPA1 (Zearfoss et al., 2011). 
This interaction alters the stability of the target mRNAs, which can lead to either a promotion or 
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inhibition in the downstream translation of the protein products, as is the case for p27Kip1 
(Larocque et al., 2005) or Aip-1 (Doukhanine et al., 2010), respectively. In addition to stabilizing 
the target mRNA, QKI has been demonstrated to regulate alternative splicing of Mag (Wu et al., 
2002; Zhao et al., 2010), and an altered ratio of splice variants for Mag (Fujita et al., 1990) and 
Mbp (Li et al., 2000) are found in the qkv/qkv mutants. qkv/qkv mice also show a mislocalized 
pattern of Mbp, with  its confinement to the nucleus (Larocque et al., 2002; Li et al., 2000). Thus, 
QKI proteins interact with target transcripts at multiple levels to control gene expression during 
oligodendroglial differentiation. 
Similar to myelin structural proteins (MBP and PLP), SIRT2 protein expression is also 
reduced in qkv/qkv mice (Zhu et al., 2012). Mammalian SIRT2 is a class III NAD+-dependent 
deacetylase (North et al., 2003), which is predicted to give rise to three isoforms, SIRT2.1, 
SIRT2.2, and SIRT2.3 (Maxwell et al., 2011). SIRT2 isoforms differ in the amino terminal but 
the functions of these isoforms are not yet clearly identified. However, SIRT2.2 is the most 
abundant isoform in OLs (Ji et al., 2011, Zhu et al., 2012) and is the only isoform incorporated 
into the myelin sheath (Werner et al., 2007). SIRT2.1 is expressed in non-neuronal cells and 
expression of SIRT2.3 increases with age in brain and spinal cord (Maxwell et al., 2011). SIRT2 
is enriched in brain and spinal cord tissue, predominately localized in the paranodal regions of 
the CNS myelin sheath (Li et al., 2007a; Werner et al., 2007; Southwood et al., 2007). During 
OL differentiation, SIRT2 is expressed early, prior to the expression of myelin specific genes 
(Zhu et al., 2012; Southwood et al., 2007; Ji et al., 2011), promoting differentiation at both the 
cellular and molecular level (Ji et al., 2011). In addition to the qkv/qkv mice, SIRT2 expression is 
reduced in the Plp null mice (Werner et al., 2007) and Plp-ISEdel mutant mice (Zhu et al., 2012). 
In Plp mutants, the loss of SIRT2 is observed primarily in the myelin sheath (Zhu et al., 2012; 
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Werner et al., 2007) but not in OPCs or OL cell bodies (Zhu et al., 2012). Moreover, no putative 
QREs have previously been identified in Sirt2 mRNA. Thus, it was postulated that QKI 
indirectly regulates SIRT2 expression during CNS myelination through co-transport with PLP 
into the myelin sheath (Zhu et al., 2012).  
To further investigate the relationship between qkI and Sirt2 in OL development, I used 
the CG4-OL cell line derived from neonatal rat forebrain O-2A progenitors and mouse primary 
OLs that undergo defined stages of differentiation under controlled media conditions (Ji et al., 
2011; Louis et al., 1992a; Louis et al., 1992b; Wang et al., 2011; Chen et al., 2007a; Niu et al., 
2012). Coordinated expression of QKI and SIRT2, was observed during differentiation. Thus, I 
sought to delineate the molecular mechanism that governs the direct or indirect interaction 
between the RNA binding protein QKI and Sirt2 during OL development. My findings 
demonstrate that there is a direct interaction between QKI and Sirt2 mRNA in OL progenitors 
and differentiating OLs. The binding site for QKI was mapped to the QRE ACUAAC at 1853-
1858 bp in the 3' UTR of Sirt2 mRNA. My findings indicate that Sirt2 is a direct target of QKI. 
Binding of QKI to Sirt2 mRNA increases the post-transcriptional stability of Sirt2 mRNA and 
controls its availability for translation.  
3.3 Materials and Methods 
3.3.1 CG4-OL cell culture 
CG4-OL is a O-2A progenitor cell line derived from rat brain and was cultured as previously 
described (Ji et al., 2011; Louis et al., 1992a; Louis et al., 1992b; Wang et al., 2011). Briefly, the 
CG4-OL cells were cultured on poly-D-lysine (Sigma) coated tissue culture dishes and 
maintained as undifferentiated progenitors in growth medium (GM) containing Dulbecco's 
 57 
modified Eagle's medium (DMEM), 50 µg/mL transferrin, 5 µg/mL insulin, 9.8 ng/mL biotin, 50 
ng/mL selenium, 1% antibiotic antimycotic solution and 30% B104 conditioned medium (CM) 
(Ji et al., 2011; Wang et al., 2011). Differentiation of CG4-OL cells was induced by culturing in 
differentiation medium (DM) containing 2% fetal bovine serum (FBS) instead of B104 CM (Ji et 
al., 2011; Wang et al., 2011). Transfection was carried out using Lipofectamine 2000 
(Invitrogen) or polyethylenimine (PEI) (Polysciences) in serum free / antibiotic free media. For 
growth conditions (GM), cells were harvested 48 hours (h) after transfection for RNA and 
protein extraction. For differentiation (DM), transfections were performed on day 0, day 2, day 
4, to maintain consistent levels of overexpression throughout six days of experimental timeline. 
3.3.2 Primary OL cell culture and electroporation 
Primary OLs were prepared from C57BL/6 mice at P1, as previously described (Chen et al., 
2007a; Niu et al., 2012). Briefly, mixed glial cells were prepared from the meninges free cortices 
isolated from neonatal mouse pups. The dissected cortices were digested with Accumax solution 
(Sigma) and passed through a 70 µm nylon cell strainer. The filtered cell suspensions were plated 
on poly-D-lysine (Sigma) coated T75 tissue culture flasks and maintained as mixed glial cells in 
mixed glial medium (MGM) containing DMEM/F12, 10% FBS and penicillin-streptomycin 
solution. Half of the culture medium was changed every other day. After seven days, to enrich 
OLs in the mixed glial cells, MGM was replaced with OL growth medium (OGM) containing 10 
ng/mL biotin, 5 µg/mL insulin, 50 µg/mL transferrin, 2 mM glutamine, 30 nM sodium selenite, 
0.1% BSA, 10 nM hydrocortisone, 1% penicillin-streptomycin solution in DMEM/F12 and 30% 
of B104 conditioned medium. After 14 days, primary OLs were shaken off (at 200 rpm; 37°C) 
from the mixed glial cultures and plated in the OGM supplemented with 10 ng/mL human 
recombinant platelet-derived growth factor (PDGF-AA) (Peprotech)  and 10 ng/mL basic 
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fibroblast growth factor (bFGF) (Peprotech). To induce differentiation, purified primary OLs 
were plated in OL differentiation medium (ODM) containing 10 ng/mL biotin, 5 µg/mL insulin, 
50 µg/mL transferrin, 2 mM glutamine, 30 nM sodium selenite, 0.1% BSA, 10 nM 
hydrocortisone, 1% penicillin-streptomycin solution in DMEM/F12, 5 µg/mL N-acetyl-L-
cysteine and 1% FBS. Transfections were carried out by electroporation (Amaxa nucleofection 
apparatus, Lonza) in 3-5 x 106 primary OLs using Ingenio electroporation solution (Mirus Bio 
LLC). Primary OLs were resuspended in OGM (supplemented with PDGF-AA+bFGF) or ODM 
and harvested 6 days after electroporation for protein and RNA extraction. Animal use was 
approved by the University of Saskatchewan’s Animal Research Ethics Board, and adhered to 
the Canadian Council on Animal Care guidelines for humane animal use. 
 
3.3.3 Vector construct and site directed mutagenesis 
The common coding region of qkI (908 bp) spanning from 489 bp (exon 1) to 1417 bp (exon 6) 
containing the RNA binding and dimerization domains (QUA1-KH-QUA2)  (Ebersole et al., 
1996; Kondo et al., 1999) was amplified by PCR using the forward 5'-
AAGGGATCCGAATATGGTCGGGGAAATG-3' and reverse 5'-
GTGGAATTCACACCACTGGGTTCAAT-3' primers and cloned into pcDNA 3.1/His between 
BamHI and EcoRI restriction sites. The 3' UTR of Sirt2 mRNA was amplified using the forward 
5'-CGCTCTAGACAGTAACCATGACCTCCCG -3' and reverse 5'-
ACGCTCTAGACATGGTTAGTTGCTTTGT -3' primers and cloned into pGL3-promoter 
luciferase vector (Promega) at XbaI site. The two putative QREs in the 3' UTR of Sirt2 mRNA at 
1639 bp (Sirt2 3' UTR-Mut1) and/or 1853 bp (Sirt2 3' UTR-Mut2) were mutated using 
QuikChange Lightning kit (Agilent Technologies) with the primers, Sirt2 3' UTR-Mut1; 5’-
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GCGGGGTAGGGTCGATTGATTTAGCCATAGGCC-3' and 5'-
GGCCTATGGCTAAATCAATCGACCCTACCCCGC-3' and Sirt2 3' UTR-Mut2; 5'-
GCCCCGACTCTAGACATGGCTCGATGCTTTGTTTTG-3' and 5'-
CAAAACAAAGCATCGAGCCATGTCTAGAGTCGGGGC-3'.  
3.3.4 Luciferase reporter assay 
CG4-OL cells maintained in GM were seeded in a white opaque 96-well plate (Costar, 3610) and 
were co-transfected with pcDNA vector or pcDNA-qkI expression vector along with Sirt2 3' 
UTR luciferase vector (pGL3-Sirt2 3' UTR) or putative QREs mutated Sirt2 3' UTR luciferase 
vector (pGL3-Sirt2 3' UTR- Mut1 or pGL3-Sirt2 3' UTR- Mut2 or pGL3-Sirt2 3' UTR-
Mut1*Mut2). pRL-CMV renilla luciferase vector was used as a control for normalizing 
transfection efficiency. Dual-Glo luciferase assay system (Promega) was used to measure the 
luciferase activity of cells co-transfected with qkI overexpression vector and wild-type or 
mutated Sirt2 3' UTR luciferase vectors. Luciferase assay was performed according to the 
manufacturer’s instruction. Briefly, 48 h after transfection, equal volume of Dual-Glo reagent 
was added to the cells in culture medium to measure the firefly luminescence. Subsequently, 
Dual-Glo Stop & Glo reagent was added to inactivate firefly luciferase activity and measure the 
renilla luciferase activity. Relative luciferase activity was calculated by normalizing the firefly 
luciferase values to its respective renilla luciferase values. Data were normalized to the Sirt2 3' 
UTR co-transfected with pcDNA control vector and represented as percentage luciferase activity.  
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3.3.5 RNA isolation, reverse transcription-PCR (RT-PCR) and quantitative real time-PCR 
(qPCR) 
Total mRNA from the CG4-OL cells was isolated using Aurum total RNA mini kit  (BioRad) as 
per the manufacturer’s protocol. First strand cDNA synthesis (Reverse transcription) was 
performed with 500 ng – 1 µg of total RNA using the Quantitect Reverse Transcription Kit 
(Qiagen) or High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) with random 
primers. RT-PCR was carried out as described before (Ji et al., 2011). The following primer pairs 
were used: (i) Sirt2 forward 5′-AGCAAGGCACCACTAGCCACC-3′ and reverse 5′-
TGTTCCTCTTTCTCTTTGGTC-3′; and (ii) Gapdh forward 5ʹ-
ACCACAGTCCATGCCATCAC-3ʹ and reverse 5ʹ-TCCACCACCCTGTTGCTGTA-3ʹ.  PCR 
products were visualized on RedSafe stained 1% agarose gel and integrated density values were 
determined for each band with AlphaView® imaging software.  
qPCR was carried out according to Doucette et al., (2010), using SYBR select master mix 
(Applied Biosystems) in Step one Real Time PCR System (Applied Biosystems) with gene 
specific primers. For analyzing the total Sirt2 mRNA levels, primers were the same as above and 
for total qkI mRNA levels, forward primer, 5′- TGAATGGCACCTACAGAGAC-3′ and reverse 
primer, 5′- CAAAGGCATTATGGTAGGGC-3′ were used. For quantifying the levels of Sirt2 
variants, common reverse primer 5′-GGGGAGCGGAAGTCAGGGAT-3′ was used in 
combination with variant specific forward primer, Sirt2.1, 5′-
CAGGAGGCTCAGGATTCAGAC-3′; Sirt2.2, 5′-CCCAGGATTCAGACTCGGACA-3′; 
Sirt2.3, 5′-CTGCTCCCCGTCGCAGGGTC -3′.  The expression levels of β-actin (Forward 5′-
ATTGTAACCAACTGGGACG-3' and reverse 5'-TTGCCGATAGTGATGACCT-3') and 18s 
ribosomal RNA (18s rRNA) (forward 5′-CGCGGTTCTATTTTGTTGGT-3' and reverse 5′-
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AGTCGGCATCGTTTATGGTC-3') were used as endogenous control. The relative levels of 
transcripts were determined by threshold cycle differences (2-ΔΔCT) of target normalized to the 
endogenous control as previously described (Doucette et al., 2010). 
3.3.6 RNA co-immunoprecipitation (RNA co-IP) 
Immunoprecipitation of mRNA-protein complexes was performed according to (Peritz et al., 
2006). The cells were harvested, either in GM or after DM-day 6, and lysed with polysome lysis 
buffer. The mixture was precleared with protein A agarose beads before immunoprecipitation to 
remove nonspecific binding to the beads. Subsequently, the supernatant was incubated with 10 
µg of rabbit monoclonal anti-QKI antibody (Abcam: ab126742) or normal rabbit anti- IgG 
(Millipore: 12-370) overnight at 4°C. The following day, fresh protein A agarose beads were 
added and incubated for 4 h at 4°C. After immunoprecipitation, the beads were collected and 
washed four times with polysome lysis buffer and then with polysome lysis buffer containing 1 
M urea. Next, 0.1% SDS and 30 µg proteinase K were added to the immunoprecipitated beads 
and heated at 50°C for 30 min to retrieve the protein-RNA complex. RNA isolation and qPCR 
was performed, as described above. 
3.3.7 mRNA stability assay 
CG4-OL cells maintained in GM were transfected with pcDNA vector or pcDNA-qkI expression 
vector and the stability of Sirt2 mRNA variants were examined by treating the cells with 
actinomycin D (Sigma) (Larocque et al., 2005; Doukhanine et al., 2010; Zhao et al., 2006). After 
48 h of transfection, actinomycin D (10 µg/mL) was added to cells and total RNA was extracted 
at indicated time points (0, 15, 30, 60 and 120 min).  RNA isolation and qPCR was performed, as 
described above. Half-life (t1/2) of Sirt2 mRNA variants were calculated as the time required for 
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each mRNA variant to reduce to 50% after actinomycin D treatment from its initial abundance at 
time 0 min. Half-lives (t1/2’s) were determined by nonlinear regression analysis (Baudouin-
Legros et al., 2005).  
3.3.8 Western blot analysis 
Total protein was extracted from CG4-OL cells using RIPA lysis buffer (150 mM NaCl, 0.5% 
SDS, 1% Trition-100, 0.1% deoxycholate, 10 mM Tris-HCl [pH 7.2], 5 mM EDTA) at 4°C. 
Protein quantification, electrophoresis, and subsequent protein detection was performed as 
described previously (Ji et al., 2011). Briefly, proteins (20-40 µg) were separated on 12% SDS-
PAGE and transferred to a PVDF membrane. Immunoblot was performed with the following 
primary antibodies: anti-QKI (1:1000, Abcam), anti-SIRT2 (1:3000, Sigma), anti-MBP (1:1000, 
Sternberger Monoclonals), anti-β-tubulin (1:1000, Developmental Studies Hybridoma) and anti-
GAPDH (1:10000, Sigma). Secondary antibodies utilized were goat anti-rabbit IgG- horse radish 
peroxidase (HRP) conjugate (1:3000, BioRad), and goat anti-mouse IgG-HRP conjugate 
(1:3000, BioRad). Bands visualized with Clarity™ Western ECL Substrate (BioRad). 
Densitometric analyses were carried out using Alpha View Imaging software. 
3.3.9 Statistical analysis 
All data are presented as mean ± standard error of the mean (SEM). Statistical analyses were 
performed using Student’s t-test or ANOVA with Bonferonni’s multiple comparisons post-test 
(Prism® Software Corporation) as indicated in the figure legends. 
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3.4 Results 
3.4.1 Expression of QKI and Sirt2 increase during OL differentiation 
In this study, I sought to delineate the molecular interaction between qkI and Sirt2 in OPC 
proliferation (i.e., growth media; GM) and OL differentiation (i.e., differentiation media; DM). 
The expression patterns of mRNA and proteins of both QKI (Fig. 3.1) and Sirt2 (Fig. 3.2) 
increased in CG4 cells over six days of differentiation. Expression of qkI mRNA (Fig. 3.1A) 
gradually increased with differentiation with a ~3-fold increase observed by day 6. There was a 
corresponding increase in expression of the QKI protein product QKI-6 isoform (~ 2 fold 
increase at DM-day 6) but not of QKI-5 or QKI-7, which co-migrate on the immunoblot (Fig. 
3.1B, C). 
The Sirt2.2 variant was the most abundant transcript in CG4-OL cells with ~4.5-fold and ~2700-
fold greater expression than Sirt2.1 and Sirt2.3, respectively, under growth conditions (Fig. 
3.2A). Expression of Sirt2.2 mRNA increased ~8-fold within 24h under differentiation 
conditions and was maintained through to day 6. Similarly, Sirt2.1 and Sirt 2.3 mRNA 
expression increased throughout differentiation. SIRT2.2 was also the most abundant protein 
isoform in CG4-OL cells (Fig. 3.2B). Expression of SIRT2.2 protein increased ~2.5-fold by day 
3 and was maintained through to day 6 (Fig. 3.2C). Although Sirt2.1 and Sirt2.3 mRNA 
increased during differentiation, this did not translate to an increase in the SIRT2.1 or SIRT2.3 
protein products. The coordinated expression patterns of qkI and Sirt2 during OL differentiation 
suggest that these two genes may interact, either directly or indirectly, to promote OL 
differentiation.   
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Figure 3.1: Expression of qkI mRNA and protein increases during differentiation. CG4-OL 
progenitor cells undergo high rates of proliferation in growth medium (GM) followed by 
differentiation into mature, pre-myelinating OLs when transferred to differentiation medium 
(DM). Whole cell lysates were collected at 24 h intervals during differentiation (day 0, 1, 2, 3, 4, 
5 and 6). (A) Quantitative Real time PCR was carried out to analyze the changes in the mRNA 
levels of qkI (n=3 biological replicates). A gradual increase in qkI, expression was observed over 
the 6 day experimental timeline. Data were normalized to β-actin and represented relative to day 
0 (mean±SEM; one-way ANOVA *p < 0.05, **p < 0.01). (B) Representative immunoblot 
showing a corresponding increase in QKI protein expression over the course of 6 day 
differentiation. (C) Densitometric analysis of immunoblots (n=3 biological replicates) shows 
QKI-6 is the predominate isoform expressed during OL differentiation. Data were normalized to 
β-tubulin and represented relative to the respective isoform at day 0 (mean±SEM; two-way 
ANOVA *p < 0.05, **p < 0.01, ***p < 0.001). 
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Figure 3.2: Expression of Sirt2 mRNA and protein increases during differentiation. CG4-
OL progenitor cells in growth medium (GM) were transferred to differentiation medium (DM) 
and whole cell lysates were collected at 24 h intervals (day 0, 1, 2, 3, 4, 5 and 6). (A) Sirt2 
mRNA expression increases under differentiation conditions. Sirt2.2 mRNA is the most 
abundant transcript expressed in CG4-OL cells and increases by day 1 of differentiation. qPCR 
data (n=3 biological replicates) were normalized to β-actin and represented relative to Sirt2.3 
variant at day 0 (mean±SEM; two-way ANOVA). ‡ denotes Sirt2.1 mRNA with p < 0.001; α 
denotes Sirt2.2 mRNA with p < 0.001 and † denotes Sirt2.3 mRNA with p < 0.001 relative to 
their respective variants at day 0 (B) Representative immunoblot showing a corresponding 
increase in SIRT2 protein expression over the course of differentiation. (C) Densitometric 
analysis of immunoblots (n=3 biological replicates) reveal that SIRT2.2 is the predominate 
isoform expressed during OL differentiation. Data were normalized to β-tubulin and represented 
relative to the respective isoform at day 0 (mean±SEM; two-way ANOVA *p < 0.05, **p < 0.01, 
***p < 0.001). 
 
 
 
 
3.4.2 Overexpression of qkI promotes the accumulation of Sirt2 mRNA and expression of 
SIRT2 protein 
In the brainstem of qkv/qkv mutant mice, a reduction in SIRT2 protein expression but not Sirt2 
mRNA has been reported in young adult animals (P40) (Zhu et al., 2012). However, little is 
known about the relationship between QKI and Sirt2 during OL differentiation. To investigate 
what role QKI may have in regulating the expression of Sirt2 during OL differentiation, qkI was 
overexpressed in CG4-OL cells by transfection with pcDNA3.1 vector containing the common 
coding sequence of the RNA binding domain from QKI-5, QKI-6 and QKI-7. The proliferating 
CG4-OLs were transfected on day 0 and the cells were harvested 48 h after transfection. The 
differentiating CG4-OLs were transfected thrice (on day 0, day 2, day 4) and the cells were 
harvested on day 6. Overexpression of qkI increased the expression of QKI protein in both 
proliferating (growth media; GM; Fig. 3.3A) and differentiating (differentiation media; DM-day 
6; Fig. 3.3B) conditions in CG4-OLs. Overexpression of qkI promoted the homodimerization of 
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QKI-His fusion protein, resulting in the appearance of QKI-His fusion protein at 45 kDa. The 
extent of OL differentiation was analyzed by quantifying the expression of mature OL marker 
MBP. Expression of Mbp mRNA (Fig. 3.3C) increased with induced differentiation reaching a 
~60-fold increase by day 6. Consistent with this, the expression of the MBP protein (Fig. 3.3D, 
E) increased with differentiation from day 4 to day 6. Upregulation of qkI increased the 
accumulation of Sirt2 mRNA under both proliferating (growth media; GM) (Fig. 3.4A) and 
differentiating (differentiation media; DM-day 6) conditions (Fig. 3.4B). In GM, Sirt2.1 and 
Sirt2.2 mRNA abundance increased ~2-fold and ~3-fold, respectively; in contrast, Sirt2.3 
abundance was not affected (Fig. 3.4A). In DM, accumulation of all three variants increased ~2-
fold in differentiating OLs (Fig. 3.4B). Upregulation of qkI also resulted in a corresponding ~1.5 
fold increase in SIRT2.1 and SIRT2.2 protein expression under both proliferating (GM; Fig. 
3.4C, D) and differentiating (DM; Fig. 3.4E, F) conditions.  
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Figure 3.3: Overexpression of qkI in CG4-OLs. (A and B) CG4-OLs were transfected with 
control pcDNA vector or pcDNA-qkI vector (containing common coding region of qkI-5, qkI-6 
and qkI-7). Immunoblot analyses show an increase in the QKI protein expression, 48 h after 
transfection with pcDNA-qkI in GM (A) and 6 days after transfection in DM (B). QKI-His 
fusion protein appeared as homodimer with a molecular mass of 45kDa. CG4-OL cells were 
allowed to differentiate and whole cell lysates were collected at 24h intervals (day 0, 1, 2, 3, 4, 5 
and 6). (C) qPCR was carried out to evaluate OL differentiation using OL mature marker Mbp 
(n=3). A gradual increase in Mbp mRNA expression was observed over the 6 day experimental 
timeline. Data were normalized to β-actin and represented relative to day 0 (mean±SEM; one-
way ANOVA **p < 0.01, ***p < 0.001). (D) Representative immunoblot (n=3) showing a 
corresponding increase in MBP protein expression over the course of 6 day differentiation.  
(E) Densitometric analysis of immunoblots (n=3 biological replicates) showing the increase in 
MBP expression during OL differentiation. Data were normalized to β-tubulin and represented 
relative to day 0 (mean±SEM; two-way ANOVA *p < 0.05). 
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Figure 3.4: Overexpression of qkI promotes the accumulation of Sirt2 mRNA and 
expression of SIRT2 protein in CG4-OLs.  CG4-OL cells were transfected with a pcDNA 
vector containing qkI cDNA (common coding region of qkI-5, qkI-6 and qkI-7, see materials and 
methods) under both growth (GM) and differentiation (DM) conditions. Overexpression of qkI 
increased the accumulation of Sirt2.1 and Sirt2.2 mRNA only in GM (A) whereas accumulation 
of all three variants of Sirt2 transcripts (Sirt2.1, Sirt2.2 and Sirt2.3) was increased in DM (B). 
qPCR data (n=3 biological replicates) was normalized to β-actin and represented relative to 
pcDNA control vector (mean±SEM; two-way ANOVA *p < 0.05, **p < 0.01, ***p < 0.001). 
Representative immunoblots (C and E) and densitometric analysis (D and F) shows a 
corresponding increase in SIRT2.1 and SIRT2.2 protein with the overexpression of qkI. SIRT2.3 
protein was below the limits of detection. Densitometry data (n=3 biological replicates) were 
normalized to β-tubulin and represented relative to pcDNA control vector (mean±SEM; two-way 
ANOVA *p < 0.05, **p < 0.01). 
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Furthermore, to examine the regulatory function of QKI in primary OLs, I overexpressed qkI in 
primary OLs isolated from the mouse brain (Chen et al., 2007a; Niu et al., 2012). Overexpression 
of qkI increased the expression of QKI protein in both proliferating (growth media; GM; Fig. 
3.5A) and differentiating (differentiation media; DM-day 6; Fig. 3.5B) primary OLs. Expression 
of Mbp mRNA (Fig. 3.5C) and protein (Fig. 3.5D, E) increased with induced differentiation in 
primary OLs. Similar to CG4-OLs, overexpression of qkI in primary OLs increased the 
accumulation of Sirt2 mRNA under both proliferating (growth media; GM) (Fig. 3.6A) and 
differentiating (differentiation media; DM-day 6) conditions (Fig. 3.6B). In proliferating primary 
OLs, upregulation of qkI increased the abundance of Sirt2.1 and Sirt2.2 mRNA ~2-fold; while, 
Sirt2.3 mRNA abundance was not altered (Fig. 3.6A). In DM, abundance of all three variants 
increased ~3-fold in differentiating primary OLs (Fig. 3.6B). There was a corresponding increase 
in SIRT2.1 and SIRT2.2 protein expression under both proliferating (Fig. 3.6C, D) and 
differentiating (Fig. 3.6E, F) conditions after overexpression of qkI. Under these experimental 
conditions, the expression of SIRT2.3 protein isoform was not detectable either with or without 
qkI overexpression (Fig. 3.4C, E and Fig. 3.6C, E). Thus, qkI appears to be a positive regulator 
of SIRT2 protein expression in developing OLs.   
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Figure 3.5: Overexpression of qkI in primary OLs. (A and B) Primary OLs purified from 
mixed glial cultures were electroporated with control pcDNA vector or pcDNA-qkI vector 
(containing common coding region of qkI-5, qkI-6 and qkI-7) on day 0 and were allowed to 
proliferate in growth medium (GM) for 48h or differentiate in differentiation medium (DM) for 6 
days. Immunoblot analyses show an increase in the QKI protein expression in both GM (A) and 
DM (B). QKI-His fusion protein appeared as homodimer with a molecular mass of 45kDa. Mbp 
mRNA (C) and protein (D) increased under differentiation conditions. (C) qPCR data (n=3) were 
normalized to β-actin and represented relative to day 0 (mean±SEM; unpaired t-test, **p < 0.01). 
(D) Representative immunoblot (n=3) showing a corresponding increase in MBP protein 
expression 6 days after differentiation. (E) Densitometric analysis showing the increase in MBP 
expression during OL differentiation in primary OLs. Data were normalized to β-tubulin and 
represented relative to day 0 (mean±SEM; two-way ANOVA *p < 0.05). 
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Figure 3.6: QKI promotes the accumulation of Sirt2 mRNA and expression of SIRT2 
protein in primary OLs.  Primary OLs were electroporated with a pcDNA vector containing 
qkI cDNA and cultured under both growth (GM) and differentiation (DM) conditions for 6 days 
after electroporation. Upregulation of qkI increased the accumulation of Sirt2.1 and Sirt2.2 
mRNA in GM (A) while accumulation of all three variants of Sirt2 transcripts (Sirt2.1, Sirt2.2 
and Sirt2.3) was increased in DM (B). qPCR data (n=3 biological replicates) was normalized to 
β-actin and represented relative to pcDNA control vector (mean±SEM; two-way ANOVA, *p < 
0.05, ***p < 0.001). Representative immunoblots (C and E) and densitometric analysis (D and 
F) shows a corresponding increase in SIRT2.1 and SIRT2.2 protein with the overexpression of 
qkI. SIRT2.3 protein was below the limits of detection. Densitometry data (n=3 biological 
replicates) were normalized to β-tubulin and represented relative to pcDNA control vector 
(mean±SEM; two-way ANOVA, *p < 0.05, ***p < 0.01). 
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3.4.3 Presence of putative QREs in Sirt2 transcripts 
Using in silico analysis, I identified the presence of two putative QREs in Sirt2 mRNA at the 3′ 
UTR (Fig. 3.7A). Both putative QREs, AUUAA(C/U) at 1639-1643bp (denoted as QRE-1) and 
ACUAA(C/U) at 1853-1858bp (denoted as QRE-2) (Fig. 3.7A) in the Sirt2 mRNA, correspond 
to the predicted consensus sequences (Wu et al., 2002; Galarneau and Richard, 2005) and are 
highly conserved (Fig. 3.7A). Thus, 3′ UTR of Sirt2 mRNA has two putative interaction sites for 
QKI.  
3.4.4 QKI binds to Sirt2 mRNA to regulate its expression 
To determine if QKI directly binds to Sirt2 mRNA at the putative binding sites, RNA co-
immunoprecipitation (RNA co-IP) was carried out using whole cell lysates from CG4-OL under 
both growth (GM) and differentiating (DM-day 6) conditions. QKI was found to bind Sirt2 
mRNA in both proliferating and differentiating CG4-OLs (Fig. 3.7B, C). In both GM and DM, 
QKI did not bind with Gapdh mRNA (Fig. 3.7B, bottom panel). Further investigation 
determined that QKI bound to all the three variants of Sirt2 in differentiating CG4-OLs (Fig. 
3.7E), but only bound Sirt2.1 and Sirt2.2 in proliferating CG4-OLs (Fig. 3.7D). In addition, 
interaction of QKI and Sirt2 mRNA in primary OLs was also examined. QKI was found to 
interact with Sirt2 mRNA in both proliferating and differentiating primary OLs (Fig. 3.8A). In 
proliferating primary OLs, QKI bound only to Sirt2.1 and Sirt2.2 mRNA (Fig. 3.8B), while in 
differentiating primary OLs, QKI bound to all the three variants of Sirt2 (Fig. 3.8C). 
Collectively, these data demonstrate that QKI interacts directly with all three variants of Sirt2 
mRNA, presumably via the putative QRE-1 and/or QRE-2 in the 3′ UTR.  
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Figure 3.7: Putative binding sites of QKI protein in the Sirt2 mRNA. (A) Schematic diagram 
and sequence alignment showing the positions of predicted QKI response elements (QRE), 
denoted as QRE-1 at 1639-1643bp and QRE-2 at 1853-1858bp, in the 3' UTR of mouse Sirt2 
mRNA. Sequence alignment of the mouse, rat and human Sirt2 mRNA 3' UTR reveals highly 
conserved residues for both the QRE-1 and QRE-2 regions (black boxes). (B and C) RNA co-
immunoprecipitation with anti-QKI antibody using the whole cell lysate from CG4-OL cells 
show binding of QKI to Sirt2 mRNA under both growth (GM) and differentiation (DM) 
conditions. (B) RT-PCR products of Sirt2 and Gapdh were detected in a RedSafe stained agarose 
gel; lanes are as indicated. (C) qPCR data (n=3 biological replicates) was normalized to β-actin 
in the input and represented relative to control IgG (mean±SEM; two-way ANOVA  ***p < 
0.001). (D and E) QKI binds to Sirt2.1 mRNA and Sirt2.2 mRNA under both growth (GM) (D) 
and differentiation (DM) (E) conditions whereas binding of QKI to Sirt2.3 mRNA was only 
observed under differentiation (DM) conditions in CG4-OLs (D). qPCR data (n=3 biological 
replicates) were normalized to β-actin and represented relative to control IgG (mean±SEM; two-
way ANOVA ***p < 0.001).   
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Figure 3.8: QKI interacts with Sirt2 mRNA in primary OLs. (A) RNA co-
immunoprecipitation with anti-QKI antibody using the whole cell lysate from primary OLs 
shows binding of QKI to Sirt2 mRNA under both growth (GM) and differentiation (DM) 
conditions. qPCR data (n=3 biological replicates) was normalized to β-actin in the input and 
represented relative to control IgG (mean±SEM; two-way ANOVA ***p < 0.001).  (B and C) In 
GM, QKI was bound only to Sirt2.1 mRNA and Sirt2.2 mRNA. (C) In DM, QKI was bound to 
all the three variants of Sirt2 mRNA. qPCR data (n=3 biological replicates) were normalized to 
β-actin and represented relative to control IgG (mean±SEM; two-way ANOVA, ***p < 0.001). 
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3.4.5 QKI binds to 3′ UTR of Sirt2 mRNA and regulates its expression 
To identify the critical QRE site(s) involved in QKI-Sirt2 interaction, RNA co-IP and luciferase 
reporter assay systems were used. The Sirt2 3′ UTR with wild-type or mutated QREs was cloned 
downstream to the firefly luciferase and transfected along with pcDNA-QKI. The QRE 
mutations were as follows (Fig. 3.9A): (i) Sirt2 3′ UTR-Mut1 for QRE-1 at 1639bp 
(AUUAAC→UCGACC) (Fig. 3.9A, B), (ii) Sirt2 3′ UTR-Mut2 for QRE-2 at 1853bp 
(ACUAAC→UCGAGC) (Fig. 3.9A, C), and (iii) Sirt2 3′ UTR-Mut1*Mut2 for combined QRE-1 
and QRE-2 mutations (Fig. 3.9A, D). RNA co-IP was performed with wild-type or mutated 
putative QREs of the Sirt2 3′ UTR transfected in HEK293T cells with or without qkI. RNA co-IP 
revealed that QKI binds to wild-type and mutated QRE-1 (Sirt2 3′ UTR-Mut1) of Sirt2 mRNA. 
Mutation of QRE-2 alone (Sirt2 3′ UTR-Mut2) or in combination (Sirt2 3′ UTR-Mut1*Mut2) 
prevented the binding (Fig. 3.10A). Luciferase reporter assay was also carried out using wild-
type or mutated QREs of the Sirt2 3′ UTR cloned downstream to the firefly luciferase, 
cotransfected in CG4-OL cells together with qkI. Overexpression of qkI resulted in an increased 
luciferase activity of Sirt2 3′ UTR (Fig. 3.10B). Mutation of QRE-1 (Sirt2 3′ UTR-Mut1) also 
resulted in increased luciferase activity indicating QKI was still able to interact with Sirt2 3′ 
UTR despite the mutation to QRE-1. In contrast, mutation of QRE-2 either alone (Sirt2 3′ UTR-
Mut2) or double with QRE-1/QRE-2 mutation (Sirt2 3′ UTR-Mut1*Mut2) failed to increase the 
luciferase activity. These results indicate that the nucleotides in QRE-2 (1853-1858bp) are 
critical for the functional interaction between QKI and Sirt2. Thus, QKI binding to Sirt2 3′ UTR 
in the QRE ACUAAC (1853-1858bp) appears to be important for regulating the expression of 
Sirt2 during OL development. 
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A 
 
B     QRE-1 at 1639 bp (Sirt2 3' UTR-Mut1)  
 
C     QRE-2 at 1853 bp (Sirt2 3' UTR-Mut2)  
 
D   QRE-1*QRE-2 at 1639 bp and 1853 bp (Sirt2 3' UTR-Mut1*Mut2) 
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Figure 3.9: Site directed mutagenesis of QREs in the 3' UTR of Sirt2 mRNA. (A) A 593 bp 
fragment of the Sirt2 3' UTR containing putative QKI binding sites was amplified and cloned 
into pGL3-promoter vector. Site directed mutagenesis of the putative QKI response elements, 
QRE-1 at 1639 bp (Sirt2 3' UTR-Mut1), QRE-2 at 1853 bp (Sirt2 3' UTR-Mut2) and both QREs 
at 1639 bp and 1853 bp (Sirt2 3' UTR-Mut1*Mut2) were carried out using QuikChange 
Lightning kit. The underlined and bold sequences represent putative QREs and the mutated 
sequences are represented in red. (B, C and D) Analysis of sequences using EMBOSS Needle 
alignment (http://www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html) shows the mutated 
QREs within the orange box.   
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Figure 3.10: QKI interacts with Sirt2 via the QRE (ACUAAC) at 1853bp in the 3' UTR. (A) 
HEK293T cells were co-transfected with pcDNA or pcDNA-qkI along with pGL3 vector 
harboring wild-type or mutated QREs in the Sirt2 3' UTR, as indicated. RNA co-
immunoprecipitation with His tag antibody in these cell extracts reveals high affinity binding of 
QKI to wild-type or mutated QRE-1 of Sirt2 3' UTR but not to QRE-2. qPCR data (top panel) 
(n=3 biological replicates) was normalized to β-actin and represented relative to pcDNA control 
vector (mean±SEM; two-way ANOVA  ***p < 0.001). RT-PCR products (bottom panel) were 
detected in a RedSafe stained agarose gel; lanes are as indicated. (B) For luciferase reporter 
assay, CG4-OL cells were co-transfected with pcDNA or pcDNA-qkI (common coding region of 
qkI-5, qkI-6 and qkI-7) along with pGL3 luciferase vector containing wild-type or mutated QREs 
in the Sirt2 3' UTR. Overexpression of qkI increased luciferase reporter activity of Sirt2 3' UTR 
and Sirt2 3' UTR-Mut1 but not of Sirt2 3' UTR-Mut2 or Sirt2 3' UTR-Mut1*Mut2. This 
indicates that QRE-2 at 1853bp is critical for the interaction of QKI with Sirt2. Relative 
luciferase activity (n=4 biological replicates) was normalized to pcDNA control vector co-
transfected with pGL3 luciferase vector and represented as percent activity (mean ± SEM; two-
way ANOVA, **p < 0.01). 
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3.4.6 QKI stabilizes and protects Sirt2 mRNA from degradation  
QKI regulates myelin gene expression during development, in part by modulating the stability of 
myelin gene transcripts. To determine if QKI stabilizes Sirt2 mRNA, a standard mRNA stability 
assay (Larocque et al., 2005; Doukhanine et al., 2010; Zhao et al., 2006) was used to assess the 
ability of QKI to protect Sirt2 transcripts from degradation. Following transfection with pcDNA 
or pcDNA-qkI (48h), actinomycin D was used to inhibit transcription in CG4-OLs under growth 
conditions (GM) and subsequent degradation of Sirt2 mRNA was monitored using qPCR. QKI 
was found to regulate the stability of Sirt2.1 and Sirt2.2 variants (Fig. 3.11A, B, D). 
Overexpression of qkI delayed the degradation of Sirt2.1 (Fig. 3.11A) and Sirt2.2 (Fig. 3.11B), 
but not Sirt2.3 (Fig. 3.11C). The half-life (t1/2) of each of the Sirt2 variants were calculated 
(Baudouin-Legros et al., 2005) by measuring the reduction in the mRNA levels to 50% from 
their respective initial mRNA level.  Sirt2.1, Sirt2.2 and Sirt2.3 mRNA t1/2 were determined to be 
38.6, 23.8, and 61.5 min in CG4-OLs transfected with blank control vector (Fig. 3.11A, B, C) 
and 78.1, 68.3 and 51.7 min in CG4-OL cells transfected with qkI, respectively. Hence, there was 
~2 fold and ~2.8 fold increase in t1/2’s of Sirt2.1 and Sirt2.2 transcripts with qkI overexpression, 
but little difference in the t1/2 of Sirt2.3 mRNA. Sirt2.2 appears to be the primary functional 
target of QKI, as >85% of the mRNA transcripts remain protected 30 min after transcription is 
blocked in CG4-OL cells transfected with qkI (Fig. 3.11B) compared to <40% of mRNA 
transcripts remaining in cells transfected with control vector. Our finding suggests that binding 
of QKI to Sirt2.1 and Sirt 2.2 mRNA increases their stabilization and, in turn, may promote 
SIRT2.1 and SIRT2.2 protein expression during OL development. 
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Figure 3.11: QKI stabilizes and protects Sirt2.1 and Sirt2.2 mRNA. (A-C) The degradation of 
Sirt2 mRNA was monitored in CG4-OL cells transfected with pcDNA and pcDNA-qkI in growth 
conditions. After 48h following transfection, transcription was blocked with actinomycin D and 
mRNA levels of all the three Sirt2 variants were determined by qPCR at the indicated time 
points (0, 15, 30, 60 and 120 min). Overexpression of qkI significantly increased the quantity of 
Sirt2.2 mRNA remaining at 15 to 120 min after actinomycin D treatment (B) and that of Sirt2.1 
mRNA remaining at 120 min after actinomycin D treatment (A). The stability of Sirt2.3 mRNA 
was not impacted (C). (A-C) qPCR data (n=3 biological replicates) were normalized to 18s 
rRNA and are represented as percentage of the Sirt2 mRNA variant levels measured at time 0 
min. (mean±SEM; one phase decay). The half-lives were calculated as the time necessary for 
each Sirt2 mRNA variant to reduce to 50% of its initial amount at time 0 min (dashed lines). (D) 
Half-lives of Sirt2.1, Sirt2.2 and Sirt2.3 mRNA are represented in minutes. (mean±SEM; two-
way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001). 
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3.5 Discussion 
In myelinating OLs, SIRT2 is predominately cytoplasmic, localizing to the paranodal 
loops (Li et al., 2007a; Werner et al., 2007; Southwood et al., 2007), and is a key regulator of OL 
development in vitro (Ji et al., 2011). As a NAD+-dependent deactylase, it has a multitude of 
cellular targets involved in gene transcription (Vaquero et al., 2006; Michan and Sinclair, 2007), 
proliferation (North and Verdin, 2007b; Vaquero et al., 2006; Inoue et al., 2007; Dryden et al., 
2003), cell polarity (Beirowski et al., 2011) and cytoskeletal remodeling (North et al., 2003, Li et 
al., 2007a, Southwood et al., 2007). We have previously shown that the expression of Sirt2 
drives OL differentiation at the cellular level by enhancing process outgrowth and arborization 
(Ji et al., 2011), presumably via tubulin deacetylation (North et al., 2003). QKI facilitates proper 
CNS myelination via post-transcriptional regulation of several transcripts during OL 
development (Chen et al., 2007b; Larocque et al., 2002; Wu et al., 2002; Li et al., 2000; Zhao et 
al., 2006a; Zhao et al., 2010; Larocque et al., 2005; Doukhanine et al., 2010; Zhao et al., 2006b; 
Zearfoss et al., 2011). Interestingly, in qkv/qkv mutant mice, there is reduced protein expression 
of SIRT2, while the expression of Sirt2 mRNA is not altered in the brain tissue (Zhu et al., 2012; 
Werner et al., 2007). In addition, it has been reported that QKI indirectly controls the expression 
of SIRT2 during myelination through co-transport with PLP to the myelin sheath (Zhu et al., 
2012; Werner et al., 2007). Although the transport of SIRT2 protein into the myelin sheath is 
dependent on PLP (Zhu et al., 2012; Werner et al., 2007), the developmental expression of Sirt2 
mRNA and protein is most likely regulated by an alternate mechanism(s) since Sirt2 is expressed 
prior to myelin structural proteins both in vitro (Zhu et al., 2012; Ji et al., 2011) and in vivo ( Zhu 
et al., 2012; Werner et al., 2007; Li et al., 2007a, Southwood et al., 2007). The present study 
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deciphers the precise molecular interactions governing the expression of qkI and Sirt2 during OL 
differentiation.  
In this study, I found that during OL differentiation, there is coordinated expression of 
qkI and Sirt2 (Fig. 3.1 and Fig. 3.2) and overexpression of qkI increased the expression of SIRT2 
(Fig. 3.4 and Fig. 3.6) raising the possibility that QKI may directly modulate Sirt2 mRNA 
expression. In silico analysis revealed two putative quaking response elements, QRE-1 
(AUUAAC) at 1639 bp and QRE-2 (ACUAAC) at 1853 bp in the 3ʹ UTR of Sirt2 (Fig. 3.7A), 
that conform to the predicted core binding sequence ACUAAY (Galarneau and Richard, 2005) 
or its variant AUUAAY (Wu et al., 2002). A direct interaction of QKI with Sirt2 transcripts was 
confirmed by RNA co-IP (Fig. 3.7B, C and Fig. 3.8A). Binding of QKI to Sirt2 mRNA was 
observed in both proliferating OLs and differentiating OLs, suggesting that the interaction 
between QKI and Sirt2 mRNA is most critical throughout OL development (Fig. 3.7B, C and 
Fig. 3.8A). Moreover, expression of Sirt2 drives differentiation at the molecular level by 
enhancing the expression of MBP (Ji et al., 2011). Thus, the interaction of QKI with Sirt2 
mRNA may be critical in OL differentiation prior to the onset of myelination. Further analysis 
revealed that the QRE sequence ACUAAC at 1853-1858 bp was essential for the binding of QKI 
to Sirt2 mRNA (Fig. 3.10A, B). This reflected the predicted sequence for high affinity binding 
(Galarneau and Richard, 2005) and was highly conserved across the mammalian Sirt2 transcripts 
(Fig. 3.7A). The ability of QKI to bind Sirt2 mRNA indicates that QKI controls SIRT2 protein 
expression during OL development through a direct interaction with Sirt2 transcripts.  
A reduction in myelin specific gene transcripts in qkv/qkv mice has been shown to be due 
to post-transcriptional regulation by QKI as transcription rates are not altered (Li et al., 2000). 
QKI has been implicated in regulating the stability (Larocque et al., 2005; Doukhanine et al., 
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2010; Zhao et al., 2006b), splicing (Wu et al., 2002, Zhao et al., 2010), transport (Larocque et al., 
2002; Li et al., 2000) and translation (Roth et al., 1985; Sorg et al., 1986) of mRNAs in 
developing OLs. Though QKI was found to bind all three variants of Sirt2 (Fig. 3.7D, E and Fig 
3.8B, C), my data shows QKI primarily modulates the post-transcriptional stability of the Sirt2.1 
and Sirt2.2 mRNA (Fig. 3.11A, B) and protects Sirt2.1 and Sirt2.2 mRNA from degradation 
(Fig. 3.11). Thus, in addition to regulating major myelin transcripts such as Mbp and Plp, QKI 
also controls the stability of Sirt2 during OL development.  
My findings demonstrate that QKI was able to, in some capacity, promote the expression 
of all three Sirt2 variants; however, the functional interaction between QKI and Sirt2.2 appears 
to be important for proper OL development. Indeed, SIRT2.2 is the most abundant isoform in 
OLs in vitro (Fig. 3.2) and in vivo (Zhu et al., 2012), and the main isoform incorporated into the 
myelin sheath (Werner et al., 2007). While there is efficient binding of QKI to both Sirt2.1 and 
Sirt2.2 transcripts, the interaction between QKI and Sirt2.2 mRNA is associated with greater 
stabilization of this transcript (Fig. 3.11B). As all QKI isoforms share a common RNA binding 
domain (Ebersole et al., 1996) and the Sirt2 QRE is located in the common 3' UTR, it is still 
unclear how preferential binding and protection with Sirt2.2 is achieved. As Sirt2.2 is the most 
abundant transcript, possibly due to preferential usage of transcriptional start site (Maxwell et al., 
2011) and/or alternative splicing, this increased availability could be the reason for a more 
prominent functional interaction with QKI. These data, along with an increase in the endogenous 
expression of both Sirt2.2 mRNA and protein at early stages of differentiation (Fig. 3.2), are 
indicative that the regulation of Sirt2.2 by direct interaction with QKI is critical for proper OL 
development.  
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The QUA1 domain in the QKI protein promotes homodimerization, which promotes the 
ability of QKI to bind to target RNA (Beuck et al., 2012). Overexpression of the common coding 
region promoted homodimerization of the QKI protein in both CG4-OLs and primary OLs. 
Interestingly, upregulation of qkI increased the accumulation of Sirt2 mRNA (Fig. 3.4A, B and 
Fig. 3.6A, B) and expression of SIRT2 protein (Fig. 3.4C-F and Fig 3.6C-F). Moreover, 
observations using primary OLs further provide evidence of physiological interaction of QKI and 
Sirt2 mRNA during OL development in vivo.  Although a similar interaction was observed in 
both CG4-OL cell line and primary OLs, the binding affinity was ~10 fold higher in primary 
OLs (Fig. 3.8). Higher expression levels of QKI isoforms in primary OLs (Fig. 3.5A, B) could 
serve to increase the interaction. All QKI isoforms contain identical RNA binding and 
dimerization (QUA1-KH-QUA2) domains (Ebersole et al., 1996; Kondo et al., 1999), and 
therefore have the ability to bind and stabilize Sirt2 transcripts. Higher expression levels of QKI 
isoforms at later stages (i.e. pre-myelinating and myelinating OLs) would stabilize mRNA 
increasing the number of copies available for translation and promoting the expression of SIRT2 
protein. This would serve to tightly control SIRT2 expression during OL differentiation (Fig. 
3.12). Further complexity is added by the potential that dimerization (Chen and Richard, 1998; 
Beuck et al., 2012) and the phosphorylation state (Zhang et al., 2003) of the different QKI 
isoforms may regulate their activity at various stages of OL development. 
Conclusively, the data in this chapter has demonstrated that QKI directly regulates SIRT2 
expression in the OLs by binding to the Sirt2 mRNA at 3′ UTR via a QRE (ACUAAC) at 
1853bp. During OL differentiation, QKI increases the stability of Sirt2 transcripts and the 
amount of transcript available for translation. This may be particularly important for dictating the 
timing of SIRT2 protein, as its expression is regulated early in differentiation and can promote 
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the downstream expression of other myelin proteins (Ji et al., 2011). The expression of QKI 
isoforms would control the availability of target mRNAs for translation and allow OLs to 
synchronize the timing of myelin protein expression during development. My finding on the 
interaction between two key regulators qkI and Sirt2, during oligodendroglial differentiation 
sheds further light into this vital aspect of OL development and myelination. 
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Figure 3.12: Schematic diagram illustrating the interaction of QKI and Sirt2 in OL 
development. When the OPCs start to differentiate into post-mitotic OL, there is increased 
expression of QKI isoforms. Interaction between QKI and Sirt2 stabilizes the mRNA and 
promotes the translation of SIRT2 protein facilitating differentiation. This would allow OL cells 
to accumulate sufficient copies of mRNA but tightly regulate their availability for translation. 
Thus, an interaction between QKI and Sirt2 would serve to regulate the timing of OL 
differentiation for proper CNS myelination. 
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Preamble to Chapter 4: LOSS OF SIRT2 IMPAIRS MYELINATION AND INCREASES 
DISEASE SUSCEPTIBILITY IN EXPERIMENTAL AUTOIMMUNE 
ENCEPHALOMYELITIS (EAE) MOUSE MODEL OF MULTIPLE SCLEROSIS 
Rationale: In the previous chapter, I demonstrated the molecular regulation of SIRT2 expression 
by QKI during OL differentiation. In this chapter, I explored the functional requirement of Sirt2 
during myelination and in MS. Myelinating ability of OLs is crucial for proper development of 
the CNS and the repair of lesions in MS, making it imperative we learn more about what controls 
this aspect of their function. In the mammalian CNS, Sirt2 is primarily expressed in OLs and is a 
major component of the myelin proteome.  However, the role of Sirt2 in CNS myelination and 
MS is largely unknown. Here, I have examined the impact of loss of Sirt2 in myelination and on 
the disease severity of experimental autoimmune encephalomyelitis (EAE), an animal model of 
MS using Sirt2 knockout (Sirt2-/-) mice. 
Contribution statement 
I designed the study, performed experiments and analyzed the data in this chapter. Adil J. 
Nazarali and J. Ronald Doucette conceived and coordinated the study. Kendra L. Furber and 
Paul P. R. Iyyanar helped with blinded clinical scoring in EAE study. Glaiza A. Tan helped with 
tissue sectioning. Bogdan F. Popescu provided human MS brain samples and assisted in 
histology of paraffin embedded brain tissue. This manuscript is in preparation.  
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4. LOSS OF SIRT2 IMPAIRS MYELINATION AND INCREASES DISEASE 
SUSCEPTIBILITY IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS 
(EAE) MOUSE MODEL OF MULTIPLE SCLEROSIS 
4.1 Summary  
The myelinating ability of OLs is crucial for proper development of the CNS and efficient repair 
of lesions in MS. The cellular and molecular mechanisms that control the myelinating ability of 
OLs remain elusive. SIRT2 is a NAD+-dependent deacetylase, predominantly expressed in OLs. 
SIRT2 is upregulated during active myelination and is incorporated into the myelin proteome. 
However, the role of SIRT2 in myelination and MS is largely unknown. In this study, I 
hypothesized that Sirt2 positively regulates CNS myelination and loss of Sirt2 increases the 
disease severity of EAE, an animal model of MS. Ultra-structural analyses reveal that the 
number of myelinated axons is decreased in Sirt2-/- mice compared to age-matched wild-type 
mice. In addition, the expression of myelin structural genes such as Mbp, Plp and Dm20 was 
decreased in Sirt2-/- mice. Deletion of Sirt2 impairs OL proliferation and differentiation. Loss of 
Sirt2 results in increased severity in EAE mouse model in Sirt2-/- mice compared to wild-type 
mice. Furthermore, immunostaining of human MS postmortem brain sections revealed that 
SIRT2 was absent in MS lesions and its expression reappears in the ‘shadow plaques’ indicating 
that it may have an important functional role during remyelination. Taken together, these 
findings suggest that SIRT2 has a critical role in the myelination of CNS axons and a protective 
role in the EAE mouse model of MS.  
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4.2 Introduction 
OLs are the glial cells responsible for the formation of myelin sheath in the CNS. OLs 
originate from OPCs in the VZ/SVZ, migrate and eventually differentiate into myelinating OLs 
(Baumann and Pham-Dinh 2001; Bergles and Richardson 2015). Myelinating OLs expand their 
cytoplasmic processes around axons ultimately leading to formation of a multilayered compact 
myelin sheath (Quarles et al., 2006). Myelination is essential for fast and efficient conduction of 
action potentials. Impairment of OLs or myelin sheath makes the axons more susceptible to 
degeneration leading to chronic demyelinating disease such as MS (Hanafy and Sloane, 2011; 
Miron et al., 2011; Kotter et al., 2011). MS causes neurological disability in adults between 20 to 
50 years of age in North America and Europe with a prevalence of 140 and 108 in 100,000, 
respectively (Multiple Sclerosis International Federation, 2013). Canada has one of the highest 
incidences of MS in the world (World Health Organization, 2008). Understanding the cellular 
and molecular mechanisms regulating differentiation of OPCs into myelinating OLs to promote 
myelination and myelin repair in the CNS is crucial for treatment interventions.  
Recently, the sirtuin (SIRTs) family of deacetylases has gained considerable attention for 
their impact on the regulation of myelination and axonal degeneration (Li et al., 2007a; Suzuki 
and Koike, 2007). SIRTs are class III NAD+-dependent protein deacetylases evolutionarily 
conserved from bacteria to mammals (Brachmann et al., 1995; Frye, 2000; North, et al., 2003). 
In mammals, seven sirtuins have been identified (SIRT1 to 7) with a conserved 275-amino-acid 
catalytic core domain (Blander and Guarente, 2004; Frye, 2000). Among them, SIRT2 is 
predominantly expressed in the cytoplasm of OLs (North et al., 2003).  Sirt2 is reportedly 
detected throughout the OL lineage, with higher abundance in mature OLs  (Werner et al., 2007).  
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Previously our group has demonstrated that SIRT2 is essential for the process formation and 
maturation of OLs in vitro (Ji et al., 2011).  
Expression of SIRT2 increases during the peak period of myelination in the CNS 
(Southwood et al., 2007) as well as in the PNS (Beirowski et al., 2011). Interestingly, the 
expression profile of SIRT2 is similar to the expression of myelin markers such as MBP and 
MPZ in CNS and PNS, respectively (Ji et al., 2011; Beirowski et al., 2011). In addition, studies 
on myelin proteome revealed that the isoform SIRT2.2 integrates into myelin sheath (Werner et 
al., 2007) in close proximity to PLP and is localized in paranodal loops (Li et al., 2007a; 
Southwood et al., 2007). In PNS, knockout of Sirt2 in Schwann cells resulted in delayed myelin 
formation with extensive outfoldings in the compact myelin near paranodes (Beirowski et al., 
2011). In Schwann cells, SIRT2 deacetylates the master regulator of cell polarity Par-3, 
decreasing the activity of atypical protein kinase C and thereby regulating myelin formation 
(Beirowski et al., 2011). However, the role of SIRT2 in CNS myelination and MS has not been 
investigated.  
In an effort to understand the role of Sirt2 in CNS myelination, I utilized Sirt2 null (Sirt2-
/-) mice to determine the impact of the loss of function of Sirt2 on myelin ultrastructure, myelin 
specific gene expression, OL proliferation and differentiation. Furthermore, to investigate the 
role of Sirt2 in the pathogenesis of MS, experimental autoimmune encephalomyelitis (EAE), an 
established animal model of MS, was induced in Sirt2-/- and wild-type mice using MOG35-55 
peptide. My findings reveal that Sirt2 plays a critical role in the myelination of axons in CNS and 
a protective role in the EAE mouse model of MS. 
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4.3 Materials and Methods 
4.3.1 Animals 
 Breeding pairs of wild-type (Strain name: C57BL/6J; Stock number: 000664) and Sirt2-/- mice 
(Strain name: B6.129-Sirt2tm1.1FWa/J; Stock number: 012772) were purchased from The Jackson 
Laboratory. The Sirt2 null mice were generated using a targeting vector for the mouse Sirt2 gene 
with floxed neomycin (neo)- selection cassette to delete exons 5, 6 and part of exon 7 of the Sirt2 
gene. The targeting construct was electroporated into 129S6/SvEvTac-derived TC1 embryonic 
stem cells. The targeted stem cells were further transiently transfected with Cre recombinase 
plasmid to remove the neo cassette and subsequently injected into C57BL6/J blastocysts. The 
resulting chimeric males were bred with 129/Sv females. The progeny of chimera were then 
backcrossed to C57BL/6 mice for 8 generations to produce homozygous Sirt2-/- mice. At The 
Jackson Laboratory, the resulting mice were bred with C57BL/6J for atleast one generation to 
establish the colony (https://www.jax.org/strain/012772). Genotyping was carried out using 
common forward primer (5'-GACTGGAAGTGATCAAAGCTC-3') and specific reverse primer 
for wild-type (5'-CAGGGTCTCACGAGTCTCATG-3') and Sirt2 mutant (5'-
TCAAATCTGGCCAGAACTTATG-3'). Mice were bred in house at the University of 
Saskatchewan animal facility in compliance with the University of Saskatchewan’s Animal Care 
Committee guidelines. Animal use was approved by the University of Saskatchewan’s Animal 
Research Ethics Board, and adhered to the Canadian Council on Animal Care guidelines for 
humane animal use. 
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4.3.2 Primary OL cell culture 
Primary OLs were prepared from the cortices of wild-type or Sirt2-/- mouse embryos at E15.5 
(Chen et al., 2007a). Briefly, meninges free cerebral cortices were dissected from the embryonic 
brains and dissociated with Accumax solution (Sigma). The cell suspensions were centrifuged to 
remove accumax and were resuspended in neurosphere growth medium (DMEM/F12, 25 mg/mL 
insulin, 100 mg/mL apo-transferrin, 20 nM progesterone, 60 mM putrescine and 30 nM sodium 
selenite) supplemented with EGF (20 ng/mL) and bFGF (20 ng/mL). The cells were passed 
through a 70 µm nylon cell strainer and plated on uncoated 100 mm cell culture dishes. After 4 
days, neurospheres were passed at 1:3 ratio. Neurospheres were dissociated to generate primary 
OLs using accumax and plated on poly-D-lysine (Sigma) coated dishes in neurosphere growth 
medium supplemented with 10 ng/mL human recombinant platelet-derived growth factor 
(PDGF-AA) and 10 ng/mL basic fibroblast growth factor (bFGF). Differentiation of primary 
OLs were induced by plating the cells in OL differentiation medium containing 10 ng/mL biotin, 
5 µg/mL insulin, 50 µg/mL transferrin, 2 mM glutamine, 30 nM sodium selenite, 0.1% BSA, 10 
nM hydrocortisone, 1% penicillin-streptomycin solution, 5 µg/mL N-acetyl-L-cysteine and 1% 
FBS in DMEM/F12.  
4.3.3 RNA isolation and qPCR  
Total mRNA from the corpus callosum (CC) was isolated using Ambion total RNA miniprep kit 
(Invitrogen) as per the manufacturer’s protocol. First strand cDNA synthesis (reverse 
transcription) was performed using High-Capacity cDNA Reverse Transcription kit (Applied 
Biosystems) with random primers. The qPCR was carried out using SYBR select master mix 
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(Applied Biosystems) in Step one Real Time PCR System (Applied Biosystems) with gene 
specific primers designed using primer-BLAST tool (Table 4.1).  
The relative levels of transcripts were determined by threshold cycle differences (2-ΔΔCT) of 
target normalized to the endogenous control (β-actin) as previously described (Doucette et al., 
2010). 
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Table 4.1: Primer sequences used for the relative quantification of myelin specific genes in 
CC by qPCR  
Genes Primer sequences 
Sirtuin2 (Sirt2) 5′-AGCAAGGCACCACTAGCCACC-3′  
5′-TGTTCCTCTTTCTCTTTGGTC-3′ 
Myelin basic protein (Mbp) 5′-CATGGCTTCCT CCCAAGGCAC-3' 
5′-GCCATGGGAGATCCAGAGCGG-3' 
Proteolipid protein (Plp) 5′-GGTACAGAAAAGCTAATTGAGACC-3′ 
5′-GATGACATACTGGAAAGCATGA-3′ 
Proteolipid protein and the 
alternatively spliced isoform of 
Plp (Plp /Dm20) 
5′-GGTACAGAAAAGCTAATTGAGACC-3' 
5′-GATGACATACTGGAAAGCATGA-3' 
β-actin 5′-ATTGTAACCAACTGGGACG-3'  
5'-TTGCCGATAGTGATGACCT-3' 
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4.3.4 Western blot analyses 
Proteins were extracted from CC using RIPA lysis buffer at 4°C. Proteins (20 µg) were separated 
on 12% SDS-PAGE and Western blot analyses were performed with the following primary 
antibodies: rabbit polyclonal anti-SIRT2 (1:3000; Sigma) antibody and mouse monoclonal anti-
β-tubulin (1:1000; Developmental Studies Hybridoma) antibody. Secondary antibodies utilized 
were goat anti-rabbit IgG- horse radish peroxidase (HRP) conjugate for SIRT2 and goat anti-
mouse IgG- HRP (Biorad) in case of β-tubulin. Blots were developed with Clarity™ Western 
ECL Substrate (BioRad). 
4.3.5 Immunohistochemistry  
Wild-type or Sirt2-/- mouse brains at P15 were harvested and fixed with 4% paraformaldehyde 
overnight at 4°C. Fixed brains were cryoprotected in 30% sucrose overnight at 4°C and 
embedded in Tissue-Tek OCT (Electron Microscopy Sciences). Coronal sections (10 µm) were 
prepared from the brain of wild-type or Sirt2-/- mice. Sections were rehydrated with phosphate 
buffered saline (PBS) for 15 min and pre-permeabilized with PBS containing 0.4% Triton X-100 
for 30 min. Sections were blocked with 10% goat serum in PBS containing 0.4% Triton X-100 
for 1 h and incubated with the rabbit polyclonal anti-MBP (Abcam®) antibody overnight at 4°C. 
The sections were then washed three times and incubated with goat polyclonal anti-rabbit IgG 
(Alexa Fluor® 594; Molecular Probes®) secondary antibody for 1 h at room temperature and 
mounted with Prolong Gold anti-fade reagent containing DAPI (Invitrogen®). 
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4.3.6 BrdU (5-bromo-2′-deoxyuridine) labeling  
For OPC proliferation analysis, wild-type or Sirt2-/- mouse were injected intraperitoneally with 
BrdU (100mg/kg; Sigma) at P7. After three hours, the mice were perfused with 4% 
paraformaldehyde, the brains were dissected out and fixed in 4% paraformaldehyde overnight at 
4°C. The percentage of proliferating OPCs was determined by double labeling brain sections 
with mouse monoclonal anti-Olig2 (Millipore) and rat monoclonal anti-BrdU antibody (Abcam). 
Coronal sections (10 µm) were rehydrated with PBS for 15 min. The sections were incubated 
with 1 N HCl for 10 min at 4°C, 2 N HCl for 20 min at 37°C and were neutralized with 0.1 M 
sodium borate buffer (pH 8.5) for 10 min. Standard immunohistochemistry protocol was 
followed as mentioned above. Brain sections were imaged using an Olympus VS110 slide 
scanner (Cameco MS Neuroscience Research Center, Saskatoon). Olig2 and BrdU positive cells 
in the whole CC region (marked with dashed line in Figure 4.6) were counted from five wild-
type and five Sirt2-/- mutant brain sections. Cell counts were carried out using Image J software 
(NIH) (Doucette et al., 2010) and expressed as the percentage proliferating OPCs (Olig2+/BrdU+ 
cells). 
4.3.7 Immunocytochemistry 
Immunocytochemistry was carried out following the protocol described by Wang et al. (2011). 
Primary OLs were cultured on a poly-D-lysine coated dish containing coverslips at a density of 2 
x 102 cells/mm2. Cells were fixed with 4% paraformaldehyde for 15 min and washed two times 
with PBS. Cells were blocked with 10% goat serum in PBS containing 0.4% Triton X-100 and 
incubated with the rabbit polyclonal anti-MBP (Abcam®) antibody overnight at 4°C. The cells 
were washed three times and incubated with goat polyclonal anti-rabbit IgG (Alexa Fluor® 594; 
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Molecular Probes®) secondary antibody for 1 h at room temperature. Coverslips were mounted 
with Prolong Gold anti-fade reagent containing DAPI (Invitrogen®).  
4.3.8 Luxol fast blue (LFB) staining 
Paraffin embedded human MS brain tissue blocks were sectioned (10 µm) and stained with 
Luxol fast blue (LFB). Deparaffinized sections were incubated with 0.1% LFB solution 
overnight at 60°C, washed with 95% alcohol, deionized water and differentiated in 0.05% 
lithium carbonate for 30-90 s. The slides were then rinsed in 70% alcohol, distilled water and 
transferred to Harris hematoxylin solution to counterstain with hematoxylin and eosin (HE). The 
sections were washed in water, acid alcohol (0.5% HCl in 95% alcohol), distilled water and 
saturated aqueous lithium carbonate.  The sections were then stained with eosin subjected to 
dehydration in a series of ethanol, ethanol/xylene, xylene and finally mounted in DPX mounting 
media (Sigma). 
4.3.9 Electron microscopy (EM) 
Postnatal day 15 (P15) Sirt2-/- and wild-type mice were anesthetized and perfused with 2.5% 
glutaraldehyde and 4% paraformaldehyde in 0.1 M sodium cacodylate buffer (Werner et a., 
2013). After perfusion, brain was dissected out and post-fixed in the same fixative used for 
perfusion. Tissue was processed and embedded in Epon resin. The cross-sections of CC from 
matching areas of Sirt2-/- and wild-type brains were visualized using transmission electron 
microscopy (TEM) (Philips 410LS electron microscope). Electron micrographs from five 
different fields of view from five different animals were used for the quantification of total 
number of myelinated axons and myelin thickness. Total numbers of myelinated axons were 
analyzed using Image J software (National Institutes of Health). Quantification of myelin 
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thickness was carried out by measuring the diameter of the individual myelin fibers in relation to 
respective axon diameters using Image-Pro Plus software and represented as g-ratio (ratio of 
axon diameter to myelin fiber diameter). Axon diameter was obtained by measuring the shortest 
diameter of each axon.  
4.3.10 EAE induction 
EAE was induced in 8 week old Sirt2-/- and wild-type mice by injecting MOG35-55 peptide (200 
µg) suspended in complete Freund’s adjuvant (CFA) subcutaneously into two different sites on 
the hind flank on days 0 and 7. Additionally, mice were subjected to intraperitoneal injection 
with Pertussis toxin on the day of immunization and two days later. A sham control group was 
immunized with PBS in CFA without antigen subcutaneously. Mice were monitored for body 
weight and scored daily for clinical disease severity according to a standard EAE grading scale 
(0, No clinical signs; 1, loss of tail tone; 2, hindlimb weakness; 3, partial hindlimb paralysis; 4, 
complete hindlimb and forelimb paralysis; and 5, moribund or dead) for 30 days. Brain and 
spinal cord samples were collected in 10% neutral buffered formalin on day 30 after EAE 
induction (Miller et al., 2007; Rafalski et al., 2013).  
4.3.11 Statistical analysis  
Data are presented as mean ± standard error of the mean (SEM). For experiments involving one 
independent variable, an unpaired t-test was performed.  For experiments with two or more 
independent variables, a two-way analysis of variance was conducted followed by Bonferroni’s 
multiple comparisons post hoc test (Graphpad prism, Prism® Software Corporation), as 
indicated in the figure legends. 
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4.4 Results 
4.4.1 Confirmation of the loss of Sirt2 expression in Sirt2-/- mice 
 To determine the impact of Sirt2 in CNS myelination and MS in vivo, I used Sirt2-/- mice 
purchased from Jackson Laboratory. The Sirt2-/- mice were generated by the targeted insertion of 
pGK-Neo cassette into exons 5, 6 and part of exon 7 of the Sirt2 gene. To validate the loss of 
Sirt2 expression in the Sirt2-/- mice, genotyping was done using specific primers for wild-type 
(WT) and Sirt2-/- mutant alleles (Fig. 4.1A). A complete loss of Sirt2 mRNA (Fig. 4.1B) and 
SIRT2 protein (Fig. 4.1C) was observed in the CC of Sirt2-/- mice. 
 
Figure 4.1: Sirt2-/- mice show complete loss of Sirt2 mRNA and protein expression. (A) 
Genotyping of Sirt2-/- mice was performed using primers specific for wild-type (WT; lane 2 and 
4) and Sirt2-/- mutants (lane 1 and 3). The presence of amplicon at 538 bp (lane 2) and absence of 
amplicon at 700 bp (lane 1) confirms the WT phenotype, whereas the presence of amplicon at 
700 bp (lane 3) and absence of amplicon at 538 bp (lane 4) confirms the Sirt2 mutant phenotype. 
(B) RT-PCR show the complete absence of Sirt2 mRNA in the corpus callosum (CC) of Sirt2-/- 
mutants.  (C) Immunoblots of lysates prepared from the corpus callosum (CC) of Sirt2-/- mice 
show complete absence of the SIRT2 protein. 
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4.4.2 Hypomyelination in Sirt2-/- mice 
Our laboratory has previously demonstrated that Sirt2 promotes process formation and 
expression of MBP in vitro in CG4-OLs (Ji et al., 2011). To determine the effect of loss of 
function of Sirt2 on the CNS myelination in vivo, TEM technique was employed to examine the 
CC of wild-type and Sirt2-/- mice at P15, a stage at which myelination peaks in rodents. Ultra-
structural analysis of myelin in CC showed that the number of myelinated axons was reduced by 
~70% in Sirt2-/- mice at P15 compared to controls (Fig. 4.2A, B, C). In the wild-type controls, 
about 63% of axons were myelinated while only 20% of axons were myelinated in the Sirt2-/- 
mice at P15 (Fig. 4.2C). Although the numbers of myelinated axons were decreased in the Sirt2-/- 
mice, the g-ratio analyses (ratio of axon diameter to myelin fiber diameter) revealed an increase 
in myelin thickness (lower g-ratio, red circles) (Fig. 4.2F). However, the myelin sheath of Sirt2-/- 
mice was uncompacted, which could explain the increased myelin thickness (Fig. 4.2D, E, F). 
Furthermore, in Sirt2 null mice, a slight decrease in the myelination of small sized axons was 
accompanied by a shift in the myelination of large diameter axons (Fig. 4.3A), although not 
statistically significant. These results suggest that the loss of Sirt2 results in severe 
hypomyelination during CNS development in vivo. 
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Figure 4.2: Hypomyelination in Sirt2-/- mice. (A and B) Electron micrographs in the CC 
sections of Sirt2-/- mice (B) show severe hypomyelination at P15 compared to wild-type controls 
(A). Scale bar = 5 µm. (C) Quantification of the total number of myelinated axons showed a 
significant reduction in Sirt2-/- mice. Data are represented as mean ± SEM. ***P < 0.001, 
Unpaired t-test (n = 5). (D and E) Representative image showing uncompact myelin in the Sirt2-
/- mice compared to wild-type. Scale bar = 500 nm. (F) Morphometric quantification of the 
myelin thickness by g-ratio analyses (ratio of axon diameter to myelin fiber diameter) shows 
increase in myelin thickness in Sirt2-/- mice (red circles) compared to wild-type (black circles).  
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Figure 4.3: Axon calibers in Sirt2-/- mice. A. Diameters of all myelinated axons were measured 
in the CC of P15 Sirt2-/- mice and WT controls. In the Sirt2-/- mice, there is reduction in 
myelination of small sized axons less than 2 µm in diameter accompanied by a shift to large 
diameter axons (grey bars). 
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4.4.3 Loss of Sirt2 gene impairs the expression of key myelin structural genes 
To investigate the impact of loss of Sirt2 on myelin gene expression, qPCR was performed in 
Sirt2-/- mice during the peak of myelination at P15. Loss of Sirt2 results in ~50% decreased 
expression of major myelin transcripts, Mbp, Plp and Plp/Dm20, which constitute the structural 
component of myelin sheaths, as compared to wild-type at P15 (Fig. 4.4A, B, C). To determine if 
the reduction in gene expression persisted in older mice, myelin specific gene expression profiles 
were assessed at P77. Expression of Mbp was reduced ~70% in Sirt2-/- mice compared to age 
matched wild-type controls (Fig. 4.4D), whereas Plp and Plp/Dm20 were reduced ~30% and 
20%, respectively, in Sirt2-/- mice (Fig. 4.4E, F). In addition, immunostaining of MBP in the 
rostral CC of Sirt2-/- mice (Fig. 4.5B, D) showed reduced expression of MBP compared to the 
wild-type controls at P15 (Fig. 4.5A and C).  
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Figure 4.4: Reduced myelin specific gene expressions in Sirt2-/- mice. qPCR (n = 3) of RNA 
isolated from CC of Sirt2-/- mice and WT controls shows a significant reduction in the expression 
of Mbp, Plp, and Plp/Dm20 at P15 (A, B and C) and at P77 (D, E and F). The bar graphs 
represent the transcript levels of Mbp, Plp, and Plp/Dm20 relative to wild-type controls. Data 
represented as mean±SEM; Unpaired t test *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 4.5: Immunohistochemical staining of myelin basic protein (MBP) on coronal 
sections of P15 brain. (A-D) Immunohistochemical analysis (n = 5) of myelin basic protein 
(MBP) in coronal sections through the rostral CC of wild-type mice (A) and Sirt2-/- mice at P15 
(B). Scale bar = 200 µm. Sirt2-/- mice show reduced expression of MBP in the rostral corpus 
callosum (B and D compared to A and C). Inserts show higher magnification of the boxed 
region (C and D). Scale bar, 100 µm. 
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4.4.4 Loss of Sirt2 impairs oligodendrogenesis and OL proliferation  
To determine if the hypomyelination observed in Sirt2-/- mice is due to impaired proliferation of 
OPCs, the percentage of proliferating OPCs was examined by double labeling brain sections with 
Olig2, an OPC marker and BrdU, proliferation marker at P7 (Fig 4.6). The total number of 
Olig2+ OPCs was severely reduced by 80% in the Sirt2-/- mice (Fig 4.6 B, D, E) compared to 
wild-type controls (Fig 4.6 A, C, E) in the CC at P7. Similarly, the percentage of proliferating 
OPCs (BrdU+/ Olig2+) was reduced by 60% in the Sirt2-/- mice (Fig 4.6 B, D, G) compared to 
wild-type controls (Fig 4.6 A, C, G). These results suggest that Sirt2 plays a critical role in OL 
cell proliferation during early development.     
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Figure 4.6: Loss of Sirt2 impairs OPC proliferation. Wild-type and Sirt2-/- mice were injected 
with BrdU (100 mg/kg) intraperitoneally at P7 and brains were harvested after three hours. Brain 
sections (n = 5) were double labeled with Olig2 (red) and BrdU (green) to quantify the 
proliferating OPCs. Representative images showing Olig2+ and BrdU+ cells in the rostral CC 
(dashed line) of wild-type mice (A) and Sirt2-/- mice (B) at P7. Scale bar, 200 µm. (C and D) 
High magnification images show less Olig2+ and BrdU+ cells in the CC of Sirt2-/- mice. Scale bar, 
100 µm. Quantification of total number of OPCs (Olig2+ cells) (E), total proliferating cells 
(BrdU+ cells) (F) and proliferating OPCs (Olig2+/BrdU+ cells) (G) show reduction in the number 
of OPCs and proliferating OPCs in the CC of Sirt2-/- mice compared to wild-type mice. 
Mean±SEM; Unpaired t test **p < 0.01, ***p < 0.001.  
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4.4.5 Loss of Sirt2 impairs OL differentiation  
To examine if loss of Sirt2 affects OL differentiation, primary OLs isolated from the brains of 
E15.5 Sirt2-/- and wild-type mice were seeded at 0.5 x 106 and allowed to differentiate in vitro for 
6 days.  The differentiated cells were stained with MBP to determine the extent of OL 
differentiation. The number of processes that arised from the Sirt2-/- primary OLs were less 
compared to wild-type primary OLs, indicating that loss of Sirt2 impairs differentiation of 
primary OLs (Fig 4.7). This indicates that in addition to OPC proliferation, Sirt2 plays a critical 
role in OL differentiation during development.      
 
Figure 4.7: Impaired OL differentiation of the primary OLs from Sirt2-/- mice. Primary OLs 
isolated from E15.5 wild-type and Sirt2-/- mice (n = 6) were allowed to differentiate for 6 days 
and immunolabeled for MBP (red) to examine the morphology of differentiated OLs. 
Representative images showing MBP labeled primary OLs from wild-type (A) and Sirt2-/- (B) 
mice. Scale bar, 100 µm. Higher magnification images of the differentiated cells from wild-type 
(C) and Sirt2-/- (D) primary OLs. Scale bar, 50 µm. 
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4.4.6 Loss of Sirt2 increases the disease severity of EAE 
To examine the impact of loss of function of Sirt2 on MS, EAE, a mouse model of human MS, 
was induced by immunizing the Sirt2-/- and wild-type mice with MOG35-55 peptide (200 µg) 
emulsified in CFA. A sham control group was immunized with PBS without the antigen. Mice 
were monitored for weight and scored daily for clinical disease severity according to standard 
EAE grading scale for 30 days after immunization (Miller et al., 2007). An increase in the 
clinical disease severity of EAE in the Sirt2-/- EAE mice, compared to the wild-type EAE mice, 
was observed around days 18 to 20 (Fig. 4.8). The sham control group did not develop any 
clinical disease signs. These results suggest that SIRT2 could plausibly play a protective role in 
EAE.  
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Figure 4.8: Increased severity of EAE in Sirt2-/- mice. Eight weeks old Sirt2-/- mice  (n = 8; red 
squares) and wild-type mice (n = 8; black circles) were immunized with MOG35-55 peptide 
emulsified in CFA to induce EAE. A sham control group was immunized with PBS without the 
antigen. The EAE clinical scores were monitored for 30 days. EAE induction increased the 
disease severity in Sirt2-/- mice compared to wild-type mice. (Mean±SEM; Two-way ANOVA 
followed by Bonferroni’s multiple comparison test; *P < 0.05, **P < 0.01). 
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4.4.7 SIRT2 expressed in the shadow plaques of human MS post-mortem brain and 
functions in myelin repair 
Clinical phenotype in MS is generally associated with active demyelination, which is 
characterized by the complete loss of myelin and appears as a plaque (Fig. 4.9A, C, G). 
Remyelinated lesions (shadow plaque) appears in some MS patients with chronic MS. Staining 
of human MS post-mortem brain sections with luxol fast blue (LFB) sharply demarcated the 
areas of chronic inactive demyelinated lesions and shadow plaques from the normal appearing 
white matter based on the amount of myelin density (Fig. 4.9C, E, G). Inactive demyelinated 
lesions are identified by the presence of macrophages wihout LFB-positive or myelin 
immunoreactive debris (data not shown). Interestingly, immunostaining of human MS post-
mortem brain sections with anti-SIRT2 antibody revealed that the distribution of SIRT2 was 
absent in the areas of MS lesions and its expression reappears in the ‘shadow plaques’ similar to 
LFB (Fig. 4.9B, D, F, H).  This indicates that SIRT2 might play a role in remyelination in 
patients with MS. 
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Figure 4.9: Human multiple sclerosis postmortem brain section stained with (A) luxol fast 
blue (LFB)/hematoxylin and eosin (LFB/HE) and (B) with an antibody against SIRT2. (A) 
LFB/HE staining reveals the normally myelinated white matter in the brain, indicated by an 
asterisk. Thick arrows indicate the demyelinated lesions where there is complete absence of LFB 
staining and thin arrows indicate ‘shadow plaques’ in which the demyelinated axons are 
remyelinated (marked by faint myelin staining). (B) SIRT2 immunohistochemistry indicates that 
the distribution of SIRT2 in the white matter is similar to that of LFB staining. (A and B) Scale 
bar, 5 mm. (C, D, E and F) The normally appearing white matter, ‘shadow plaques’ and 
demyelinated lesions can be clearly distinguished based on the intensity of LFB. The borders are 
indicated with dashed lines. The expression of SIRT2 reappears in the ‘shadow plaques’ (D and 
F). (G and H) In lesions where axons are demyelinated there is complete absence of LFB. 
Sparse staining of SIRT2 in (H) (thick arrow) appears to be background staining. Scale bar, 50 
µm. 
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4.5 Discussion 
In the CNS, SIRT2 is predominantly expressed in premyelinating and myelinating OLs 
(North et al., 2003). SIRT2 expression is upregulated during active myelination and is an 
important component of myelin proteome (Li et al., 2007a; Southwood et al., 2007; Werner et 
al., 2007). Moreover, Sirt2 has been demonstrated to play a significant role in the PNS 
myelination (Beirowski et al., 2011). However, its role in the CNS myelination and disease 
severity of EAE, a mouse model of human MS is not known. In this study, using Sirt2-/- mice I 
have shown that the loss of Sirt2 results in hypomyelination with downregulation of myelin 
specific gene expression and impaired OL development. In addition, EAE induction has 
demonstrated that the loss of Sirt2 results in an increased severity of EAE in Sirt2-/- mice 
compared to wild-type mice. My findings demonstrate that SIRT2 may play a crucial role in 
myelination and a protective role in the EAE mouse model of MS. 
SIRT2 is primarily located in paranodal loops where it could potentially play a role in 
axo-glial interactions and mediate long-term axonal integrity (Li et al., 2007a). In the PNS of 
Sirt2-/- mice, there is a delay in myelin formation by Schwann cells with extensive outfoldings in 
compact myelin close to paranodes (Beirowski et al., 2011). In this study, ultra-structural 
analyses with EM reveal that the numbers of myelinated axons are reduced in the CNS of Sirt2-/- 
mice, and their myelin sheath is uncompact. These findings demonstrate the importance of 
SIRT2 in maintaining the integrity of the myelin sheath. During the peak of myelination, the 
myelinogenic potential of OLs rapidly increases and OLs synthesize higher amounts of major 
myelin proteins, lipids, and other cytoskeletal elements (Ishii et al., 2012). SIRT2 is expressed in 
OLs prior to expression of myelin proteins and continues to be expressed along with myelin 
proteins in differentiated and mature OLs (Ji et al., 2011; Li et al., 2007a). My findings here 
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show that the expression of myelin specific genes such as Mbp and Plp is downregulated in Sirt2-
/- mice. This failure in the up-regulation of myelin specific genes during active myelination 
suggests a possible role of Sirt2 in activating effector molecules and the signaling network that 
aid in the up-regulation of myelin genes.  
Li et al. (2007a) reported that Sirt2 decelerates OL differentiation, preventing premature 
maturation by modulating the rate at which OLs differentiate into myelinating glia. These 
observations were made based on overexpression and knockdown of Sirt2 in vitro, which lead to 
a decrease or increase in the complexity of these arborizations, respectively. However, these 
researchers also reported that OLs with higher levels of endogenous Sirt2 expression have more 
complex cellular arborizations. In addition, postnatal increase in SIRT2 protein in cerebellum 
and spinal cord from day 0 to 60 coincides with an increase in CNP, a marker of 
differentiating/myelinating glia (Li et al., 2007a). Hence, Sirt2 does not appear to be inhibitory to 
OL differentiation. Furthermore, Sirt2 was reported to be an early OL differentiation marker in 
CNS (Southwood et al., 2007). In the present study, the hypomyelination observed in Sirt2-/- 
mice was associated with a defect in OL proliferation and maturation. These results indicate 
that Sirt2 promotes the myelinating ability of OLs. This is in agreement with the findings in 
CG4-OLs that Sirt2 positively regulates OL differentiation in vitro (Ji et al., 2011). 
MS is a chronic demyelinating disease of the CNS characterized by multiple focal areas 
of myelin loss, called lesions or plaques (Noseworthy et al., 2000; Popescu et al., 2013). While 
remyelination occurs in early and late stages of MS, shadow plaques, sharply circumscribed 
regions of reduced myelin staining that stain pale blue with LFB, are completely remyelinated 
lesions that are sometimes present in a subset of patients with MS. In the present study, 
distribution of SIRT2 was evaluated to understand the involvement of SIRT2 in MS lesions. 
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Immunostaining of human MS postmortem brain sections reveal that SIRT2 was absent in the 
areas of demyelinating lesions and its expression reappears in the ‘shadow plaques’. Since Sirt2 
promotes OL differentiation (Ji et al., 2011), the reappearance of SIRT2 suggests that it might 
promote differentiation of OLs and play a role in remyelination. However, increased numbers of 
biopsies are required to validate the significance of SIRT2 in MS remyelinated lesions. It would 
be intriguing to investigate the expression of SIRT2 in normal healthy age-matched control 
brains. In addition, remyelination followed by cuprizone (copper chelator)-induced 
demyelination would be helpful to identify the impact of SIRT2 in remyelination.  
EAE induction in Sirt2-/- mice reveals the contribution of Sirt2 in the pathogenesis of 
MS. Loss of Sirt2 results in an increased severity of EAE. Inhibition or loss of function of SIRT2 
has been reported to promote microglia activation-mediated inflammation (Pais et al., 2013; 
Yuan et al., 2016). In addition, SIRT2 interacts and deacetylates p65 subunit of NF-κB, which 
down-regulates NF-κB-dependent inflammatory genes (Rothgiesser et al., 2010). Inhibition of 
SIRT2 enhanced neuroinflammation in experimental traumatic brain injury by promoting p65 
acetylation and activation of NF-κB-dependent inflammatory genes (Yuan et al., 2016). Hence, 
SIRT2 might play a protective role in the EAE mouse model of MS possibly by inhibiting 
microglial activation and inflammation. However, staining brain and spinal cord sections from 
wild-type and Sirt2-/- EAE mice with microglial marker (Iba1) would confirm if loss of Sirt2 
promotes microglial activation in EAE. Further analysis is required to verify if EAE induction in 
Sirt2-/- mice increased the disease severity due to uncompact myelin, which could increase the 
accessability of MOG in myelin sheath. This could be evaluated by inducing EAE in Sirt2 
overexpressing mice or by using less accessable myelin protein such as MAG to induce EAE.  
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Together, the resu l t s  demonstrate that SIRT2 plays a critical role in oligodendrocyte 
development, myelination, and in the pathogenesis of MS (Fig. 4.10). I anticipate this research 
will advance the existing knowledge on cellular and molecular mechanisms to identify target 
molecules that regulate the myelinating ability of OLs in the adult animal leading to the 
development of potentially new nutrient and pharmacological therapies for MS. 
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Figure 4.10: Schematic diagram representing the loss of function of Sirt2 in myelination 
and disease severity of the EAE mouse model of MS. During early postnatal development, the 
expression of SIRT2 increases, which positively regulates the expression of myelin specific 
genes and myelination. Loss of function of Sirt2 gene impairs myelin gene expression and 
stability of myelin sheath leading to hypomyelination. Mice lacking Sirt2 are more susceptible to 
EAE induction. Thus, Sirt2 may play a crucial role in myelination and a protective role in the 
EAE mouse model of MS. 
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Preamble to Chapter 5: SIRT2 DOES NOT REGULATE CHOLESTEROL 
BIOSYNTHESIS DURING OLIGODENDROGLIAL DIFFERENTIATION IN VITRO 
AND IN VIVO 
Rationale: In the previous chapter, I demonstrated that Sirt2 plays a critical role in the 
myelination of axons in the CNS and a protective role in the EAE mouse model of MS. In this 
chapter, I investigate the plausible targets through which Sirt2 could regulate myelination. 
Cholesterol is essential for myelin biogenesis and impairment in cholesterol biosynthesis 
significantly reduces myelination. SIRT2 has previously been implicated in cholesterol 
biosynthesis by promoting the nuclear translocation of SREBP-2. Hence, I examined whether the 
defect in myelination observed in Sirt2-/- mice was due to a defect in cholesterol biosynthesis. In 
this study, I evaluated the role of Sirt2 in cholesterol biosynthesis in OLs in vivo using Sirt2 null 
(Sirt2-/-) mice and in vitro using CG4-OL cells and mouse primary OLs.  
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5. SIRT2 DOES NOT REGULATE CHOLESTEROL BIOSYNTHESIS DURING 
OLIGODENDROGLIAL DIFFERENTIATION IN VITRO AND IN VIVO 
5.1 Summary 
SIRT2 is a deacetylase enzyme predominantly expressed in myelinating glia of the CNS. We 
have previously demonstrated that Sirt2 expression enhances oligodendrocyte (OL) 
differentiation and arborization in vitro, but the molecular targets of SIRT2 in OLs remain 
speculative. SIRT2 has been implicated in cholesterol biosynthesis by promoting the nuclear 
translocation of SREBP-2. I investigated this further in CNS myelination by examining the role 
of Sirt2 in cholesterol biosynthesis in vivo and in vitro employing Sirt2-/- mice, primary OL cells 
and CG4-OL cells. My results here demonstrate that the expression of cholesterol biosynthetic 
genes in the CNS white matter or cholesterol content in purified myelin fractions did not differ 
between Sirt2-/- and age-matched wild-type mice. Cholesterol biosynthetic gene expression 
profiles and total cholesterol content were not altered in primary OLs from Sirt2-/- mice and in 
CG4-OLs when Sirt2 was either down-regulated with RNAi or overexpressed with vector 
constructs. In addition, Sirt2 knock-down or overexpression in CG4-OLs had no effect on 
SREBP-2 nuclear translocation. These results indicate that Sirt2 does not impact the expression 
of genes encoding enzymes involved in cholesterol biosynthesis, total cholesterol content or 
nuclear translocation of SREBP-2 during OL differentiation and myelination. 
 
	  
 126 
5.2 Introduction 
In the developing CNS, OPCs proliferate and migrate throughout the cortical white 
matter, such as the CC, and ultimately differentiate into mature, myelinating OLs (Baumann and 
Pham-Dinh, 2001; Bergles and Richardson, 2015; Nicolay et al., 2007). These differentiating 
OLs, which are rich in myelin lipids and structural proteins, extend their plasma membranes to 
wrap axons with compact, multilayered membranous sheath. Proper myelination is critical for 
rapid signal conduction and long-term axonal survival (Baumann and Pham-Dinh, 2001; Simons 
and Nave, 2015). 
Myelin contains greater than 70% lipids in its dry weight with 25% cholesterol in the 
total lipid content (Norton and Poduslo, 1973a; Saher and Simons, 2010). In the brain, 
cholesterol biosynthesis increases during the peak of myelination (Dietschy and Turley, 2004; 
Jurevics et al., 1997; Jurevics and Morell, 1995; Muse et al., 2001) and cholesterol needed for 
the myelin biogenesis is primarily derived from the in situ biosynthesis in differentiating OLs 
with little imported via circulation (Jurevics et al., 1997; Jurevics and Morell, 1995). In addition 
to being a large structural component of myelin membranes, cholesterol may also facilitate 
transport and sorting of proteins to form compact myelin sheath (Saher and Simons, 2010; Saher 
et al., 2005; Saher et al., 2009; Simons et al., 2000; Werner et al., 2013). Inactivation or mutation 
of enzymes involved in the cholesterol biosynthetic pathway in OLs, such as squalene synthase 
(SQS; Saher et al., 2005) and Hmg-CoA synthase 1 (HMGCS1; Mathews et al., 2014), perturb 
myelin gene expression and axon ensheathment. Thus, the supply of cholesterol is a rate-limiting 
factor for proper CNS myelination (Mathews et al., 2014; Mathews and Appel, 2016; Saher et 
al., 2005). 
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Two master regulatory transcription factors, sterol regulatory element binding protein 
(SREBP)-1 and SREBP-2, regulate lipid and cholesterol biosynthesis, respectively (Brown and 
Goldstein, 1997; Eberlé et al., 2004). SREBP-2 is synthesized as a precursor (125 kDa) and is 
bound to SREBP cleavage activating protein (SCAP) in the endoplasmic reticulum. Under low 
sterol levels, SREBP-SCAP complex is exported to the golgi where the cytoplasmic N-terminal 
active domain of SREBP-2 is cleaved (Sakai et al., 1996; Wang et al., 1994; Yabe et al., 2002; 
Yang et al., 2002). Subsequently, this mature form (N-terminal domain) of SREBP-2 (68 kDa) 
translocates to the nucleus and binds to SRE inducing the genes encoding enzymes involved in 
cholesterol biosynthesis (Amemiya-Kudo et al., 2002; Eberlé et al., 2004; Horton et al., 2002; 
Horton et al., 2003). The activity of SREBP family of transcription factors is regulated by 
acetylation and deacetylation of lysine residues within the DNA binding domain, which 
modulates SREBP activity and downstream target gene expression (Giandomenico et al., 2003; 
Ponugoti et al., 2010; Walker et al., 2010). However, relatively little is known about the 
regulatory factors governing SREBP-2 activity and cholesterol biosynthesis during OL 
differentiation and myelination in the developing CNS. 
SIRT2, a NAD+-dependent deacetylase enzyme has been implicated in cholesterol 
biosynthesis by facilitating the nuclear translocation of SREBP-2 (Luthi-Carter et al., 2010; 
Taylor et al., 2011). SIRT2 is primarily expressed in OLs and incorporated into the myelin 
sheath near paranodal loops (Li et al., 2007a; Werner et al., 2007). Sirt2 expression promotes 
process formation and induces myelin gene expression during OL differentiation in vitro (Ji et 
al., 2011). Loss of Sirt2 in the PNS delays Schwann cell myelin formation via deacetylation of 
partitioning defective 3 (Par-3), master regulator of cell polarity (Beirowski et al., 2011). In the 
previous chapter, I demonstrated that Sirt2 is critical for CNS myelination and myelin specific 
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gene expression in vivo. It was reported that pharmacological inhibition of SIRT2 or deacetylase 
mutation in Sirt2 impairs cholesterol biosynthesis by reducing nuclear translocation of SREBP-2 
leading to downregulation of several key genes in cholesterol biosynthetic pathways in neuronal 
cultures (Luthi-Carter et al., 2010). In contrast, Bobrowska et al., (2012) reported no effect on 
nuclear translocation of SREBP-2 or cholesterol biosynthesis in brain tissue from one month-old 
Sirt2-/- mice. As SIRT2 expression is upregulated dramatically during the peak of myelination 
(Li et al., 2007a; Southwood et al., 2007; Werner et al., 2007; Zhu et al., 2012), I hypothesize 
that SREBP-2 may be a target of SIRT2 in CNS white matter when OLs are undergoing active 
differentiation and myelination. 
In the present study, I have used Sirt2-/- mutant mice to investigate the role of Sirt2 in 
regulating cholesterol biosynthesis in the developing CNS white matter and primary OL cultures. 
Furthermore, I evaluated the impact of loss or gain of Sirt2 function in CG4-OLs on the 
expression of cholesterol biosynthetic genes, cholesterol content and nuclear translocation of 
SREBP-2.  
5.3 Materials and methods  
5.3.1 Animals 
Sirt2-/- mice (lacking exons 5, 6 and part of exon 7 of the Sirt2 gene) (Strain name: B6.129-
Sirt2tm1.1FWa/J; Stock number: 012772) and C57BL6/J mice were obtained from the Jackson 
Laboratory for breeding in house at the University of Saskatchewan. Genotyping was performed 
using the following primers, Common – 5’-GACTGGAAGTGATCAAAGCTC-3’, Wild-type – 
5’-CAGGGTCTCACGAGTCTCATG-3’, Mutant – 5’-TCAAATCTGGCCAGAACTTATG-3’. 
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Animal use was approved by the University of Saskatchewan’s Animal Research Ethics Board, 
and adhered to the Canadian Council on Animal Care guidelines for humane animal use  
5.3.2 Primary OL cell culture  
Primary OLs were isolated from C57BL/6 mice or Sirt2-/- mice at P1, as previously described 
(Chen et al., 2007a; Niu et al., 2012). Briefly, cortices from the neonatal pups were digested with 
accumax solution (Sigma®) and passed through a 70 µm nylon cell strainer. The filtered cell 
suspensions were maintained as mixed glial cells in medium containing DMEM/F12, 10% FBS 
and penicillin-streptomycin solution. After 7 days of culture, mixed glial cells were grown in OL 
growth medium (OGM) containing 10 ng/mL biotin, 5 µg/mL insulin, 50 µg/mL transferrin, 2 
mM glutamine, 30 nM sodium selenite, 0.1% BSA, 10 nM hydrocortisone, 1% penicillin-
streptomycin solution and 30% of B104 conditioned medium in DMEM/F12 to enrich OL 
progenitors. After 14 days of culture, primary OLs were shaken off (at 200 rpm; 37°C) and 
isolated from the mixed glial cultures. Differentiation was induced in purified primary OLs by 
plating in OL differentiation medium (ODM) containing 10 ng/mL biotin, 5 µg/mL insulin, 50 
µg/mL transferrin, 2 mM glutamine, 30 nM sodium selenite, 0.1% BSA, 10 nM hydrocortisone, 
1% penicillin-streptomycin solution, 5 µg/mL N-acetyl-L-cysteine and 1% fetal bovine serum 
(FBS) in DMEM/F12. In some experiments primary OLs were differentiated using 1% 
delipidated FBS (DLFBS; cholesterol-depleted FBS) to avoid the interference of any external 
source of cholesterol from the media components. Primary OLs were harvested 6 days after 
differentiation for RNA extraction and cholesterol assay.  
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5.3.3 CG4-OL cell culture, small interference RNA, overexpression vector construct and 
transfection 
The CG4-OL cell line was derived from O-A2 progenitors isolated from the rat forebrain (Louis 
et al., 1992). CG4-OLs were cultured on poly-D-lysine (Sigma) coated tissue culture dishes in 
growth medium (GM) containing Dulbecco's modified Eagle's medium (DMEM), 50 µg/mL 
transferrin, 5 µg/mL insulin, 9.8 ng/mL biotin, 50 ng/mL selenium, 1% antibiotic antimycotic 
solution and 30% B104 conditioned medium (CM) (Ji et al., 2011; Louis et al., 1992; Wang et 
al., 2011). Differentiation was induced by changing GM to differentiation medium (DM) 
containing DMEM, 50 µg/mL transferrin, 5 µg/mL insulin, 9.8 ng/mL biotin, 50 ng/mL 
selenium, 1% antibiotic antimycotic solution and 2% FBS or DLFBS (Ji et al., 2011; Wang et al., 
2011) .  
Sirt2 siRNA with sense sequence 5′-AGGGAGCAUGCCAACAUAGAU-3′ commercially 
synthesized (Qiagen®) and pcDNA vector carrying full length Sirt2 insert have been described 
previously (Ji et al., 2011). Transfection was carried out with 40 nM of scramble control siRNA 
or Sirt2 siRNA and 3 µg of pcDNA-Sirt2 vector on day 0, day 2, and day 4 using 0.3% 
Lipofectamine 2000 (Invitrogen®) in serum free / antibiotic free media. Cells were harvested for 
biochemical analyses after 6 days of differentiation. 
5.3.4 RNA isolation, RT-PCR and qPCR 
Total RNA was isolated from the CC, primary OLs or CG4-OL cells using Ambion® total RNA 
miniprep kit (Invitrogen®) as per the manufacturer’s protocol. RNA concentration was 
determined using NanoVue UV/Visible spectrophotometer (GE Healthcare Life Sciences). First 
strand cDNA synthesis was performed with 250-500 ng of total RNA using High-Capacity 
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cDNA Reverse Transcription kit (Applied Biosystems®) with random primers. Final 
concentration of total RNA for RT-PCR or qPCR was 5-25 ng/µL. RT-PCR was carried out for 
Sirt2 in CG4-OLs transfected with Sirt2 siRNA and pcDNA-Sirt2 according to Ji et al. (2011). 
The following primer pairs were used: (i) Sirt2 forward 5′- TGAATGGCACCTACAGAGAC-3′ 
and reverse 5′- CAAAGGCATTATGGTAGGGC-3′; and (ii) β-Actin forward 5ʹ-
ATTGTAACCAACTGGGACG-3ʹ and reverse 5ʹ-TTGCCGATAGTGATGACCT-3ʹ. The qPCR 
was carried out using SYBR select master mix in ABI 7300 (Applied Biosystems®) with cDNA 
samples from CG4-OL cells, primary OLs or corpus callosum of mouse brain. Expression levels 
of Srebp-2, Hmgcr, Sqs, Sqle and Dhcr7 were quantified using the following primers pairs: (i) 
Srebp-2 - forward 5′-TGCAGGTCAAAGTCTCTCCT-3' and reverse 5′-
GCAGGACTTGAAAGCTGGT-3'; (ii) Hmgcr - forward 5′-CTGGTCCTAGAGCTTTCTCG-3' 
and reverse 5′-TGCTGTTCTGAGGAGAAGGA-3'; (iii) Sqs - forward 5′-
GAAGATTCGGAAGGGGCAAG-3' and reverse 5′-CTCAAGTACTGCCAGCTCAG-3'; (iv) 
Sqle forward 5′-TAAGAAATGCGGGGATGTCA-3' and reverse 5′-
GAATATCTGAGAAGGCAGCG-3'; and (v) Dhcr7 forward 5ʹ- 
TTTATGGCCATGTGACCAAC-3ʹ and reverse 5ʹ- AACAGGTCCTTCTGATGGTT -3ʹ. 
Relative quantification of transcripts was determined by threshold cycle differences (2-ΔΔCT) of 
target normalized to the endogenous control β-actin as described previously (Doucette et al., 
2010).  
5.3.5 Immunocytochemistry  
Immunocytochemistry was carried out as previously described in (Wang et al., 2011). CG4-OL 
cells were cultured on coverslips at a density of 2 x 102 cells/mm2. Cells were fixed with 4% 
paraformaldehyde and rinsed twice with PBS for 10 min. Cells were blocked with 3% skim milk 
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in PBS containing 0.1% Triton X-100, incubated with the anti-SREBP-2 (Abcam®) antibody 
overnight at 4°C followed by incubation with Alexa Fluor® 594 (Molecular Probes®) secondary 
antibody for 1 h at room temperature. Coverslips were mounted with Prolong Gold anti-fade 
reagent containing DAPI (Invitrogen®) to visualize nuclei. Blinded cell counts were performed 
(Doucette et al., 2010) using Image J software (NIH). Mean % nuclear SREBP-2 (SREBP-
2/DAPI co-localization) was calculated by counting >1500 cells and expressed as a percentage of 
total cells (DAPI). 
5.3.6 Cholesterol assay  
Cholesterol assay was carried out using Amplex Red Cholesterol Assay Kit (Invitrogen 
Molecular Probes®) according to manufacturer’s instructions. CG4-OLs and primary OLs were 
rinsed with 1×PBS and lysed with reaction buffer (Invitrogen®). Cholesterol assay in wild-type 
and Sirt2-/- mice were carried out using purified myelin fractions. Total cholesterol values were 
normalized to total protein as estimated with the BCA Protein Assay (Pierce®). 
5.3.7 Preparation of purified myelin fraction  
Myelin was isolated from whole brain of wild-type and Sirt2-/- male mice at P15 as described 
previously (Larocca and Norton, 2007; Norton and Poduslo, 1973b). Briefly, brain was 
homogenized in ice-cold 0.3 M sucrose solution containing 20 mM Tris-Cl buffer (pH 7.45), 1 
mM EDTA, 1 mM DTT, 100 µM phenyl methyl sulfonyl fluoride and 10 µg/mL leupeptin. Brain 
homogenate was layered over 0.83 M sucrose and centrifuged in an ultracentrifuge at 75,000 x g. 
Myelin membranes were recovered from the 0.3 M and 0.83 M interface and further purified by 
two rounds of hypoosmotic shock by resuspension in Tris-HCl buffer, followed by a second 
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round of centrifugation in a sucrose gradient. Purified myelin was collected from the interface 
and resuspended in Tris-HCl buffer. 
5.3.8 Statistical analysis 
All quantitative data were compared using student’s t-test (Prism® Software Corporation) and 
are presented as mean ± standard error of the mean (SEM).  
5.4 Results 
5.4.1 Cholesterol biosynthesis is not altered in the CNS white matter of Sirt2-/- mice  
To investigate the role of Sirt2 in regulating cholesterol biosynthesis in vivo, gene expression 
profiles of key cholesterogenic enzymes were examined in Sirt2-/- mice during the period of peak 
myelination (P15) and in adulthood (P60). Expression levels of Srebp-2, Hmgcr, Sqs, Sqle, and 
Dhcr7 mRNA were not altered in the CC of Sirt2-/- mice compared to their age-matched wild-
type (WT) controls at P15 (Fig. 5.1A) or P60 (Fig. 5.1B). In addition, total cholesterol content in 
the purified myelin isolated from the whole brain of Sirt2-/- and WT mice did not differ 
significantly (Fig. 5.1C).  
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Figure 5.1: Cholesterol biosynthesis is not altered in the CNS white matter of Sirt2-/- mice. 
Quantification of mRNA expression of key cholesterol biosynthetic genes by qPCR at P15 (A) 
and P60 (B) showed no difference between in Sirt2-/- mice and age matched wild-type (WT) 
mice. The bar graphs represent the transcript levels of Srebp2, Hmgcr, Sqs, Sqle, and Dhcr7 
normalized to the housekeeping gene β-actin and represented relative to WT controls (n=6). Data 
represented as Mean ± SEM; unpaired t-test. (C) Quantification of total cholesterol content from 
purified myelin fraction of whole brain at P15 showed no difference between Sirt2-/- and WT 
mice. Protein content in the purified myelin fraction was used to normalize total cholesterol 
(n=4). Data represented as Mean ± SEM; unpaired t-test. 
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5.4.2 Sirt2 does not regulate the cholesterol biosynthesis pathway in OLs 
To directly evaluate the impact of Sirt2 on cholesterol biosynthesis in OLs, progenitor cells were 
isolated from the neonatal forebrain of Sirt2-/- and WT mice followed by differentiation in serum-
supplemented media for 6 days. The loss of Sirt2-/- in primary OLs did not result in altered 
expression of Hmgcr or Sqle when cultured in FBS (Fig. 5.2A) or in DLFBS (Fig. 5.2C). 
Consistent with this, the total cholesterol content did not differ between Sirt2-/- and WT OL 
cultures (Fig. 5.2B, D).  
Furthermore, Sirt2 was knocked-down or overexpressed in CG4-OL cells during differentiation 
in media containing either FBS or DLFBS. In Sirt2-siRNA treated CG4-OLs, expression of Sirt2 
mRNA was significantly downregulated by ~70% compared to control siRNA treated cells (Fig. 
5.3A, B). However, the expression of Hmgcr, Sqs, and Sqle (Fig. 5.3C, E) and total cholesterol 
content (Fig. 5.3D, F) were not altered in Sirt2-siRNA treated cells. In CG4-OLs transfected with 
pcDNA-Sirt2, expression of Sirt2 mRNA is significantly upregulated by ~500 fold (Fig. 5.4A, 
B). Again, neither the expression of Hmgcr, Sqs, and Sqle (Fig. 5.4C, E) nor the total cholesterol 
content (Fig. 5.4D, F) was altered in cells overexpressing Sirt2.  
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Figure 5.2: Cholesterol biosynthesis is not altered in primary OLs isolated from Sirt2-/- 
mice. Primary OLs isolated from WT and Sirt2-/- mice were allowed to differentiate for 6 days. 
Quantification of mRNA expression levels of Hmgcr and Sqle by qPCR showed no change in 
Sirt2-/- primary OLs compared to WT primary OLs cultured with FBS (A) or with DLFBS (C). 
qPCR data were normalized to the housekeeping gene β-actin and represented relative to WT 
controls (n=6). Mean ± SEM; unpaired t-test; n.s. Quantification of total cholesterol content 
showed no difference between Sirt2-/- and WT primary OLs cultured with FBS (B) or with 
DLFBS (D). Protein content in the cell lysate was used to normalize total cholesterol (n=6). 
Mean ± SEM; unpaired t-test. 
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Figure 5.3: Expression of cholesterol biosynthetic genes and total cholesterol content in 
CG4-OLs after knock-down of Sirt2. CG4-OLs were transfected with control siRNA or Sirt2 
siRNA under differentiation conditions. (A and B) Transfection with Sirt2 siRNA downregulated 
the expression of Sirt2 mRNA after 6 days. qPCR data normalized to β-actin and represented 
relative to control siRNA (n=3). Mean ± SEM; unpaired t-test; ***p < 0.001. Knockdown of 
Sirt2 did not alter the expression of Hmgcr, Sqs, and Sqle mRNAs in CG4-OL cells 
differentiated with FBS (C) and DLFBS (E). qPCR data were normalized to the housekeeping 
gene β-actin and represented relative to control siRNA (n=3). Mean ± SEM; unpaired t-test. 
Total cholesterol content did not change after knock-down of Sirt2 in CG4-OL cells 
differentiated with FBS (D) or DLFBS (F). Protein concentration in the cell lysate was used to 
normalize total cholesterol (n=3). Mean ± SEM; unpaired t-test. 
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Figure 5.4: Expression of cholesterol biosynthetic genes and total cholesterol content in 
CG4-OLs overexpressing Sirt2. CG4-OLs were transfected with pcDNA or pcDNA-Sirt2 under 
differentiation conditions. (A and B) Overexpression of Sirt2 displays ~500 fold increase in the 
Sirt2 mRNA levels in CG4-OL cells after 6 days. qPCR data normalized to β-actin and 
represented relative to pcDNA control vector (n=3). Mean ± SEM; unpaired t-test; **p < 0.01. 
Overexpression of Sirt2 did not alter expression of Hmgcr, Sqs, and Sqle mRNAs in CG4-OL 
cells differentiated with FBS (C) or with DLFBS (E).  qPCR data were normalized to the 
housekeeping gene β-actin and represented relative to pcDNA vector (n=3). Mean ± SEM; 
unpaired t-test. Total cholesterol content did not change after overexpression of Sirt2 in CG4-OL 
cells differentiated with FBS (D) or DLFBS (F). Protein content in the cell lysate was used to 
normalize total cholesterol (n=3). Mean ± SEM; unpaired t-test. 
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5.4.3 Sirt2 does not impact nuclear translocation of SREBP-2  
Nuclear translocation of SREBP-2 was assessed in CG4-OL cells transfected with Sirt2-siRNA 
or pcDNA-Sirt2 by immunostaining with SREBP-2 antibody (Fig. 5.5A-B, D-E). SREBP-2 was 
largely expressed in the perinuclear region of differentiating OLs. Approximately 35-40% of 
cells also showed nuclear localization of SREBP-2. Knock-down (Fig. 5.5C) or overexpression 
(Fig. 5.5F) of Sirt2 did not change the subcellular distribution of SREBP-2 compared to their 
respective controls. 
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Figure 5.5: Sirt2 knock-down or Sirt2 overexpression in CG4-OL cells does not impact the 
nuclear translocation of SREBP-2. Representative images of CG4-OLs cells transfected with 
the control siRNA (A) and Sirt2 siRNA (B) or pcDNA (D) and pcDNA-Sirt2 (E) at day 6 under 
differentiation conditions. Scale bar, 100 µm. Blinded counts (n=3; >1500 cells) of SREBP-2 
(red) expression in the nucleus (DAPI; blue) showed no difference in the subcellular localization 
of SREBP-2 in CG4-OL cells after Sirt2 downregulation (C) or Sirt2 overexpression (F). Mean 
± SEM; unpaired t-test. 
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5.5 Discussion 
Myelin is highly enriched in cholesterol, comprising ~80% of total brain cholesterol 
(Dietschy and Turley, 2004; Muse et al., 2001). Cholesterol is thought to play a vital role in 
transport and sorting of the myelin proteins (Saher and Simons, 2010; Saher et al., 2005; Saher et 
al., 2009; Simons et al., 2000; Werner et al., 2013). Cholesterol-enriched membrane domains in 
OPCs may also be important for efficient signal transduction to facilitate the differentiation 
(Mathews and Appel, 2016). Defects in the cholesterol biosynthesis pathway can cause 
dysmyelination, reduced myelin gene expression, and impaired axon wrapping in both the CNS 
(Mathews et al., 2014; Mathews and Appel, 2016; Saher et al., 2005) and PNS (Saher et al., 
2009; Verheinjen et al., 2009).  
SREBP-2 is a key transcription factor that modulates cholesterol biosynthesis. SREBP-2 
is synthesized in the endoplasmic reticulum, where it binds to SCAP. Low cellular sterol level 
induces SREBP-2 processing and translocation to the nucleus where it activates downstream 
target genes (Horton et al., 2002; Horton et al., 2003). Previous studies using SIRT2 specific 
inhibitors AGK2, AK-1, and AK-7 were reported to show that the deacetylase activity of SIRT2 
impacted sterol biosynthesis by regulating nuclear trafficking of SREBP-2 protein in neuronal 
cells (Luthi-Carter et al., 2010; Taylor et al., 2011). Overexpression of Sirt2 increased nuclear 
translocation of SREBP-2, while overexpression of deacetylase-deficient Sirt2 (Sirt2H150Y) or 
pharmacological inhibition of SIRT2 reduced the nuclear translocation of SREBP-2 (Luthi-
Carter et al., 2010; Taylor et al., 2011). In silico analysis revealed the presence of two lysine 
residues at K310 and K329 in the DNA binding domain of SREBP-2 (Fig. 5.6A). These lysine 
residues are highly conserved across various SREBPs of which K283 and K303 in SREBP-1c 
have been shown to be deacetylated by SIRT1 (Ponugoti et al., 2010; Walker et al., 2010). 
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Hence, it is possible the two conserved lysine residues in SREBP-2 would be potential 
deacetylation sites for SIRT2.  
Loss of Sirt2 function in Schwann cells has been shown to delay myelin formation in 
PNS (Beirowski et al., 2011). Sirt2 expression is also upregulated during OL differentiation and 
in CNS myelination (Ji et al., 2011; Li et al., 2007a; Werner et al., 2007; Zhu et al., 2012). 
Previous work from our lab demonstrates that Sirt2 expression promotes differentiation in CG4-
OLs, including upregulation of MBP expression and enhanced outgrowth of cellular processes 
(Ji et al., 2011). While α-tubulin has been identified as a primary target of SIRT2 in 
oligodendroglial cells in vitro (Li et al., 2007a), this may not be the case in vivo (Bobrowska et 
al., 2012). Thus, it is postulated that SREBP-2 may be a possible target of SIRT2 during OL 
differentiation and myelination. This would not only drive sterol synthesis for the formation of 
myelin membranes (Saher et al., 2005; Mathews et al., 2014) but may indirectly facilitate myelin 
gene expression (Mathews and Appel, 2016). 
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Figure 5.6: Schematic diagram depicting speculative role of Sirt2 in SREBP-2 nuclear 
trafficking and cholesterol biosynthesis. (A) In-silico analysis revealed putative lysine 
acetylation sites in the DNA binding domain of SREBP-2 protein. Sequence alignment of the 
conserved lysine residues in mouse, rat and human SREBP proteins with predicted acetylation 
lysine residues highlighted in red. (B) Acetylation/deacetylation regulates nuclear trafficking and 
activity of mature SREBP-2 (N-terminal fragment). In the nucleus, SREBP-2 binds to sterol 
responsive element (SRE) and activates the downstream genes encoding enzymes involved in 
cholesterol biosynthesis. Collectively, our findings show no impact of Sirt2 expression on the 
cholesterol biosynthesis pathway indicating that SREBP-2 is not a primary target of SIRT2 
during oligodendroglial differentiation. 
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In the present study, I found no impact of Sirt2 expression on cholesterol biosynthesis in 
the CNS white matter in vivo and OL cultures in vitro (Fig. 5.6B). Although Sirt2-/- mice lack 
Sirt2 mRNA and SIRT2 protein expression in white matter tracts, the expression level of Srebp2 
or four of the key genes in the biosynthesis pathway were not altered significantly (Fig. 5.1). 
Furthermore, there was no significant difference in cholesterol content of purified myelin from 
Sirt2-/- and WT mice. Although OLs are thought to be primarily responsible for the production of 
sterol required for myelin formation, cholesterol derived from extracellular sources may help to 
maintain the integrity of myelin sheath (Saher et al., 2005; Verheijen et al., 2009). Thus, it is 
possible that in Sirt2-/- mice OLs might depend upon external sources of cholesterol for myelin 
synthesis in vivo. To negate this caveat, primary OL and CG4-OL cultures were differentiated in 
vitro to assess the role of SIRT2 in cholesterol biosynthesis. In mammalian cells, the presence of 
excess sterol induces feedback regulation by promoting the retention of SREBP-SCAP complex 
in the endoplasmic reticulum and inhibiting SREBP processing (Wang et al., 1994; Yang et al., 
2002). To control the presence of cholesterol in the media, CG4-OLs and primary OLs were 
cultured in media containing normal serum (FBS) or delipidated serum (DLFBS). The loss of 
Sirt2 in primary OLs (Fig. 5.2), as well as knockdown of Sirt2 or overexpression of Sirt2 in 
CG4-OLs (Fig. 5.3 and 5.4), did not alter expression of cholesterol biosynthetic genes and total 
cholesterol content.  
The findings presented here are in agreement with Bobrowska et al., (2012) who did not 
find a change in the gene expression profile of enzymes involved in cholesterol biosynthesis in 
the cortex, hippocampus or brain stem of Sirt2-/- mice. Unlike neuronal cells (Luthi-Carter et al., 
2010; Taylor et al., 2011), knockdown or overexpression of Sirt2 did not impact nuclear 
translocation of SREBP-2 in OLs (Fig. 5.5). This discrepancy could be due to the cell type 
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specific differences in the expression pattern, as Sirt2 is more abundantly expressed by OLs than 
other cell types in the CNS (Zhang et al., 2014). Moreover, the predominate isoform in OLs is 
SIRT2.2 (Zhu et al., 2012), whereas in neurons its SIRT2.1 (Luthi-Carter et al., 2010), which 
may result in selective deacetylation targets. However, usage of neurons isolated from Sirt2-/- and 
WT mice, as a positive control would confirm that SIRT2 plays role in cholesterol biosynthesis 
in neurons. In addition, loss of Sirt2 could activate compensatory sirtuins to restore cholesterol 
biosynthesis. In summary, I have presented several lines of evidence (Fig. 5.6B) to conclude that 
Sirt2 does not impact cholesterol biosynthesis during OL differentiation and myelination in the 
developing CNS white matter. 
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6. GENERAL DISCUSSION 
This thesis uncovers the molecular mechanism by which the expression of Sirt2 is 
regulated during OL development and addresses the functional role of Sirt2 in CNS myelination 
and MS. It was previously known that the expression of SIRT2 increases as OLs differentiate (Ji 
et al., 2011), although the mechanism involved in regulating the expression of SIRT2 during 
oligodendrogenesis was largely unknown. The RNA binding protein QKI regulates the 
expression of several myelin-specific transcripts either directly or indirectly for proper OL 
development and myelination (Chen et al., 2007b; Larocque et al., 2002; Wu et al., 2002; Li et 
al., 2000; Zhao et al., 2006a; Zhao et al., 2010; Larocque et al., 2005; Doukhanine et al., 2010; 
Zhao et al., 2006b; Zearfoss et al., 2011). Although SIRT2 protein is absent in qkv/qkv mutant 
mice (Zhu et al., 2012), it was not known whether QKI directly interacts with Sirt2 mRNA to 
modulate OL development. In this study, I have conclusively demonstrated that QKI directly 
binds to the QRE present at 1853 bp in the 3ʹUTR of Sirt2 mRNA (Chapter 3). This interaction 
stabilizes Sirt2 mRNA and increases the accumulation and availability of Sirt2 transcripts for 
translation. The increase in the expression of QKI during OL differentiation could promote the 
expression of SIRT2 in premyelinating and myelinating OLs, where it is highly expressed (North 
et al., 2003). A definitive role for QKI and Sirt2 interactions in the regulation of myelination in 
vivo remains unclear, but it is plausible that binding of QKI to Sirt2 mRNA at early stages of OL 
development is important for regulating the timing of differentiation. 
The involvement of Sirt2 in OL process formation and maturation in vitro was identified 
previously in our lab using CG4-OLs (Ji et al., 2011). However, the role of Sirt2 in CNS 
myelination in vivo and disease severity of EAE, a mouse model of human MS, remained 
elusive. To address this, I have used Sirt2 null mice to determine the impact of loss of Sirt2 on 
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myelination and MS. My findings reveal that in the absence of Sirt2, the expression of myelin 
specific genes such as Mbp and Plp are downregulated in the CNS white matter. In addition, the 
proliferation and differentiation of OLs in the Sirt2-/- mice were impaired (Chapter 4). These 
findings are in agreement with our previous report (Ji et al., 2011) that Sirt2 promotes the 
expression of MBP and cell arborization in CG4-OLs in vitro. Electron microscopic analysis 
revealed a reduction in the number of myelinated axons in Sirt2-/- mice with uncompact myelin 
sheath. This indicates that Sirt2 plays a critical role in OL development and myelination of axons 
in the CNS.  
The EAE induction study shows that loss of Sirt2 results in an increased severity of 
EAE (Chapter 4). This suggests the potentially important contribution of Sirt2 in the 
pathogenesis of MS. Recently, EAE models were criticized as some of the therapies developed 
using EAE models were inefficient in human MS (Longbrake and Racke, 2009; Procaccini et al., 
2015). This discrepancy could be due to genetic and environmental factors that contribute to the 
complexity of MS in humans. Another drawback of the EAE model is that it affects spinal cord 
white matter primarily with little involvement of brain (Procaccini et al., 2015). In addition to 
EAE, Theiler’s murine encephalomyelitis virus (TMEV) and cuprizone are used to study CNS 
demyelination.  However, EAE is the commonly used animal model of MS because of its 
immunological and pathological similarity with human MS (Gold et al., 2006; Simmons et al., 
2013; Bittner et al., 2014). Immunostaining analysis of human MS postmortem brain sections 
revealed the presence of SIRT2 in the shadow plaques. This indicates the putative role of SIRT2 
in myelin repair. EAE induction using a higher dose of MOG (200 - 300ug) hinders 
remyelination efficiency with infiltrating macrophages and microglia, and further investigation 
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using lower doses of MOG (50ug), which induces relapsing-remitting disease course could 
provide insight on the role of SIRT2 in remyelination. 
In neuronal cells, SIRT2 has been demonstrated to play a role in cholesterol biosynthesis 
by promoting the nuclear translocation of SREBP-2 (Luthi-Carter et al., 2010; Taylor et al., 
2011). Cholesterol is essential for myelin formation and defects in cholesterol biosynthesis 
significantly reduce myelin gene expression and myelination (Mathews et al., 2014; Mathews 
and Appel, 2016; Saher et al., 2005). I hypothesized that SREBP-2 is a possible target of SIRT2 
through which Sirt2 could regulate myelin gene expression and myelination. However, 
expression of cholesterol biosynthetic genes and total cholesterol content was not altered in the 
CNS white matter in vivo and OL cultures in vitro in the absence of Sirt2. Knock-down or 
overexpression of Sirt2 in CG4-OLs did not impact nuclear translocation of SREBP-2. Thus, 
SREBP-2 and the downstream sterol biosynthesis pathway is not regulated by SIRT2 in OLs 
during CNS myelination (Chapter 5). This finding is consistent with a previous study where no 
change in the expression of enzymes involved in cholesterol biosynthesis was observed in the 
whole brain of Sirt2 knock-out mice (Bobrowska et al., 2012) . However, further analysis on the 
expression and activity of other sirtuins could give an idea on whether another SIRT plays a 
compensatory role in the absence of Sirt2. 
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7. FUTURE DIRECTIONS 
7.1 QKI-Sirt2 interaction 
QKI post-transcriptionally regulates the expression of several myelin-specific transcripts by 
modulating target mRNA stability, splicing, localization and translation. In this thesis, I have 
reported the interaction of QKI with the Sirt2 mRNA at a common QKI binding site present in 
the 3' UTR, which promotes the stability of Sirt2 mRNA. In addition to the two putative QREs in 
the 3' UTR of Sirt2 mRNA, I observed the presence of a QRE at intron 2 of Sirt2 pre-mRNA. 
Furthermore, presence of putative QRE was reported in the exon 2 of Sirt2 mRNA (Darbelli et 
al., 2016), suggesting that QKI may also regulate the splicing of Sirt2 mRNA, which remains to 
be explored. The role of QKI in Sirt2 mRNA splicing could be characterized by generating a 
Sirt2 minigene reporter construct containing the genomic DNA starting from exon 1 to exon 4 of 
the Sirt2 gene with wild-type putative QREs or mutated putative QREs. Transfection of the Sirt2 
minigene reporter construct with wild-type putative QREs or mutated putative QREs in 
HEK293T cells followed by RNA co-IP would reveal the involvement of QKI in Sirt2 mRNA 
splicing. The functional importance of QKI-Sirt2 interaction in the regulation of myelination in 
vivo remains unclear. To address this, CRISPR-Cas9 system could be used to mutate or delete 
the QRE at 1853 bp in the 3ʹUTR of Sirt2 mRNA or the whole 3' UTR of Sirt2 mRNA with 
guide RNAs. This could uncover the role of QKI-Sirt2 interaction in vivo. Although in practice, 
the CRISPR-Cas9 system creates off-target deletions, selection of target sites with low GC 
content (≤ 35%) and designing guide RNAs with 17-18 nucleotides have been reported to reduce 
off-target effects (Peng et al., 2016). 
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7.2 Sirt2 in CNS myelination and MS 
In this thesis I have demonstrated the importance of SIRT2 in OL development, 
myelination and MS using constitutive Sirt2 knockout mice, in which the target gene is 
inactivated in a whole animal. However, specific deletion of Sirt2 in OLs using Olig2cre 
(immature OLs) or Plpcre (mature OLs) will reveal the stage specific role of Sirt2 in OL 
proliferation and differentiation. Given that SIRT2 undergoes incorporation into the myelin 
sheath near PLP in paranodal loops (Li et al., 2007a; Werner et al., 2007), evaluating the 
distribution of paranodal proteins, Caspr and Ankyrin G, by immunostaining brain and spinal 
cord sections from Sirt2-/- mice would give insights into the role of SIRT2 in maintaining the 
integrity and stability of paranodal junctions. Electron microscopic analysis of longitudinal 
sections could be used to assess the ultra-structural defects in the organization of paranodal 
loops. In addition, the role of SIRT2 in axo-glial interactions will be investigated using OL- 
dorsal root ganglion co-cultures by overexpressing and knocking down Sirt2 in vitro. Further, 
RNA sequencing using the brain samples of Olig2cre or Plpcre Sirt2 knockout mice could be used 
to evaluate the downstream targets through which OL-specific SIRT2 regulates myelination and 
myelin repair. Similarly, proteomic analysis of white matter from wild-type and Sirt2-/- mice 
would shed light on the functional importance of SIRT2 deacetylase activity in myelin assembly.   
EAE induction and clinical scoring revealed the protective role of SIRT2 in a mouse 
model of MS. Further brain and spinal cord sections from the EAE mouse model could be 
immunostained for various myelin proteins and inflammatory markers to determine the extent of 
myelin loss and the severity of inflammation, respectively. Expression of SIRT2 in the shadow 
plaques of human MS postmortem brain sections indicates a plausible role for SIRT2 in 
remyelination; however, a definitive role in remyelination is lacking. Cuprizone (copper 
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chelator)-induced demyelination and cuprizone withdrawal-induced remyelination could be used 
to study the role of SIRT2 in remyelination. In addition, lower doses of MOG could be utilized 
to induce a relapsing-remitting EAE disease course to provide further insight into the role of 
SIRT2 in remyelination. 
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8. CONCLUSION 
Together, these findings suggest that expression of Sirt2 is regulated by QKI for proper 
OL development and Sirt2 positively regulates OPC proliferation, OL differentiation and 
myelination of axons in CNS. Furthermore, loss of Sirt2 results in an increased severity in the 
EAE mouse model of MS. SIRT2 may have an important functional role during remyelination in 
human MS. However, Sirt2 is not involved in SREBP-2 dependent cholesterol biosynthesis in 
OLs. Downstream targets of Sirt2 remain to be explored to identify potential molecular targets 
for nutrient and pharmacological interventions that target myelin repair in MS.  
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